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Cancer cells have been historically characterized as having hijacked normal 
cellular machinery in order to acquire a proliferative advantage, thus posing the 
fundamental challenge in the treatment of cancer. The conceptual origins and 
motivation for this thesis lie in my desire to systematically investigate the newly 
discovered reprogramming of glutamine metabolism that occurs specifically in cancer 
cells, with the hope that this will lead to the development of new targets and 
therapeutic strategies for the treatment of cancer. Transformation of normal cells is 
often accompanied by a dramatic shift in glucose metabolism, most notably an 
increase in the glycolytic flux. However, in cancer cells, the end product of glycolysis, 
pyruvate, is diverted from entering the respiratory TCA cycle and instead secreted 
from the cell as lactate. In order to compensate for the decrease in glucose-derived 
carbon entering the TCA cycle, glutamine is taken up and converted to glutamate by 
the mitochondrial enzyme glutaminase C (GAC), where glutamate can then feed an 
entry point of the TCA cycle upon conversion to -ketoglutarate. 
The first objective of my thesis study is to investigate the activation of GAC in 
vitro using a novel fluorescence resonance energy transfer (FRET) assay. Using this 
assay, I gain insights into the mechanism of action of two recently described classes of 
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allosteric glutaminase inhibitors; the benzophenanthridines, and bis-thiadiozoles, the 
latter being currently developed as a therapeutic for targeting the altered metabolism 
in cancer cells. 
A second objective is designed to complement these in vitro results by 
employing an in vivo model cell system engineered to express the Dbl oncogene in an 
inducible tetracycline-dependent manner. The in vitro FRET assay provides important 
information regarding how the ability of GAC to undergo a dimer-to-tetramer 
transition is coupled to the activation of its enzymatic activity, as well as the mode of 
inhibition of GAC by small molecule inhibitors. The inducible cell model allows me 
to tie these results to the formation of oligomers in vivo and extend this study to 
human cancer cell lines. The results presented herein add to an emerging detailed 
portrait of metabolic transformation and a deeper understanding of the role GAC plays 
in supporting cancer cell growth. 
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CHAPTER ONE 
INTRODUCTION 
1.1.1 Metabolic changes as a hallmark of cancer 
Cancer is generally considered to be a disease characterized by uncontrolled 
cellular growth. This uncontrolled growth, as defined by the current understanding of 
the molecular and genetic mechanisms that govern cellular physiology, is supported 
by the increased expression of tumor promoting genes and decreased expression of 
tumor suppressor genes. The underlying changes leading to the sustained deregulation 
of these tumor promoters and suppressors is acquired through alterations within 
particular segments of DNA. A diverse set of genomic alterations have now been 
characterized that play essential roles to initiate, support, and sustain unregulated 
cellular proliferation that gives rise to neoplasia and subsequent malignancies. These 
discoveries have led to the predominant view that cancer cells develop specific 
adaptations that enable their sustained survival and growth, and are generally referred 
to as “hallmarks”. Douglas Hannahan and Robert Weinberg (2000) first described 
these hallmarks and presented them as a simplified list of the quintessential 
characteristics of cancer cells. These alterations are described as promoting the cell’s 
ability to stimulate proliferation, enable motility, initiate the growth of new blood 
vessels, obtain replicative immortality, disable the influence of growth suppressors, 
and maintain cellular viability [1]. Ten years later, Hannahan and Weinberg revised 
their originally proposed hallmarks to reflect the rapid advances in cancer research. 
They added to their original hallmarks the avoidance of immune destruction and the 
deregulation of cellular metabolism, as well as adding the cancer-enabling 
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characteristics of genome instability and inflammation [2]. Defining these hallmarks 
has provided a common language for cancer researchers in considering the great 
diversity of altered cellular events that give rise to and support the oncogenic state. 
The multiple pathologies that encompass the range of human cancers, reflected in a 
variety of cell types that can give rise to neoplasms, appear heterogeneous, but in fact 
are generally supported by highly similar and often redundant mechanisms. 
Hannahan and Weinbergs’ recognition of the importance of cellular 
metabolism in cancer is not a new discovery, and in fact it was observed in one of the 
first published studies of tumor growth [3]. This seminal work was carried out by the 
Nobel laureate Otto Warburg in the 1920’s using the then newly developed animal 
models of tumor formation, such as Flexner-Jobling’s rat carcinoma or Jensen’s rat 
sarcoma [3], [4]. Using these contemporary models of cancer, Warburg described the 
glucose and oxygen consumption of arterial and venous blood of growing tumors, 
which led him to propose that neoplastic disease was in fact caused by metabolic 
abnormalities arising in normal cells. When comparing tumor to normal tissue he 
found that tumors ferment glucose at aberrantly high rates to produce lactate, while 
normal tissues primarily rely on respiration, whereby glucose is fully oxidized to 
produce carbon dioxide [4]. These observations led to his landmark discovery; that 
tumors harbor a significantly altered metabolism from normal cells that relies on the 
fermentation of glucose to form lactate, even in the presence or absence of oxygen 
(Figure 1.1A). More specifically, his work lead him to postulate that cancer cells 
undergo aerobic fermentation as a result of respiratory dysfunction [5].   
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FIGURE 1.1– The Warburg effect observed in tumors and cells. (A) Arterial 
blood, abundant in glucose and oxygen, supplies the growing tumor. Venous blood 
is found to have consumed virtually all of the glucose, except instead of fully 
oxidizing it to carbon dioxide, the primary waste product is lactate. (B) Depiction 
of the Warburg effect in cells, where glucose is imported at high rates and 
converted to pyruvate, where the bulk of pyruvate is secreted from the cell as 
lactate as opposed to being imported into the mitochondria as acetyl-CoA. To 
compensate, cells resort to other metabolic pathways, principally glutamine 
catabolism, where intracellular glutamine serves as an anaplerotic source.  
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Today, this metabolic reprogramming is termed the “Warburg effect”, and is a 
fundamental characteristic of cancer cells altered metabolism. This metabolic 
phenotype in proliferating cells results in the bulk of glucose carbon being secreted 
from the cell as lactate, leaving the mitochondria depleted of glucose-derived carbon 
normally used to fuel the TCA cycle (Figure 1.1B). In order to provide the TCA cycle 
with an alternative source of catabolic substrates, the amino acid glutamine serves as 
the primary anaplerotic metabolite in proliferating cells, entering the cycle upon 
conversion to -ketoglutarate. The current appreciation of this shift to glutamine 
dependence represents a new paradigm in cancer research and with it the hope of 
discovering new opportunities for therapeutic intervention [6]. 
Although there is a renewed interest in describing the altered metabolism that 
accompanies oncogenic transformation, this general approach to cancer therapy has a 
significant historical legacy. There are many cases throughout the past century that 
have exploited the metabolic alterations of cancer cells to treat patients. Perhaps the 
most well-known and seminal in the field of chemotherapy was Sydney Farber’s 
development of anti-folates in 1948 [7]. His initial observation came by supplying 
doses of folic acid, which at that time was understood to be a dietary factor important 
for normal bone marrow function, to children with acute leukemia, and found that 
these supplements exacerbated their cancer [8, pp. 28–29]. This lead him to develop a 
theory that leukemic cells must rely on folic acid for sustained growth, and therefore 
antagonists of folic acid might inhibit those cells [9], [10]. Folic acid antagonists, 
known as antifolates, indeed became one of the first chemotherapies to be developed 
and shown to be effective, earning Farber the colloquial title of “the father of modern 
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chemotherapy” [7]. It soon became clear following Farber’s investigation into 
antifolates for the treatment of childhood leukemia, that this vitamin is a crucial 
cofactor for DNA synthesis, a characteristic thought to be important among the altered 
metabolic requirements of cancer cells [11], [12]. The discovery of antifolates was 
made alongside the development of nitrogen mustards by Goodman and Gilman in 
1946, the latter initially proving effective in patients with non-Hodgkin’s lymphoma, 
although they subsequently underwent severe relapses and this therapy was 
discontinued [13]. Farber’s contribution to the study of cancer chemotherapies is the 
first example of intentionally targeting the altered metabolic requirements of cancer 
cells. Hoping to build on this initial success, scientists interested in developing more 
effective chemotherapeutics, such as Hitchings and Elion, followed Farber’s lead. 
They began by developing purine antimetabolites, known as thiopurines, just a few 
years after Farber’s antifolates gained appreciation [14]. Thiopurines were 
subsequently shown to be effective in the clinic and became the first line therapies for 
hematopoietic cancers, leading to the awarding of the Nobel prize in 1988 for this 
discovery [7], [15]. Only six years later, following this trend of targeting metabolites 
that are vital to cancer cells, Heidelberger and colleagues discovered the 
antimetabolite 5-fluorouracil (5-FU), which is still in use today as a frontline therapy 
for a many cancers [16]. It is now known that 5-FU, once phosphorylated in the cell 
by thymidine phosphorylase (TP) to form the active antimetabolite 5-
fluorodeoxyuridine monophosphate (FdUMP), acts as a competitive inhibitor of 
thymidylate synthase (TS) through formation of a ternary complex with 5,10-
methylene tetrahydrofolate (CH2THF) [17]. Taken together, the above examples 
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provided the first proof of principle that cancer could be effectively targeted with 
small molecule drugs, and underscored the important role cell metabolism plays in 
supporting the growth of cancer cells. 
 It is worth noting that the targeting of the altered metabolism characteristic of 
cancers was developed at a time when the primary metabolic networks studied today 
were not very well understood. In fact, Hans Krebs, a former student of Otto 
Warburg’s, first began describing the metabolism of amino acids and the oxidation of 
carbohydrates through the TCA cycle almost a decade after Warburg’s description of 
tumor metabolism [18]–[22]. The work done by Warburg, Farber, and others preceded 
the discovery of the DNA double helix by Watson and Crick in 1953 and the 
chemiosmotic theory of mitochondrial function proposed by Peter Mitchell in 1961 
[23], [24]. Despite Warburg’s initial discovery that tumors harbor an altered 
metabolism distinct from normal non-transformed cells, and the subsequent 
development of effective chemotherapies targeting altered metabolism, the study of 
cancer metabolism was soon superseded by the rapid advances in molecular genetics 
and the identification of viral oncogenes that caused cancer in animal models [1].  
Until very recently, advances of cancer research have been driven by the 
characterization of the genetic basis of cancer, namely the consequential lesions 
occurring in oncogenes and tumor suppressors that give rise to neoplasia and 
subsequent malignancies. Exhaustive sequencing studies of a great many cancers have 
revealed that there are dominant genetic events that frequently occur to drive 
malignant transformation. These dominant genetic events are referred to as ‘driver 
genes’, and so far a surprisingly low number (approximately 140 of the more than 
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20,000 genes in the human genome) have been shown to promote cancer. 
Furthermore, these genes can be further subdivided into 12 well-characterized 
signaling pathways to control only three core processes: cell fate, cell survival, and 
genome maintenance [25]–[27], emphasizing the common features among a variety of 
cancers. Even with this wealth of information, clinicians are still in need of new 
approaches for the treatment of cancer. Initial efforts for developing a new generation 
of chemotherapeutics focused on targeting the common driver genes themselves. 
While these treatments are effective in many cases, these targeted therapies often give 
rise to resistance and recurrence [28]–[32]. To further complicate the development of 
targeted therapies, some of the most potent oncogenes are in fact termed 
“undruggable”. This is due in part to the lack of small molecule binding pockets 
within proteins. A few principal examples for this would be the small GTPase Ras, the 
transcription factor Myc, or the tumor suppressor p53 [33]–[36]. Combined, these 
three proteins are deregulated in some form in virtually all cancer types, representing 
the fundamental challenge for cancer researchers. Therefore, in the search for new 
approaches to treat human cancers, strategies that target cellular processes that 
commonly support transformation, such as altered cellular metabolism, are a 
promising area of interest. 
The study of altered cancer cell metabolism is in the midst of a renaissance. 
This is due not only to a few recent discoveries in which metabolic enzymes were 
discovered to be in the “driver’s” seat for the first time [37]–[39], such as the case for 
mutations in the genes encoding the mitochondrial enzymes succinate dehydrogenase 
(SDH), isocitrate dehydrogenase (IDH), and fumarate hydratase (FH), but also from 
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new paradigms from the decades of research in primary metabolism and cellular 
physiology being revisited. One such paradigm has been that the outcome of the 
Warburg effect leads to a complete rewiring of central metabolic pathways, in order to 
generate the biosynthetic precursors needed to sustain proliferation and redox control 
(Figure 1.1B). Now, experimental advances have provided access to the information 
needed to study the role altered cell metabolism plays in cancer development. In fact, 
a new field is emerging from recent studies that track intermediates in metabolic 
pathways, or alternative side products produced from mutated metabolic enzymes, that 
promote transformation and neoplasia [40]–[44]. Changes in metabolism, stimulated 
by driver genes, along with genetic events that produce oncometabolites, represent 
new opportunities for the detection, diagnosis, and treatment of human cancers. 
1.1.2 Metabolic enzymes’ pleiotropic roles promote more than just the Warburg 
effect 
 A discovery that set in motion the recent attention regarding the metabolic 
changes that accompany oncogenic transformation, was a set of experiments that 
connected proliferative signaling events, in the form of receptor tyrosine kinase 
activation, to a key enzyme in glycolysis [45]–[47]. This enzyme, named pyruvate 
kinase (PK), was shown to directly give rise to and support the Warburg effect [47]. 
Pyruvate kinase catalyzes the final step in glycolysis, i.e. the transferring of a 
phosphate group from phosphoenolpyruvate (PEP) to an ADP molecule to form ATP 
and release pyruvate. Early on, it was shown that the exclusive expression of the 
embryonic isoform of this metabolic enzyme, pyruvate kinase isoform 2 (PKM2), was 
present in cancer cells but not normal cells [48]. More recently, it was suggested that 
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the switch from pyruvate kinase isoform 1 (PKM1) to PKM2 expression directly 
enables the Warburg effect (i.e. the shift from oxidative phosphorylation to aerobic 
glycolysis) [47]. In addition to showing PKM2, but not PKM1, is involved in 
orchestrating the Warburg effect, this study also elucidated two distinct levels of 
regulation of PKM2. First, that PKM2 is a phospho-tyrosine binding protein, capable 
of sensing the stimulation by extracellular growth factors through tyrosine kinases 
(TKs) [46]. Secondly, the direct phosphorylation of PKM2 on tyrosine 105 by the 
fibroblast growth factor receptor (FGFR1) was demonstrated. The phosphorylation at 
Y105 disrupts the binding of the allosteric activator fructose-1,6-bisphosphate (FBP) 
thereby inhibiting its activity [49]. These observations provided evidence that the 
regulation of metabolic enzymes occurs not only at the genetic level of PK isoform 
switching, but also as a result of downstream oncogenic proliferative signals (Figure 
1.2A). 
PKM2 catalyzes the rate limiting step for the entry of carbon derived from 
glucose into the mitochondria, where the mitochondrial enzyme pyruvate 
dehydrogenase (PDH) converts pyruvate to acetyl-CoA to be incorporated into the 
TCA cycle [50]–[52]. Early studies identified two distinct genes that give rise to the 
two isozymes of pyruvate kinase, which are further classified by two isoforms for each 
isozyme. The liver form (PKL) and the form found primarily in red blood cells (PKR) 
are the result of tissue specific promotion of exon splicing of the “L gene”, whereas 
both the M1 and M2 isoforms are the result of alternate splicing of the “M gene” [53], 
[54]. Early kinetic studies and crystal structures of pyruvate kinase revealed that the 
enzyme is a homotetramer when active, and a dimer when inactive [55]–[57]. 
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Furthermore, it was discovered that the metabolic intermediate in glycolysis, fructose-
1,6-bisphosphate (FBP), is an important allosteric activator of the pyruvate kinase’s R, 
L, and M2, but not M1, through its binding at the dimer-dimer interface to promote 
tetramer formation (Figure 1.2A)  [58]. It is here where the PKM2 isoform is distinct 
from the M1 isoform, where PKM2 contains an alternate amino acid sequence that 
confers the FBP binding pocket that imparts PKM2’s activity dependent on FBP 
binding, whereas PKM1 is a constitutively active pyruvate kinase not regulated by 
FBP [59], [60]. Together, these observations have led to the current model where 
increased PKM2 expression in cancer cells is correlated with decreased enzymatic 
activity. This is due to PKM2 being regulated by the upstream metabolite, FBP, 
thereby acting as a rheostat for the glycolytic flux. This decreased PK activity, when 
coupled with the upregulation of  lactate dehydrogenase (LDH) activity, promotes the 
Warburg effect by directing glucose carbons from entering the TCA cycle to secretion 
as lactate [61], [62]. 
 It is important to note that not long after this model was proposed, small 
molecule activators were developed that bind to PKM2 and induce tetramer formation, 
thereby stimulating its activity (Figure 1.2A). Indeed, these molecules were used in 
mouse tumor models to establish the potential of this discovery in the development of 
new therapeutics [63]–[65]. Although these small molecule activators are not yet in 
clinical trials for the treatment of human cancers, they are being developed for the 
inherited hematological metabolic disorder known as pyruvate kinase deficiency [66]. 
Perhaps once these activators are validated in Phase I safety trials, researchers will 
begin investigations into whether these therapies will have a benefit in treating 
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cancers. In any case, these discoveries demonstrate PKM isoform switching 
accompanied by oncogenic signaling events provide a molecular mechanism for the 
Warburg effect. 
Along with these new insights regarding the role of PKM2 in the Warburg 
effect, researchers also identified novel pleiotropic functions of this metabolic 
enzyme. First, an allosteric regulator was identified that specifically stimulated PKM2 
activity, but not the alternative splice isoform PKM1, which differs from PKM2 by 
only 22 residues. This allosteric activator, known as SAICAR 
(succinylaminoimidazolecarboxamide ribose-5’-phosphate), is a metabolic 
intermediate within the de novo nucleotide synthesis pathway. It was shown that the 
concentration of this small molecule was dependent on glucose metabolism, and more 
specifically, the pentose phosphate pathway (PPP), where upon glucose starvation 
SAICAR would accumulate and thus stimulate PKM2 activity [67]. These results 
suggest that PKM2 is capable of sensing the pool of biosynthetic precursors necessary 
for nucleotide production in the cell through the binding of this allosteric activator 
(Figure 1.2B). At the same time that this newly discovered allosteric control of PKM2 
activity by SAICAR was being described, an additional mode of allosteric regulation 
was identified, that provided for a feedback regulation of PKM2 activity by an 
intermediate in 1-carbon metabolism, L-serine [68]. The de novo synthesis of the 
amino acid serine in proliferating cancer cells was shown to be derived from glucose 
upon starvation of exogenously supplied serine. The increase in glucose-derived serine 
was shown to be a direct result of the decrease of PKM2 activity, and hence a buildup 
of glycolytic intermediates available to be shuttled into anabolic pathways.  
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FIGURE 1.2 – PKM2 is a central metabolic enzyme directing the Warburg 
effect. (A) X-ray crystal structure of PKM2 in complex with the allosteric 
activators FBP and the pharmacological small molecule TEPP-46 (4B2D), 
aligned with a structure of PKM2 with the allosteric activator L-serine bound 
(3U2Z). The allosteric regulation of PKM2 is modulated by surface contacts at 
the dimer-dimer interface. (B) Cartoon depiction of the pleiotropic roles of 
PKM2, where PKM2 activity acts as a rheostat for intracellular metabolites 
through directly binding metabolic intermediates from glycolysis, amino acid, and 
de novo nucleotide pathways. Alternatively, extracellular signals, such as PKM2 
binding to phospho-tyrosine residues or direct tyrosine phosphorylation itself, 
function to abrogate activation signals of PKM2 by antagonizing the action by 
metabolites. As a dimer, PKM2 is not able to act as a small molecule kinase to 
produce ATP, but instead is able to translocate to the nucleus where it adopts a 
protein kinase function to activate gene transcription through direct phospho-
transfer from PEP to Tyr residues on transcription factors such as STAT3.  
 
-14- 
 
  
B 
A 
-15- 
 
Together, these results showed that the conversion of PEP to pyruvate, a control step 
in glycolysis critical for maintaining the altered metabolism in cancer cells exhibiting 
the Warburg effect, is subject to tight regulation by the de novo nucleotide and amino 
acid synthetic pathways (Figure 1.2B).  
 Concurrent with this newly discovered metabolite SAICAR being reported, 
PKM2 was identified as having protein phosphorylating activity, together with being 
localized within the nucleus to regulate gene expression [69], [70]. Notably, this 
protein phosphorylation activity, whereby a phosphate group from PKM2’s substrate 
PEP is transferred to both tyrosine and serine/threonine residues of a variety of 
proteins, is only observed when PKM2 is in the dimeric state. This leads to a model 
whereby cytosolic PKM2, when in a tetrameric state, functions within glycolysis by 
acting on PEP to produce ATP and pyruvate, but when in the dimeric state is 
translocated to the nucleus where it uses PEP to phosphorylate protein substrates 
(Figure 1.2B). Importantly, the regulation of these pleiotropic activities of PKM2 is 
dependent on the nutrient status of the cell, where the metabolites SIACAR and FBP 
act as allosteric regulators of PKM2 activity and thus determine whether the enzyme 
functions as a pyruvate kinase in the cytoplasm, or a protein kinase in the nucleus [71].  
Recent studies have identified other metabolic enzymes that contribute to 
oncogenesis through unconventional mechanisms, which are distinct from their 
traditional roles within primary metabolism. One example is hexokinase-2 (HK2), 
which performs the first irreversible metabolic reaction for glucose utilization in cells. 
Much like PKM2, HK2 is one of the four isozymes found in human tissues, where it is 
often highly expressed in aggressive cancers. The HK2 enzyme has the highest 
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catalytic efficiency of the four HK isozymes, due to two distinct structural 
characteristics. First, HK2 harbors two duplicated catalytic-active domains within one 
polypeptide chain, as a result of gene duplication during evolution, whereas the other 
three isozymes have one [72], [73]. Second, the HK2 isozyme contains an N-terminal 
hydrophobic domain that promotes its association with the outer mitochondrial 
membrane [74]. The anchoring of HK2 to the outer mitochondrial membrane allows it 
to sense the viability of mitochondria through the binding of the integral membrane 
protein and voltage-dependent anion channel (VDAC). In addition, sequestering HK2 
on the mitochondrial membrane promotes its enzymatic activity by giving it access to 
mitochondrial ATP and shielding it from product inhibition by glucose-6-phosphate 
(G-6-P) [75], [76]. Together these characteristics make the HK2 isoform a highly 
efficient glucose kinase, thereby promoting the Warburg effect (Figure 1.3A). The 
increased HK2 efficiency, compared to other HK isoforms, has been shown to be 
responsible for supporting aerobic glycolysis (i.e. the Warburg effect) and cancer cell 
proliferation, and a direct downstream target of the PI3K/Akt signaling cascade [77]–
[79]. Importantly, this dramatic increase in a virtually irreversible metabolic step 
within glucose metabolism enables radiologists to take advantage of this metabolic 
shift by using an 
18
F-deoxyglucose (FGD) probe for positron emission tomography 
(PET), which has become the standard imaging technique for many solid tumors [76], 
[80] (Figure 1.3B,C). 
The targeting of HK2 in cancer has long been a challenge due to the highly 
accessible and polar surface of the substrate binding site, as well as the inhibitory 
allosteric site for the product, glucose-6-phosphate (G6P) [81]. However, Lin and 
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colleagues (2016) have recently identified glucosamine derivatives through high-
throughput screening efforts to find HK2 selective inhibitors. These glucosamine 
derivatives represent a new strategy for the selective inhibition of HK2, but not HK1 
isozymes, through the competitive binding of the substrate glucose. The finding of 
HK2-specific inhibitors through targeting the glucose binding site is an unexpected 
result. These new small molecules open the door for the development of new 
therapeutics to target the principal step that initiates the Warburg effect.  
Despite HK2’s role in promoting the Warburg effect in many cancers, perhaps 
an equally important function for HK2 in cancer cells is its involvement in apoptosis. 
Early observations of hexokinase activity within cellular extracts of cancer cells 
showed a localization of this activity with the mitochondrial fraction. More 
specifically, this activity was found on the outer mitochondrial membrane [82]. 
Investigations into this observation found that the prevalent form of hexokinase in 
cancer cells, HK2, was associated with the outer mitochondrial membrane through the 
binding of VDAC (Figure 1.3A). This interaction of HK2 with VDAC was shown to 
act as a sensor for mitochondrial membrane potential, where disruption of the proton 
gradient within the inner-membrane space would dissociate the adenosine nucleotide 
transporter (ANT) from VDAC, releasing HK2, and allowing apoptotic proteins with 
BH3 domains, such as Bax and Bad, to bind to VDAC and facilitate the release of 
cytochrome C [79], [82]–[84]. Cytochrome-c release results in the initiation of caspase 
activation, triggering apoptosis throughout the cell. This release of cytochrome c 
following oxidative stress provides a molecular mechanism for HK2, involved at the 
first step of glycolysis, to couple nutrient stress with the apoptotic response. 
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FIGURE 1.3 – HK2 is an efficient glucose kinase that drives the Warburg effect 
and enables the use of 
18
F-FDG PET to image cancers. (A) X-ray crystal structure 
of HK2 in complex with the allosteric inhibitor, glucose-6-phosphate (G6P), and a 
glucosamine derivative in the glucose binding pocket (5HG1). The 15-residue 
long hydrophobic N-terminus of HK2 is shown associating with the outer 
mitochondrial membrane, where the N-terminus of HK2 binds to the ion channel 
VDAC, which couples to the adenosine nucleotide transporter (ANT) on the inner 
mitochondrial membrane. (B) The use of 
18
F-deoxyglucose as a diagnostic tool 
depends on the import of glucose through abundant glucose transporters, such as 
GLUT1, on the plasma membrane. Upon import, FDG is readily phosphorylated 
in highly proliferative cells, but not normal cells, and becomes trapped within the 
cell and unable to be metabolized further. (C) An example of the utility of FDG-
PET in human cancers [79]. Here, a patient with non-small cell lung cancer 
(NSCLC) is monitored using FDG-PET imaging following treatment with the 
EGFR kinase inhibitor erlotinib. The solid tumor (left, red arrow) is visualized 
before, but not after, 14 days of treatment.  
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1.1.3 Metabolic enzymes as oncogenes and tumor suppressors 
Both of these enzymes, HK2 and PKM2, are examples of how metabolic 
enzymes, and in particular isozyme switching of the enzymes, can play vital roles in 
orchestrating the Warburg effect. However, neither of these enzymes are sufficient by 
themselves to drive oncogenesis, and are therefore thought to be essential for 
supporting the transformed state, but not driving it. In contrast, genetic mutations in a 
few metabolic enzymes have been shown to drive cells to the transformed state, 
resulting in the formation of solid tumors. Interestingly, the altered enzymes that have 
been identified are all localized to the mitochondria and function within the TCA 
cycle.  
The first metabolic enzyme identified to drive tumor formation was the product 
of inherited genetic variants of the succinate-ubiquinone oxidoreductase complex II, 
known more commonly as succinate dehydrogenase (SDH). These genetic variants 
were within the nuclear gene encoding the D subunit, SDHD [39], [85], [86]. 
Respiratory complex II is a multi-protein complex comprised of four subunits, SDHA, 
SDHB, SDHC, and SDHD, that act together to oxidize the TCA cycle intermediate 
succinate to fumarate (Figure 1.4). This is accomplished by an initial hydride transfer 
from succinate to a bound flavin adenine dinucleotide (FAD
+
) molecule in SDHA to 
produce FADH2 and release fumarate. The reduced FADH2 then transfers the 
electrons to iron sulfur clusters in SDHB, where the electrons are finally accepted by 
the ultimate carrier molecule ubiquinone (Q) to form hydroquinone (QH2) within the 
mitochondrial transmembrane subunits SDHC and SDHD. Respiratory complex II is 
an integral membrane protein within the mitochondria, that functions to not only 
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maintain the TCA cycle turnover, but also to add reducing equivalents of 
hydroquinone and fuel the proton transport of respiratory complex III, a prerequisite 
for generating a membrane potential. Therefore, defects in this enzyme that result in 
ablating its activity have drastic effects on both the metabolite pools throughout the 
cell, and the membrane potential necessary to maintain healthy mitochondria. 
Originally, germline mutations in the SDH subunits D, and later both B and C, 
were identified in cases of familial head and neck paragangliomas and sporadic 
pheochromocytomas.  Paragangliomas are of neuroendocrine origin derived from the 
sympathetic nervous system along the cranial nerves and vasculature [39], [87], 
whereas pheochromocytomas are extra-adrenal tumors derived from the adrenal 
medulla cells and produce catecholamines, often causing the hypertension that 
characterizes the condition [85], [86]. These tumors are well studied because they are 
often driven by germline mutations in well-known proto-oncogenes and tumor 
suppressors, such as RET, NF1, Myc association factor (Max), VHL, HIF2A, or 
TMEM127. In the course of searching for the drivers in tumors that do not harbor the 
known proto-oncogene and tumor suppressor mutations, germline and somatic 
mutations in the SDH gene products were subsequently discovered [88]. In addition to 
a variety of mutations identified in the principal components of the heterotetrameric 
SDH enzyme, occurring in the SDHA, B, C, and D subunits, point mutations have also 
been identified in the gene that encodes the flavin-transferase for SDH, named SDH5 
[89]. SDH5 is a recently characterized mitochondrial protein that associates with 
SDHA to facilitate the covalent attachment of the flavin adenine dinucleotide (FAD
+
) 
moiety through a poorly understood mechanism. 
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FIGURE 1.4 – Enzymes of the TCA cycle and glutaminolysis pathways. Each 
subunit of a mitochondrial complex is colored in blue or cyan, representing 
oligomeric species of each enzyme along the pathway. Substrates and cofactors 
are displayed when available as spheres in CPK coloring, highlighting the general 
trend of binding sites being proximal to oligomer-contacts. Enzymes that function 
as tumor suppressors, where mutations or deletions give rise to human cancers, 
are highlighted with red boxes. PDB files used for each enzyme are as follows. 
Pyruvate dehydrogenase, only the E1 subunit octahedral supercomplex is shown 
where the E2 and E3 subunits are omitted for simplification (1B5S), citrate 
synthase (1CTS), aconitase (7ACN), and isocitrate dehydrogenase 2 (3BLW). 
Alpha-ketoglutarate dehydrogenase was constructed using the E1 dehydrogenase 
(2JGD). Also included are E2 dehydrogenase (1E2O), and E3 dehydrogenase 
(2EQ7), succinyl-CoA synthetase (2FP4), succinate dehydrogenase (1NEK) with 
the newly described flavoprotein transferase SH5 (2LM4), fumarate hydratase 
(3E04), malate dehydrogenase (4WLU), glutamate dehydrogenase (1HWY), 
glutamate-pyruvate transaminase (3IHJ), glutamate-oxaloacetate transaminase 
(5AX8), and glutaminase (3UO9). 
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Mutations of SDH5 found in human tumors occur at a highly conserved fold 
mapped to the binding interface of SDH5 to SDHA, and are associated with an 
inactive SDH enzyme [89], [90]. These mutations in components of the SDH complex 
all result in an inactive form of the enzyme, thereby increasing the metabolite pool of 
succinate. The excess succinate acts to competitively inhibit critical enzymes that use 
the TCA cycle intermediate -ketoglutarate (KG) as a substrate. The enzymes that 
have been shown to be most impacted by increased levels of succinate in SDH 
deficient cells are the KG-dependent prolyl hydroxylases (PHDs) that function to 
regulate the tumor suppressor HIF, as well as the nuclear Jumonji demethylases and 
TET hydroxylases, by impairing DNA and histone methylation levels [91]–[94]. The 
accumulation of the intracellular pool of succinate, that is a result of deficiencies in 
SDH activity, has severe impacts on oxidative stress and epigenetic regulation of gene 
expression. This has provided important insights as to the role primary metabolism 
plays in growth, differentiation, and cancer. As is the case with SDH, mutations in 
other TCA cycle enzymes, namely fumarate hydratase (FH) and isocitrate 
dehydrogenase (IDH), also give rise to oxidative stress, induction of hypoxia-related 
genes, and epigenetic changes [95].  
The identification of cancer causing mutations within the gene encoding 
fumarate hydratase, also known as fumarase, followed a similar path to discovery as 
that of SDH. Initially, genetic alterations in the chromosome 1q42.3-q43 region were 
found to be associated with familial inheritance of cutaneous and uterine 
leiomyomatomas, which are benign smooth muscle tumors, and type II papillary renal 
cell carcinoma [96]–[98]. Fumarate hydratase functions to metabolize fumarate in both 
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the cytoplasm, where fumarate is a byproduct of the urea cycle, and the mitochondria, 
where fumarate is a key TCA cycle intermediate [99]. Currently, it is thought that FH 
requires the formation of homotetramers in order to be catalytically active, although 
structural studies of the human enzyme are lacking [100]. However, there seem to be a 
variety of truncations, point mutations, and missense mutations that have been 
identified and associated with tumorigenesis. Again, as is the case for SDH, FH 
mutants are associated with a loss of enzyme activity and therefore an increase of 
intracellular levels of the TCA cycle intermediate fumarate and the upstream substrate 
succinate. Indeed, the increased level of fumarate in cells has been shown to promote 
the Warburg effect through activation of HIF genes by inhibiting the prolyl 
hydroxylase enzymes that act to keep HIF levels regulated in oxygen-abundant 
environments [41]. In addition to the activation of HIF driven transcription, fumarate 
has been shown to be involved in the post-translational modification of free thiol 
groups of both glutathione and cysteine residues within proteins in FH-deficient cells, 
promoting oxidative damage by ROS [42], [101], [102]. These observations further 
support the view that disabling mutations within the TCA cycle can promote 
neoplasia, by causing the accumulation of tumor promoting oncometabolites. 
Perhaps one of the most significant breakthroughs in the field of 
oncometabolites was the discovery that mutations within the active site of the TCA 
cycle enzyme isocitrate dehydrogenase (IDH) are found in a large percentage (~12%) 
of tumors of glioblastoma multiforme (GBM), with an even greater occurrence in 
higher grades of glioblastoma [103]–[105]. Moreover, the mutations in the active site 
confer a neomorphic enzyme activity, producing the unnatural byproduct D-2-
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hydroxyglutarate (2-HG) from KG [106]. There are three isoforms of IDH, a 
cytosolic form (IDH1) and two mitochondrial forms (IDH2/3), which function in their 
respective cellular compartments to catalyze the decarboxylation of isocitrate to 
produce KG and release CO2 upon concomitant reduction of NADP
+
 to NADPH for 
IDH1/2, or NAD
+
 to NADH for IDH3. The mutations that have since been identified 
in not just GBM, but also other cancers such as renal cell carcinoma (RCC) or acute 
myelogenous leukemia (AML), all have the same specific point mutation of a critical 
arginine residue within the active site (R134 in IDH1, either R172 or R140 in IDH2) 
[105], [107], [108]. Interestingly, the IDH3 isozyme possesses not only a different 
substrate specificity for NAD
+
 (as opposed to NADP
+
), but also a distinct quaternary 
structure. Specifically, IDH1 and IDH2 exists as homo-dimers, whereas IDH3 forms a 
hetero-trimer of subunits alpha, beta, and gamma [109]. To date, no mutations in the 
IDH3 isozyme have been associated with tumorigenesis or cancer progression, 
highlighting the unique property of IDH1/2 mutants to promote cancer [110]. The 
accumulation of the oncometabolite 2-HG appears to act through a similar mechanism 
as that observed for accumulations of intracellular succinate, where both act as 
competitive inhibitors of KG-dependent enzymes. The result is an activation of the 
transcriptional program that results from HIF1 stabilization as well as changes in 
DNA methylation that act together to promote oncogenesis [37], [40], [43].  
Taken together, these observations highlight the role that core metabolic 
enzymes can play in supporting the transformed state and directly driving 
tumorigenesis. The dysregulation of the metabolic enzymes IDH, SDH, and FH, 
through either hereditary or somatic mutations has shifted the paradigm and 
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underscored the important role metabolic pathways play in cellular transformation.  
1.1.4 Glutaminolysis as an anaplerotic source for cells under metabolic stress 
As mentioned earlier, the shift of cancer cells under metabolic stress from 
oxidative phosphorylation to aerobic glycolysis leaves the mitochondrial TCA cycle 
without glucose-derived carbon sources such as acetyl-CoA. Therefore, cells 
exhibiting the Warburg effect require an alternative carbon source to replenish the 
TCA cycle intermediates. It has been shown in a variety of cell culture and tumor 
models that the increase in aerobic glycolysis is often accompanied by an increase in 
glutamine metabolism [111]–[116]. In this way, glutamine, being the most abundant 
amino acid in the blood, is deamidated by mitochondrial glutaminase (GLS) to 
produce stoichiometric amounts of glutamate and ammonia. The glutamate produced 
from the glutaminase reaction is then deamidated by the mitochondrial enzyme 
glutamate dehydrogenase (GDH), or by one of the two mitochondrial transaminases, 
pyruvate transaminase (GPT) or oxaloacetate transaminase (GOT), to result in 
production of -ketoglutarate that can directly enter the TCA cycle (Figure 1.4). 
The metabolite -ketoglutarate plays an essential role in the proliferating cell, 
where it is a common substrate for many metabolic pathways. In addition, it has 
recently been shown in many cancers that -ketoglutarate can be carboxylated to 
produce citrate by the TCA cycle enzyme IDH1/2 (discussed above) in a process 
termed reductive carboxylation [117]–[119]. Reductive carboxylation is emerging as a 
process critical for the production of lipids within the cytoplasm/endoplasmic 
reticulum. It is here where mitochondrial citrate is exported to the cytoplasm and 
converted to acetyl-CoA, the building block for lipid synthesis, by the enzyme ATP-
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citrate lyase (ACL) [120]. Efforts to develop small molecule inhibitors of ACL hold 
promise for the treatment of human cancers that are driven by Akt/mTORC1 
metabolic phenotypes [121]–[123]. However, to date only one clinical trial is active, 
and that is for the targeting of hyperlipidemia (Esperion Therapuetics©). Perhaps, as is 
the case with the targeting of PKM2 (discussed above), these small molecules that 
target metabolic enzymes will prove useful in metabolic disorders first, where clinical 
trials for specific cancer groups or treatment regimens will follow.  
As mentioned above, glutamine fueled reductive carboxylation is an adaptive 
mechanism for highly proliferative cells using high aerobic glycolytic flux, by 
providing the biosynthetic precursors for the additional lipids required for continual 
cell division and growth. In this way, targeting the first committed step of 
glutaminolysis, namely the mitochondrial glutaminase, provides a way of targeting 
transformed cells that rely on glutamine metabolism. However, the regulation of 
glutaminase remains poorly understood despite its apparent upregulation in a variety 
of oncogenic signaling pathways, such as those involving c-Myc over-expression, 
HIF1 stabilization, and Rho-GTPase dependent transformation [114], [124]–[127]. 
Human glutaminase (hGLS) consists of two isozymes, GLS1 and GLS2, where GLS1 
has two alternatively spliced isoforms, kidney-type (KGA) and glutaminase C (GAC), 
with the GAC isoform being the primary isoform expressed in cancer cells (Figure 
1.5) [111], [128]–[130]. 
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FIGURE 1.5 – Isozymes and isoforms of glutaminase enzymes. The crystal 
structures of the liver-type and kidney-type glutaminases are presented, with their 
domains and corresponding residue assignments depicted above. Both 
glutaminases crystalize as homotetramers, despite having distinct catalytic 
properties. The short form, GAC, is primarily upregulated in cancer cells. 
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It has previously been shown that the activity of GAC is dependent on the oligomeric 
state of the enzyme. Increased activation in vitro is promoted by the allosteric 
regulator inorganic phosphate, which causes GAC to undergo a dimer (inactive) to 
tetramer (active) transition [131], [132]. However, thus far a mechanistic 
understanding for GAC activation has been lacking, and a detailed picture of this 
would shed light on how its activation in cancer cells can be blocked by newly 
characterized small molecule inhibitors, and how one might improve existing 
platforms [137], [138].  
PROPOSED STUDIES 
In the initial phase of the this thesis, I will take advantage of a Fluorescence 
Resonance Energy Transfer (FRET) assay that I have developed to directly monitor 
the dimer-to-tetramer transition of GAC in combination with real time and single point 
activity assays in order to probe the dependence of its oligomeric state on activity 
(Chapter 2). After validating these approaches, I then use them in studies to gain 
insights into the mechanism of action of the two glutaminase-specific inhibitors, 
derivatives of the benzophenanthridines (e.g. 968), and BPTES (bis-2-(5 
phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide) (Chapters 3 and 4, respectively). 
In order to specifically study the role of GAC up-regulation and activation in 
oncogenic transformation and its possible role in glutamine addiction, I make use of a 
model cell system using tetracycline controlled gene expression in mouse embryonic 
fibroblasts (MEFs) to examine the effects of the induced expression of the oncogenic 
Rho GTPase GEF (guanine nucleotide exchange factor) Dbl (for Diffuse B-Cell 
Lymphoma) and subsequent hyper-activation of Rho GTPases (Chapter 5). Our 
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laboratory and others have reported the activation of glutaminase in mitochondrial 
extracts from transformed cells in response to mitogenic stimuli and the hyper-
activation of Rho GTPases, or upon EGF stimulation in a Raf-Mek-Erk-dependent 
manner [127], [133]. In addition, using the mechanistic insights gained from Chapters 
2-4, I investigate the oligomeric status of the GAC enzyme in Dbl-induced 
transformed cells and in non-transformed (uninduced) cells, and show that an increase 
in glutaminolysis in Dbl-induced cells correlates with the shift from a GAC dimer to a 
GAC tetramer (Chapter 5). Additionally, I use these biophysical approaches to analyze 
mouse tissues, showing that these oligomeric states are indeed conserved in biological 
tissues, and present methods to purify and characterize a newly discovered high-
molecular weight GAC species (Chapter 5). 
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CHAPTER TWO 
Fluorescence resonance energy transfer (FRET) assay to read-out GAC tetramer 
formation and its response to allosteric activators and inhibitors. 
2.1 INTRODUCTION 
Recent advances in the understanding of cancer onset and progression have 
helped shed light on the interconnection between signal transduction pathways 
frequently observed in human tumors, and metabolic remodeling, which often 
accompanies oncogenic transformation [1], [2]. The relationship between canonical 
signal transduction pathways often mutated in human cancers, and accompanying 
changes in cellular metabolism that support neoplastic growth, provides the motivation 
to understand these altered metabolic pathways more clearly and identify potential 
targets for therapeutic intervention. The two major metabolic pathways that have been 
shown to have aberrant regulation in cancer cells, when compared to their non-
transformed precursors, are the glycolytic pathway responsible for oxidizing glucose 
to pyruvate, and glutaminolysis, which converts imported glutamine to glutamate, 
where glutamate can be metabolized further in a variety of energetic and biosynthetic 
pathways [2]–[6]. The mitochondrial enzyme glutaminase is responsible for the 
deamidation of cellular glutamine, producing glutamate and ammonia.  Its regulation 
still remains poorly understood despite its critical role in a variety of oncogenic 
signaling pathways, such as those involving c-Myc over-expression, HIF1- 
stabilization, and Rho-GTPase dependent transformation [2], [7]–[9].  
Human glutaminase (hGLS) consists of two isozymes, GLS1 and GLS2, where 
GLS1 has two alternatively spliced isoforms, kidney-type (KGA) and glutaminase C 
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(GAC), with GAC being the primary isoform expressed in cancer cells [10]–[15]. It 
has been shown previously that the activity of GAC is dependent on the oligomeric 
state of the enzyme, suggested to be a homo-tetramer [16]–[18]. Additionally, GAC 
activity was notably stimulated in vitro by the allosteric regulator inorganic phosphate, 
suggesting that the binding of phosphate to GAC stabilizes the active form (tetramer) 
of the enzyme [18]–[20]. 
Initial studies of glutaminase enzymes (EC 3.5.1.2) identified various oligomeric 
forms of these proteins from different tissues. The three oligomeric species originally 
described for the GLS1 proteins were a KGA dimer, tetramer, and high molecular 
weight oligomer (i.e. greater than a 20-mer) [16], [17], [21]–[23]. The high molecular 
weight oligomer was shown to be induced by the addition of multivalent anions, such 
as phosphate, sulfate, and borate. In fact, original methods for the purification of 
glutaminase enzymes involved protein precipitations of solubilized tissues using these 
anionic salts, where glutaminase enzymes would be found in the pellet of centrifuged 
tissue lysates [21]. Once purified, biochemical studies of these native enzymes indeed 
established that they exhibited high glutaminase activity, following the addition of 
anionic salts, and in particular, when activated by inorganic phosphate [23], [24]. The 
activation by phosphate was shown to be dose dependent and highly cooperative in 
nature. Studies using analytical centrifugation and size-exclusion chromatography 
showed the presence of different oligomeric enzyme species, including a dimer, 
tetramer, and higher molecular weight form of the enzyme. How these different states 
were able to interconvert, which state exhibited maximal activity, and overall 
mechanistic basis for the regulation of these interconversions, remained elusive.  
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The most significant clue regarding how these oligomeric forms of glutaminase 
were assembled came when the X-ray crystal structures of the mouse and human 
forms of GAC were determined [11], [25], [26]. These structures showed a GAC 
tetramer in the asymmetric unit, giving a clear picture of the subunit contacts (Figure 
2.1). The crystal structures revealed two principal interfaces of the enzyme, namely 
the dimer-dimer and monomer-monomer interfaces (Figure 2.1, top inset). The 
monomer-monomer interface included a large surface area, with the major contacts 
between the two subunits resembling a lock-and-key fit. However, the dimer-dimer 
interface included significantly less surface area, and seemed to be governed by the 
association of two anti-parallel -helices (Figure 2.1, bottom inset).  
Thus far, the mechanistic basis for GAC activation has not been elucidated in 
great detail, and in particular, how its activation in cancer cells can be blocked by 
newly characterized small molecule inhibitors, despite the great deal of interest in 
targeting this pathway [7], [11], [13], [18], [26]–[33]. In the initial phase of this study, 
I take advantage of a fluorescence resonance energy transfer (FRET) assay that I have 
recently developed to directly monitor the dimer-to-tetramer transition of GAC, 
together with real time and single point activity assays to probe the dependence of its 
oligomeric state on activity. These approaches will set the stage for studies that should 
provide insights into the mechanism of action of the two glutaminase-specific 
inhibitors, BPTES (bis-2-(5 phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide), and 
derivatives of the benzophenanthridines (e.g. 968) reported previously by our 
laboratory and others [7], [18], [28], [31], [34]. 
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FIGURE 2.1 – X-ray crystal structure of tetrameric GAC. The crystal structure of 
GAC is depicted with surface representation, where the monomers of a GAC 
dimer are represented in either blue or cyan (3UO9) [9]. The dimer and tetramer 
interfaces are highlighted to display critical polar contacts between the two 
monomers and dimers, respectively. Residue numbering is for mouse GAC. 
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2.2 METHODS 
2.2.1 Recombinant glutaminase preparation and labeling with spectroscopic 
probes 
A plasmid encoding the mouse kidney-type glutaminase isoform 2 (GAC, 
NP_001106854.1) (residues 72-603) was cloned into a pET23a vector containing an 
N-terminal histidine (His)-tag and thrombin cleavage site. The expressed protein was 
purified using Co
2+
 affinity beads (Clontech), followed by His-tag cleavage with 
human thrombin (Haemetologic Technologies) overnight at 4°C, and subsequently 
purified by anion exchange (GE healthcare) and gel filtration chromatography.  
Purified GAC was stored in a high salt-containing buffer (20 mM Tris-HCl pH 8.5, 
500 mM NaCl, 1 mM NaN3) at -80°C, following snap freezing in liquid N2 for long 
term use.  Labeling recombinant GAC with small molecule probes was performed by 
exchanging 1.5 mg of enzyme into 50 mM HEPES, pH 7.2, and 100 mM NaCl 
(labeling buffer), using a PD10 desalting column (GE healthcare). The enzyme was 
then incubated with 50 M (5-fold excess of enzyme) of either AlexaFluor 488 
succinimidyl ester or QSY9 succinimidyl ester (Molecular Probes) for 1 h at 4°C.  
After 1 h, the labeling reaction was quenched with 150 mM Tris-HCl, pH 8.5, and 
unreacted probe was separated from labeled-enzyme using a PD10 desalting column, 
eluting labeled-GAC back into the high salt-containing buffer.  The stoichiometry of 
labeling was determined using the probe manufacturer’s reported molar absorptivity 
values and instructions. Briefly, the concentration of GAC was determined by first 
correcting absorbance at 280 nm for the Abs280 of each probe, using the reported 
correction values (0.11 for AlexaFluor 488 and 0.23 for QSY-9) and their absorbance 
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values at their absorbance maxima (495 nm and 562 nm, respectively).  The corrected 
Abs280 was used along with the experimentally determined molar absorptivity of GAC 
(280 = 38,850 M
-1
 cm
-1
).  AlexaFluor 488 and QSY-9 probes were quantified using 
their respective absorbance maxima and the manufacturer’s reported molar 
absorptivity values (495 = 71,000 M
-1
 cm
-1
 and  = 85,000 M
-1
 cm
-1
).  The labeling 
stoichiometry for 488-labeled and QSY-9 labeled GAC was found to be 0.49 ± 0.09 
and 1.00 ± 0.05 respectively, where stoichiometry is defined as moles probe/moles 
protein.  
2.2.2 FRET assays  
Fluorescence experiments were performed using a Varian Cary Eclipse Fluorometer in 
the counting mode.  Excitation and emission wavelengths were 490 and 520 nm, 
respectively.  Experiments were all performed using 1-mL samples with continuous 
stirring at 20°C in 50 mM Tris-Acetate, pH 8.5, 0.1 mM ethylenediamine tetraacetic 
acid (EDTA).  For wild-type (WT) GAC titrations in the absence of inorganic 
phosphate, 25 nM 488-GAC was equilibrated with 25 L of QSY9-GAC (at varying 
concentrations) and allowed to equilibrate for 10 minutes, at which point 75 L of the 
appropriate concentration of unlabeled WT GAC was added to provide a 10-fold 
excess over labeled-GAC.  To test whether the purified GAC mutants can form 
oligomers with WT GAC, 200 nM QSY9-GAC (D391K) or 200 nM QSY9-GAC 
(D391K, K316E, R459E) was added to an equilibrated sample of 20 nM 488-WT 
GAC.  When assaying the effects of BPTES and 968 on oligomer formation, BPTES 
or 968 was added following equilibration of a sample of 25 nM QSY9-WT GAC and 
25 nM 488-WT GAC.  Both BPTES and 968 were prepared in DMSO, and 
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appropriate dilutions were made so that less than 2% (v/v) DMSO was added to an 
experimental sample. 
2.2.3 Real-time 968 binding and enzyme activity assays 
Real-time fluorescence monitoring of 968 binding and GAC activity through 
production of NADH was performed on a Varian Cary Eclipse Fluorometer, whereas 
small molecule inhibition and binding titrations were performed in a 96-well format in 
a Tecan Saphire absorbance and fluorescence plate reader.  Samples for monitoring 
real-time binding of 968 to 488-GAC were prepared by adding 10 L of varying 
concentrations of 968 prepared in DMSO to an equilibrated 1 mL sample of 10 nM 
488-GAC, while observing 488 fluorescence (490 nm excitation/520 nm emission).  
Similarly, this method was replicated for monitoring real-time binding of 968 to 
mutant forms of GAC, namely 488-labeled GAC (GD391K) and 488-GAC (D391K, 
K316E, R459E).  Real-time activity assays monitoring 968 binding and NADH 
production were prepared in 1 mL samples, where 10 units of glutamate 
dehydrogenase (Sigma) and 2 mM NAD
+
 (Sigma) were prepared in 50 mM Tris-
Acetate, pH 8.5, 0.1 mM EDTA and equilibrated at 20°C.  WT GAC (10 nM) was 
added and allowed to equilibrate 2 minutes before monitoring the fluorescence 
emission of 488-GAC (490 nm excitation, 520 nm emission) and NADH (340 nm 
excitation, 490 nm emission).  Appropriate dilutions of 968 or BPTES prepared in 
DMSO were introduced after 30s and allowed to equilibrate for 2 minutes before a 
180 L solution of K2HPO4 and glutamine was added to make a final concentration of 
50 mM K2HPO4 and 20 mM glutamine, to initiate GAC activation.  The activity of 
GAC was measured in a coupled assay, by monitoring the NADH produced by 
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glutamate dehydrogenase, which converts the product of the glutaminase-catalyzed 
reaction, glutamate, to α-ketoglutarate and ammonia by reducing NAD+ to NADH.  
Because solutions containing glutamine undergo non-enzymatic degradation to 
glutamate, samples were further analyzed by subtracting the NADH produced by 
glutaminase in the presence of 968, BPTES, or the equivalent volume of DMSO as a 
control, from the NADH produced in the absence of glutaminase under identical 
experimental conditions.  NADH was quantified using a standard curve of freshly 
prepared NADH (Sigma) in 50 mM Tris-Acetate, pH 8.5, and 0.1 mM EDTA.  
2.2.4 End-point glutaminase activity assays  
Activity assays used to compare FRET values and evaluate the activity of GAC 
mutants followed a two-step protocol adapted from Robinson et al. (2007) (2).  
Briefly, 20 L of 20 mM glutamine, 50 mM Tris-acetate, pH 8.5, and 0.1 mM EDTA, 
in either the presence or absence of a K2HPO4, was added to a UV-transparent Costar 
96-well plate (Corning). To initiate the reaction, 5 L of a solution of the appropriate 
concentration of GAC, prepared in 20 mM Tris-HCl, pH 8.5, 100 mM NaCl, and 1 
mM NaN3, was added to the glutamine solution and incubated at 23°C for 2 min 
before the reaction was quenched using 2.5 L of 3 M HCl.  For reactions that 
contained more than 250 nM GAC, the first reaction was quenched at 30 seconds 
instead of 2 min.  The second step was initiated by the addition of 200 L of 12 
units/L GDH, 2 mM NAD+, 100 mM hydrazine (Sigma), and 100 mM Tris-HCl, pH 
9.2, on top of the first quenched reaction and incubated for 45 min at 23°C before 
reading NADH absorbance.  Glutamate produced by the first reaction was determined 
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from the amount of NADH generated in the second reaction by using the extinction 
coefficient for NADH (6,220 M
-1 
cm
-1
). 
2.2.5 Multi-angle light scattering (MALS) 
Purified GAC and GAC mutants were subjected to multi-angle light scattering 
(MALS) as previously described by Moller et al. (2013) (3).  Briefly, 50 L samples 
of 5 mg/mL GAC were injected onto a WTC-030S5 size-exclusion column (Wyatt 
technology), coupled to a static 18-angle light scattering detector (DAWN HELEOS-
II) and a refractive index detector (OptiLab T-rEX, Wyatt Technology), at 23°C.  The 
size-exclusion column was equilibrated with 20 mM Tris-HCl, pH 8.5, and 200 mM 
NaCl with or without 50 mM K2HPO4.  The flow rate was kept at 1 mL/min.  RMS 
radius and mass distribution (polydispersity) were analyzed using the ASTRA 
software, with monomeric BSA (Sigma) serving to normalize the light scattering 
signal. 
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2.3 RESULTS 
2.3.1 Development of a real-time assay to detect tetramer formation of GAC 
The dimer-to-tetramer transition of GAC been suggested to be essential for 
enzyme activity [17], [23]. Additionally, allosteric activators have been proposed to 
promote activation by inducing the formation of tetramers. However, GAC tetramer 
formation and its role in enzyme activation have not been well characterized, having 
only been investigated through bulk enzyme assays and by ultra-centrifugation 
techniques [16], [21]. Thus, we sought to develop a highly sensitive fluorescence 
resonance energy transfer (FRET) assay that detects the formation of GAC tetramers 
from dimers, in order to describe the oligomer dynamics in real-time. Figure 2.2 
depicts the proposed FRET assay, where oligomer formation is monitored between 
two populations of purified recombinant GAC, labeled with either the highly 
fluorescent AlexaFluor 488 (donor) probe, or with the non-fluorescent QSY9 
(acceptor) chromophore (Figure 2.2). These two probes have a Förster distance (R0) of 
64 Å, making them highly useful for monitoring FRET between two GAC dimers 
within the tetrameric complex, where the largest dimension of the unit cell from 
solved X-ray crystal structures for tetrameric GAC is ~150 Å. Additionally, a major 
advantage of using FRET as a direct read-out for GAC tetramer formation is the 
ability to perform measurements at the relatively low concentrations of GAC 
commonly used for assaying its enzymatic activity. 
The labeling of GAC by the FRET donor, AlexaFluor 488-succinimidyl-ester, 
resulted in the rapid and stoichiometric covalent modification of GAC, where 488-
GAC was easily identified using SDS-PAGE (Figure 2.3A). 
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FIGURE 2.2 – FRET assay for GAC tetramer formation. A population of highly 
fluorescent 488-labeled GAC subunits are quenched by the addition of the FRET 
pair of non-fluorescent QSY9-labeled GAC subunits.  
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Additionally, the labeling of GAC did not alter the oligomeric state of the enzyme, as 
determined by analytical size exclusion chromatography (SEC) (Figure 2.3B), and the 
substrate and allosteric activator affinities for labeled GAC were also maintained 
(Figures 2.3C,D). Labeling GAC with the fluorescence donor and acceptor pair, 488- 
and QSY9-succinimidyl-ester, under identical conditions, resulted in a moderate 
inhibition of GAC activity. However, the Vmax is the only kinetic property that was 
altered by this covalent modification, where both the Km value for glutamine and K1/2 
value for phosphate were in good agreement with the values for WT GAC, suggesting 
the modification does not significantly alter the affinity for either the substrate or 
allosteric activators (Figure’s 2.3C,D). The site of covalent modification was shown to 
be within the conserved glutaminase domain, by means of mass spectrometry 
identification of peptide fragments produced by partial trypsin digestion and 
separation by SDS-PAGE (Appendix Figures 7.1A-D). 
Figure 2.4A depicts the FRET assay, where the addition of increasing 
concentrations of QSY9-GAC to 20 nM 488-GAC yielded a dose-dependent 
quenching of the donor 488 emission due to FRET. Additionally, the FRET signal was 
shown to be reversible upon the addition of excess unlabeled GAC subunits, which act 
to dilute the FRET pairs (i.e. tetramers), demonstrating that GAC tetramer formation is 
a dynamic process. Figure 2.4B represents the dose-dependent binding isotherm 
obtained from the QSY9-GAC titration profile from Figure 2.4A, which yielded an 
apparent KD of 164 nM (± 20 nM) for tetramer formation (Figure 2.4B, ()).  
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FIGURE 2.3 – Labeling of GAC with FRET probes. (A) 10 M GAC was reacted 
with 50 M 488-succinimidyl ester (pH = 7.2) and was monitored using SDS-
PAGE and visualized under UV illumination (i.e. fluorescence). The longest time 
point was analyzed adjacent to MW standards (left panel), and the time dependent 
labeling shown in the right panel. (B) Analytical gel filtration profiles of a 2.5 
mg/mL injection of WT GAC (—) and 488-labeled GAC (—), where the elution 
of the 488 probe (abs 490 nm, (—)) overlaps the A280 curves for both unlabeled 
and 488-labeled GAC. (C),(D) Glutamine and phosphate dependent activity 
curves of 50 nM WT, 488-labeled, and QSY9-labeled GAC, where 488 and 
QSY9-GAC exhibited a change in the maximum velocity. Labeled GAC was 
found to have a lower Vmax (by ~50%), but a highly similar K1/2 for phosphate (D, 
15 mM for 488-GAC and 27.3 mM for QSY9-GAC vs 21.5 mM for WT GAC), 
while retaining the WT Km for glutamine (C, 4.8 mM for 488-GAC and 3.7 mM 
for QSY9-GAC vs 4 mM for WT GAC).  
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The ability of GAC to form tetramers, as read out by this FRET assay, directly 
correlated with the basal activation of GAC that occurs at increasing protein 
concentrations (i.e. due to tetramer formation through mass-action)  (Figure 2.4B, 
()). Next, we investigated the effects of the known allosteric activator, inorganic 
phosphate, using this FRET assay. Inorganic phosphate was added to a population of 
GAC that consisted of 25 nM 488-GAC and 75 nM QSY9-GAC, so that the FRET 
signal was not maximal before addition of the allosteric activator. Figure 2.5A 
represents the real-time FRET measurements with and without the addition of 
inorganic phosphate, where phosphate was observed to induce a FRET signal upon 
injection. Indeed, this phosphate-induced FRET was dose-dependent, and was in good 
agreement with the activation of the WT enzyme (Figure 2.5B, compare () to ()). 
Together, these results support the contention that the GAC tetramer is the minimal 
unit for enzymatic activity, and that the potent allosteric activator, inorganic 
phosphate, promotes tetramer formation to elicit its effects on enzyme activity.  
Although these FRET measurements reflect the oligomerization of GAC, and 
suggest that oligomerization is required for activation, we were interested in 
developing specific oligomer-deficient mutations that would block both the monomer-
monomer interactions necessary for forming dimers, and the dimer-dimer interactions 
that give rise to tetramers. To accomplish this, we made use of available X-ray crystal 
structures, where the structure of GAC has been solved as a homo-tetramer in its 
asymmetric unit. Figure 2.1 illustrates a space filling model of a GAC tetramer, where 
the dimer and tetramer units are presented (left), along with zoomed in regions of the 
monomer-monomer and dimer-dimer interfaces (right).
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FIGURE 2.4 – Real-time fluorescence assay detecting GAC tetramer formation.  
(A) 25 nM 488-GAC (donor) fluorescence is quenched upon addition of QSY9-
GAC (acceptor) in a dose-dependent manner and reversed with the addition of a 
10-fold excess of unlabeled GAC. (B) FRET resulting from the titration of 25 nM 
488-GAC with increasing amounts of QSY9-GAC () overlaid with 
concentration-dependent in vitro activation of GAC ().  FRET data was fit to a 
quadratic binding isotherm. 
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FIGURE 2.5 – FRET assay as a read out for phosphate-induced GAC tetramers.  
(A) Addition of 100 mM HPO4
2-
 to an equilibrated population of 25 nM 488-GAC 
and 75 nM QSY9-GAC quenches 488-fluorescence. (B) FRET resulting from the 
titration of Pi to an equilibrated population of 488:QSY9-labeled GAC () 
overlaid with phosphate activation profile of unlabeled WT GAC (). Both curves 
were fit to a Hill equation and found to have a K1/2 for phosphate of 20.1 mM 
determined from FRET and 16.8 mM determined from enzyme activation assays. 
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Residues that were identified to be the principal electrostatic contacts at each interface 
are highlighted, where mutations that reversed the charge on one of the contacts were 
made. In particular, introduction of a lysine for the native aspartate at position 391, to 
create the D391K  mutant, was shown by multi-angle light scattering (MALS) to be 
sufficient for prohibiting the formation of GAC tetramers, and hence to being trapped 
in the dimeric state (Figure 2.6A, (—)). In addition to this new dimer mutant, 
mutations were made at the monomer-monomer interface within the D391K mutant 
background (i.e. by changing both the native lysine at position 316 and arginine at 
position 459 to glutamate residues), in order to create the K316E-D391K-R459E triple 
mutant, which yielded a constitutive GAC monomer (Figure 2.6A, (—)).  
These oligomeric-deficient GAC mutants, trapped in either the dimeric or 
monomeric form, were then labeled with the QSY9 FRET acceptor probe and used in 
FRET assays. Addition of these mutants to 488-labeled WT GAC resulted in the 
complete ablation of FRET when the constitutive monomer (QSY9-labeled K316E-
D391K-R459E) was added, with only a minor amount of FRET being observed for the 
constitutive dimer (QSY9-labeled D391K), when compared to the addition of QSY9-
labelled WT GAC (Figure 2.6B). These results show that the FRET signal resulting 
from the addition of QSY9-WT GAC to 488-labeled WT GAC is specifically 
dependent on the ability of GAC dimers to form tetramers. Furthermore, both of these 
oligomeric-deficient GAC mutants were shown to be inactive over a range of 
concentrations when assayed in the presence or absence of inorganic phosphate, 
showing that the ability of GAC to form tetramers is also required for enzyme 
activation. 
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FIGURE 2.6 – FRET assay is specific for GAC tetramer formation, but not 
the inactive dimer or monomer. (A) Multi-angle light scattering profiles of 250 
g (each) of WT GAC (—), D391K-GAC (—), and K316E/D391K/R459E-
GAC (—), where the solid line represents the elution of each species by 
monitoring refractive index (R.I.), and the broken line designates the 
calculated molecular weight for the species eluted at that time.  Reference lines 
for the molecular weights of the monomeric, dimeric, and tetrameric forms of 
the enzyme are included at 58 kD, 116 kD, and 232 kD respectively. (B) FRET 
assays upon addition of 200 nM WT QSY9-labeled GAC (—), the dimeric 
QSY9-GAC (D391K) (—), and QSY9-GAC (K316E/ D391K/ R459E) 
monomer (—) to 20 nM WT 488-labeled GAC. (C) Concentration-dependent 
enzymatic activities of WT GAC, GAC (D391K) dimer, and GAC (K316E/  
D391K/ R459E) monomer, without addition of phosphate and (D) with the 
addition of 100 mM phosphate. Activities were measured in a 2-step end-point 
activity assay where GAC was incubated in the presence of glutamine for 2 m 
at concentrations under 250 nM GAC, and for 30 s at concentrations above 
250 nM GAC. 
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2.3.2 Examining the effects of 968 and BPTES on the dimer-to-tetramer 
transition of GAC  
Having developed a FRET assay which detects the ability of GAC to form 
tetramers, we next examined how allosteric inhibitors of GAC affected its ability to 
form tetramers. There are currently two classes of allosteric inhibitors of GAC (Figure 
2.7A). One such class is comprised of derivatives of bis-thiadiazoles, where the small 
molecule BPTES is the prototype and has been shown by X-ray crystallographic 
studies to bind at the dimer-dimer interface of the GAC tetramer. The second class of 
compounds represents derivatives of the benzophenanthridines, with compound 968 
being the prototype. Thus far, 968 and its analogues have not been extensively 
characterized in terms of how they bind to GAC or how they inhibit the enzyme. To 
investigate the effects of these two classes of inhibitors on the ability of GAC to 
undergo tetramer formation, they were added to a mixture of WT QSY9-labeled and 
488-labeled GAC (Figure 2.7B).  
Consistent with previous findings that BPTES stabilizes an inactive, tetrameric 
form of GAC [18], [28], [35], we found that it caused an immediate quenching of 488-
GAC fluorescence emission when added to a mixture of 488-GAC and QSY9-GAC 
(Figure 7B, (—)), i.e. due to the ability of BPTES to induce the formation of 488-
GAC:QSY9-GAC (donor:acceptor) tetramers. The formation of these stable 
GAC:BPTES tetrameric complexes was dose-dependent, and less susceptible to 
reversal by the addition of unlabeled GAC (compare the (—) versus (—) traces in 
Figure 2.8A). Interestingly, 968 elicited a markedly different response, causing a 
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significant change in the fluorescence emission of 488-GAC, followed by a partial 
fluorescence recovery upon the addition of excess unlabeled GAC (Figure 2.7B, (—)).   
The recovery of 488-GAC fluorescence, upon addition of excess unlabeled GAC was 
due to the elimination of FRET between 488-GAC and QSY9-GAC, i.e. via the 
formation of mixed tetramers between 488-GAC or QSY9-GAC and unlabeled GAC.  
The quenching of the fluorescence was dose-dependent, but the fluorescence recovery 
by the addition of excess unlabeled GAC was not dependent on the concentration of 
968 (Figure 2.8B). Thus, 968 does not appear to interfere with GAC tetramer 
formation.  However, the inability to achieve a full recovery of the fluorescence 
emission suggested that 968 binding was directly affecting 488-GAC donor 
fluorescence emission.  Indeed, we found that 968 caused a dose-dependent quenching 
of 488-GAC emission (in the absence of the FRET acceptor QSY9-GAC) that 
matched the 968-mediated inhibition of GAC activity (Figures 2.9A,B). Taken 
together, these findings show that 968 does not mimic the actions of BPTES by 
trapping GAC in an inactive tetrameric state, but instead regulates GAC activity 
through a distinct allosteric mechanism. 
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FIGURE 2.7 – The FRET assay can distinguish between different allosteric 
inhibitors. (A) Structures of the two distinct allosteric inhibitors of GAC, 968 
and BPTES. (B) Addition of either BPTES (—) or 968 (—) to an equilibrated 
mixture of 25 nM 488-GAC and 75 nM QSY9-GAC quenches 488 
fluorescence, however, to different extents. For the case of BPTES, the 
quenching of 488-GAC fluorescence is not reversible by the addition of 
unlabeled subunits, whereas in the case of 968, some of the 488-GAC 
fluorescence is recovered, due to FRET pairs being substituted with unlabeled 
subunits. 
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FIGURE 2.8 – Quenching of 488-GAC by both BPTES and 968 is dose-
dependent. (A) Addition of increasing concentrations of BPTES to 25 nM 488-
GAC and 25 nM QSY9-GAC induces tetramer formation that is not reversible 
by addition of 10-fold excess unlabeled GAC; whereas addition of increasing 
concentrations of 968 (B) induces a dose-dependent quenching of 488-GAC 
fluorescence with partial recovery by addition of 10-fold excess unlabeled 
GAC. 
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2.3.3 968 preferentially binds to the monomeric state of GAC 
Docking analyses using the x-ray structure of the GAC tetramer, together with 
mutagenesis studies, suggested that 968 binds in a cove between the monomer-
monomer interface [31]. Therefore, we were interested in developing a direct binding 
assay that would discern whether 968 preferred to bind to a distinct oligomeric state. 
To address this, we took advantage of the newly developed oligomeric-deficient 
mutants, along with the novel direct binding assay using 488-labeled GAC, where the 
constitutive GAC dimer mutant (D391K) and the constitutive GAC monomer mutant 
(K316-D391K-R459E) were labeled with the AlexaFluor-488 succinimidyl-ester. 
These 488-labeled mutants were then subjected to fluorescence assays, where the 
quenching of the 488 probe upon addition of 968 was used as a direct binding read-
out. 
We found that 968 was capable of binding to WT 488-GAC, as well as to both 
the dimeric GAC (D391K) and the monomeric GAC (D391K-K316E-R459E), with 
the monomeric GAC having the highest affinity for 968 (Figure 2.10A).  These results 
suggested that 968 should be most effective at inhibiting WT GAC at relatively low 
enzyme concentrations, i.e. where equilibrium conditions favor GAC initially existing 
as a monomer. Figure 2.10B shows that when the concentration of GAC was 
decreased from 50 nM to 5 nM, 968 was able to inhibit GAC activity with a 
significantly greater potency. Furthermore, the 968-mediated inhibition of GAC 
activity at these low enzyme concentrations correlated well with its inhibition of 
oncogenic transformation.   
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FIGURE 2.9 – Quenching of 488-GAC fluorescence by 968 as a real-time 
read out for binding. (A) Fluorescence quenching upon addition of different 
concentrations of 968 to 20 nM 488-GAC in the absence of QSY9-GAC. (B) 
Quenching of 20 nM 488-labeled GAC fluorescence by 968 () and inhibition 
of 20 nM unlabeled WT GAC as measured by real-time NADH fluorescence 
emission (), where unlabeled WT GAC (20 nM) was assayed in place of 
488-labeled GAC.   
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These results show that 968 allosterically inhibits GAC activity by binding to the 
monomeric form, and inducing an inactive state of the enzyme. This is in stark 
contrast to the mechanism by which BPTES binds to and inhibits GAC activity. Figure 
11 illustrates the model of the activation of GAC, where inactive monomers form 
inactive dimers, which can ultimately form the active tetrameric species. BPTES, a 
prototype for a distinct class of allosteric inhibitors of glutaminase activity, binds to 
the tetrameric form of GAC at the dimer-dimer interface to promote inactive stable 
tetramers. Alternatively, the allosteric inhibitor 968 binds at the monomer-monomer 
interface of the inactive monomeric form of GAC. 
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FIGURE 2.10 – Examination of 968 binding to GAC monomeric and dimeric 
mutants. (A) 968 binding monitored by its quenching of the fluorescence of WT 
488-labeled GAC, the dimeric 488-GAC (D391K), and the monomeric 488-GAC 
(K316E/D391K/R459E) (10 nM total monomer in each sample). (B) In vitro 
inhibition curves of 50 nM () and 5 nM WT GAC () pre-incubated with 
increasing concentrations of 968. Overlaid is the dose-dependent inhibition by 968 
of Dbl-induced focus formation (▲). 
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FIGURE 2.11 – Model of allosteric regulation of glutaminase activity by small 
molecules and oligomer formation. Monomeric units of GAC associate to form 
dimers, where both monomer and dimer GAC species are catalytically inactive. 
GAC dimers then bind to form tetramers, which represents the active oligomer. 
BPTES (yellow spheres) binds at the GAC dimer-dimer interface to induce an 
inactive form of the tetrameric species (PDB 3UO9). Alternatively, 968 (orange 
spheres) binds to the monomeric form of GAC, presumably at the monomer-
monomer interface as suggested by Katt et al. 2013 [29]. These 968 bound 
monomers can form dimers, and prohibit the activation of the enzyme. 
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2.4 DISCUSSION 
 Previous studies of glutaminase isoforms described the oligomerization of these 
enzymes as a prerequisite for activation. However, it has remained unclear whether 
tetramer formation was required for activation, because no direct measurements have 
been made on the binding affinity of two dimers. Here, we set out to describe the 
formation of GAC tetramers using a direct binding assay, where one population was 
labeled with the highly fluorescent probe AlexaFluor488 to act as a FRET donor, and 
another labeled with the non-fluorescent QSY9 probe as the FRET acceptor. We found 
that this highly sensitive FRET assay enabled us to directly readout GAC tetramer 
formation, by monitoring the quenching of 488-labeled WT GAC following the 
addition of QSY9-labeled GAC. This FRET signal was readily reversible upon the 
addition of unlabeled GAC subunits, demonstrating the dynamic equilibrium of 
tetramer formation. Furthermore, we found that the dose dependent GAC tetramer 
formation directly correlated with enzyme activation, demonstrating that tetramer 
formation was indeed required for activation.  
 To show that this FRET assay was a direct read-out for tetramer formation, we 
made use of novel GAC mutants that were trapped in either the dimeric or monomeric 
state. The FRET signal was completely ablated when the acceptor-labeled monomeric 
GAC mutant was added to the donor-labeled WT GAC, and only a minor FRET was 
observed for the addition of the dimeric mutant, which is most likely due to the FRET 
resulting from a minor amount of monomer-monomer exchange. Lastly, we tested the 
activity of these GAC oligomeric-deficient mutants in the presence and absence of the 
allosteric activator, inorganic phosphate, and found that they were entirely inactive. 
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Taken together, these results show that the FRET assay developed here is an accurate 
read-out for the formation of GAC tetramers, and that tetramer formation is absolutely 
required for activation of the WT enzyme.  
 We then set out to understand how the allosteric inhibitors BPTES and 968 
inhibit the activity of GAC.  Because BPTES, a well characterized allosteric inhibitor 
of GAC, has been shown to bind and stabilize an inactive tetrameric form of the 
enzyme, one possibility was that 968 had a similar effect.  The highly sensitive FRET 
assay enabled us to directly monitor the effects of 968 and BPTES on the dimer-to-
tetramer transition.  We found that BPTES induced the formation of stabilized GAC 
tetramers, which was not reversible, as would be expected by previous studies. 
However, unlike BPTES, 968 does not influence the tetramer formation of GAC.  In 
fact, we discovered that the binding of 968 to GAC resulted in a quenching of the 
reporter group fluorescence, thus providing us with a direct spectroscopic read-out for 
the ability of this inhibitor and various analogs to bind to the enzyme. This direct 
spectroscopic read-out was found to be dose dependent, with its dose response directly 
correlated with inhibition of enzymatic activity. 
By taking advantage of a direct binding assay for 968, together with the recent 
development of GAC mutants that exist as monomers or dimers, we discovered that 
968 has a marked preference for binding to the monomeric form of the enzyme.  
While 968 is able to bind, albeit more weakly, to a GAC dimer, as well as to a GAC 
tetramer that has been activated by the allosteric regulator inorganic phosphate, it is 
unable to inhibit the activity of the activated enzyme tetramer. Therefore, 968 
preferentially binds to an inactive, monomeric state of GAC and prevents it from 
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undergoing activating conformational changes, whereas, if GAC reaches an activated 
state prior to 968-binding, then 968 is unable to inhibit enzyme activity.  
 These findings highlight the distinction between the two classes of allosteric 
GAC inhibitors for which BPTES and 968 are the prototypes. BPTES is able to bind 
and inhibit activated GAC, whereas 968 binds preferentially to and stabilizes an 
inactive state of the enzyme. In addition, we now understand the reason for previous 
discrepancies when comparing the 968 dose-dependencies for the inhibition of 
recombinant GAC activity versus oncogenic transformation [10]. Specifically, in those 
earlier experiments, the concentrations of recombinant GAC routinely being assayed 
represented a mixture of dimers and tetramers.  Consequently, the IC50 values for 968 
reflected its weaker binding to these oligomeric GAC species. Indeed, when the 
binding of 968 to GAC, together with its ability to inhibit enzyme activity, is assayed 
at GAC concentrations where it exists predominantly as a monomer, the dose response 
profiles for these binding assays match the dose-dependent inhibition of 
transformation in cell culture. 
 In conclusion, we show that 968 is capable of directly binding to GAC, the key 
enzyme responsible for elevated glutamine metabolism in transformed cells and 
cancer cells, and that 968 preferentially binds to a monomeric, inactive state of the 
enzyme. While an x-ray crystal structure of 968 bound to GAC has not yet been 
achieved, these findings shed new light on why this has been so challenging, given 
that crystallization trials have been routinely performed at GAC concentrations where 
it exists as a tetramer, i.e. the least favorable species for binding 968. Our ability to 
generate monomeric GAC mutants now provides new opportunities for achieving such 
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a structure.  Moreover, the availability of a direct binding read-out adapted for plate-
reader assays offers exciting possibilities for the identification of 968-like allosteric 
inhibitors that could yield new therapeutic strategies against cancer.  
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CHAPTER THREE 
Novel dibenzophenanthridine derivatives as GAC inhibitors: a coupled high 
throughput binding-inhibition assay leads to the development of tool compounds 
useful in vitro and in transformed cells. 
3.1 INTRODUCTION 
As discussed in Chapter 1, the mitochondrial enzyme glutaminase (GLS1) has 
gained significant attention as a therapeutic target for cancer [1]–[3].  GLS1 catalyzes 
the hydrolysis of glutamine to glutamate, which is used in the TCA cycle of cancer 
cells undergoing an aberrant glycolytic flux (i.e. the “Warburg effect”) as a non-
glucose-derived source for anaplerosis. The elevation in glutamine metabolism 
exhibited by many cancer cells (“glutamine addiction”) is critical for sustaining their 
proliferative capacity as well as for other aspects of their transformed phenotypes [4]–
[9].  Work from our laboratory has shown that a specific GLS1 splice variant, GAC, 
plays an essential role in the transformation of NIH 3T3 fibroblasts by Rho GTPases, 
as well as in the proliferative and invasive activities of various cancer cells [10]–[12].  
Thus, given the importance of GAC expression and activation for oncogenic 
transformation, the identification of inhibitors that target this metabolic enzyme offers 
new opportunities for the development of anti-cancer drugs. 
As outlined in Chapter 2, our laboratory identified a class of small molecules 
containing a benzophenanthridine scaffold, that potently inhibited Rho-GTPase 
dependent transformation [10]. The prototype for this inhibitor scaffold, compound 
968, was shown to target the mitochondrial enzyme, GAC. The identification of GAC 
as the target of 968 was shown through a pull-down assay using an active fragment of 
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968 (the phenyl bromo-dimethylamine ring, or “hot spot”) immobilized on a solid 
support. Using mass spectrometry, the short isoform of GLS1 (i.e. GAC), was 
identified. However, significant questions remained concerning the mechanism by 
which the 968-class of small molecules inhibited GAC activity, and how these 
inhibitors might be developed into cancer therapeutics.  
Selected derivatives around the central 968 scaffold have been described by 
our laboratory, and highlight the efficacy of this compound in cell proliferation assays 
of cancer cells [11]. Ligand-docking studies have suggested 968 binds within a 
hydrophobic pocket at the monomer-monomer interface of the GAC dimer, which is in 
good agreement with previous studies presented in Chapter 2 (Section 2.3.3), above. 
Interestingly, other groups have identified highly similar molecules using high-
throughput non-biased screening. Thomas and colleagues (2013) identified a natural 
product benzophenanthridine, named Chelerythrine, as a potent inhibitor of GAC 
activity [13]. This natural product alkaloid, derived from a member of the poppy 
family, has previously been assayed for its biological activity, and was proposed to be 
an inhibitor of cAMP-dependent kinase (PKC) activity, eliciting anti-proliferative and 
anti-inflammatory responses [14]–[17]. However, more recent studies have shown that 
Chelerythrine inhibits cancer cells through a mitochondrial mechanism that is distinct 
from PKC inhibition [17]–[19]. Perhaps most interestingly is the finding that 
Chelerythrine treatment of HeLa cells induced apoptotic events that were associated 
with the activation of the p38 and JNK signaling pathways. Chelerythrine-induced 
apoptosis could be rescued by the treatment with the antioxidants glutathione and N-
acetyl-cysteine, pointing towards a depleted pool of glutathione within Chelerythine-
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treated cells, an outcome of the inhibition of glutamine metabolism [4], [18], [20]. 
Moreover, our laboratory has recently shown a direct relationship between c-Jun 
expression, JNK activity, and GAC expression in a panel of breast cancer cells, thus 
connecting glutamine metabolism to JNK signaling [21]. 
Collectively, these studies suggest that members of the benzophenanthridine 
class of small molecules are possible lead compounds for a new class of therapeutics. 
However, these studies have also helped to identify the challenges of developing these 
small molecules as targets for drug development, as they have poor solubility and 
pharmacological properties [10], [11], [13], [22]. Therefore, new scaffolds need to be 
developed to elucidate the specific binding mechanism of these small molecules and 
increase their chances as potential drug candidates.  
In order to profile newly synthesized 968 derivatives, we began by developing 
a robust screening assay that would be highly specific to this class of inhibitors. 
Having this high-throughput assay in hand, we then made minor substitutions around 
the 968 scaffold in search of new 968-analogues to improve the central scaffold. Using 
the binding and inhibition assays, we went on to show that a new, smaller, 968 
derivative could be optimized such that it was as potent an inhibitor as 968 itself. This 
opens a route for discovering new lead compounds. Additionally, we made use of the 
968 structure to install useful physical properties to study the action of 968 both in 
vitro and in vivo. We developed a highly fluorescent 968 derivative that could serve as 
a spectroscopic read-out, followed by the addition of photo cross-linking groups, to 
covalently modify a target (i.e. the GAC protein) with this new fluorescent 968-
molecule. Having developed these novel compounds, together with the robust 
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screening assay, we were able to generate covalently modified GAC protein for 
biophysical studies, as well as for use in cellular assays, enabling the subcellular 
localization of intracellular 968-cross linked targets. These assays provide a strong 
foundation for the advancement of this unique class of GAC inhibitors, to gain a 
deeper understanding of how 968 treatment exerts such an effective inhibition of 
cellular transformation.  
3.2 METHODS 
3.2.1 Real-time 968 binding and enzyme activity assays 
Real-time fluorescence monitoring of 968 binding and GAC activity through 
production of NADH was performed on a Varian Cary Eclipse Fluorometer, whereas 
small molecule inhibition and binding titrations were performed in a 96-well format in 
a Tecan Saphire absorbance and fluorescence plate reader.  Samples for monitoring 
real-time binding of 968 to 488-GAC were prepared by adding 10 L of varying 
concentrations of 968 prepared in DMSO to an equilibrated 1 mL sample of 10 nM 
488-GAC, while observing 488 fluorescence (490 nm excitation/520 nm emission).  
Similarly, this method was replicated for monitoring real time binding of 968 to 
mutant forms of GAC, namely 488-labeled GAC (GD391K) and 488-GAC (D391K, 
K316E, R459E).  Real-time activity assays monitoring 968 binding and NADH 
production were prepared in 1 mL samples, where 10 units of glutamate 
dehydrogenase (Sigma) and 2 mM NAD
+
 (Sigma) were prepared in 50 mM Tris-
Acetate, pH 8.5, 0.1 mM EDTA and equilibrated at 20°C.  WT GAC (10 nM) was 
added and allowed to equilibrate 2 minutes before monitoring the fluorescence 
emission of 488-GAC (490 nm excitation, 520 nm emission) and NADH (340 nm 
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excitation, 490 nm emission).  Appropriate dilutions of 968 or BPTES prepared in 
DMSO were introduced after 30s and allowed to equilibrate for 2 minutes before a 
180 L solution of K2HPO4 and glutamine was added to make a final concentration of 
50 mM K2HPO4 and 20 mM glutamine, to initiate GAC activation.  The activity of 
GAC was measured in a coupled assay, by monitoring the NADH produced by 
glutamate dehydrogenase, which converts the product of the glutaminase-catalyzed 
reaction, glutamate, to α-ketoglutarate and ammonia by reducing NAD+ to NADH.  
Because solutions containing glutamine undergo non-enzymatic degradation to 
glutamate, samples were further analyzed by subtracting the NADH produced by 
glutaminase in the presence of 968, BPTES, or the equivalent volume of DMSO as a 
control, from the NADH produced in the absence of glutaminase under identical 
experimental conditions.  NADH was quantified using a standard curve of freshly 
prepared NADH (Sigma) in 50 mM Tris-Acetate, pH 8.5, and 0.1 mM EDTA.  
Procedures for the real-time binding and inhibition assays were adapted for 96-
well microtiter format with minor alterations.  Briefly, 2 L of inhibitor or DMSO was 
distributed across the 96-well plate, followed by addition of 200 L 10 nM 488-GAC, 
unlabeled WT-GAC, or in the absence of added GAC as a negative control, in 50 mM 
Tris-Acetate, pH 8.5, and 0.1 mM EDTA, followed by immediate monitoring of 488 
fluorescence (490 nm/520 nm excitation/emission, 5 nm/20 nm excitation/emission 
slits).  The 488-fluorescence was measured every 2 min with 90s of orbital shaking, 
followed by 30s resting between each cycle for a total of four cycles (i.e. 6 min).  A 
mixture of GDH and NAD
+
 (20 L) was then added to give 10 units of GDH and 2 
mM NAD
+
. To activate GAC, 30 L of a mixture of glutamine and K2HPO4 was 
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added to give a total concentration of 50 mM K2HPO4 and 20 mM glutamine in each 
well.  NADH fluorescence was measured (340 nm/460 nm excitation/emission, 10 
nm/10 nm excitation/emission slits) every minute with 30s orbital shaking, and a 30s 
rest between each reading, for 10 cycles (i.e. 9 min).  Three wells were prepared for 
each experimental condition (i.e. each concentration of compound) alongside one well 
where 2 L of DMSO was added in place of inhibitor, and one well that contained the 
small molecule inhibitor but no GAC.  To analyze 488-quenching by the added 
compound, 488-fluorescence (F) was normalized to the DMSO control (F0).  
Quenching was quantified as follows: 1-F/F0. For compounds that emitted 
fluorescence within the observed range, fluorescence measured in the well that 
contained the compound but lacked GAC was used to subtract added fluorescence due 
to the compound. Similarly, samples were analyzed for NADH fluorescence by 
subtracting the fluorescence measured for the experimental condition from the NADH 
fluorescence in the well that contained the added compound but no GAC. Percent 
inhibition at each drug concentration was calculated using the adjacent DMSO control. 
3.2.2 Preparation of 968 analogs 
Compounds 742 and 031 were obtained by commercial vendors (ChemBridge and 
Specs, respectively). Starting materials for chemical synthesis were used without 
further purification.   
3.2.2.1 3-Bromo-4-(dimethylamino)benzaldehyde [23]  
4-(Dimethylamino) benzaldehyde (6.7 mmol) was suspended in 1,4 dioxane (13 mL), 
N-bromosuccinimide (7.0 mmol) was added at once and stirred at RT for 3 h. Water 
(50 mL) and ethyl acetate (50 mL) were added and the organic layer washed with two 
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more portions of water (50 mL) then removed and dried with magnesium sulfate. The 
solvent was removed by rotary evaporation and the crude product purified by silica gel 
chromatography using 2:1 CH2Cl2:hexane as the eluent to give 0.84 g of a clear oil 
(55% yield). 
1
H NMR (400 MHz, CDCl3): = 9.80 (1 H, s), 8.03 (1 H, d, J = 1.84 
Hz), 7.73 (1 H, dd, J = 8.24 Hz, 1.84 Hz), 7.06 (1 H, d, J = 8.24 Hz), 2.94 (6 H, s). 
3.2.2.2 General procedure for synthesis of 968, SU-1, and SU-14
 
[24] 
The appropriate arylamine, 3-bromo-4- (dimethylamino)benzaldehyde and dimedone 
(2 mmol each) were heated to reflux in 10 mL ethanol for 1 hour, upon which time a 
precipitate formed. The precipitate was filtered, washed with ethanol and dried to give 
the product. 
3.2.2.3 General procedure for synthesis of SU-7, SU-8, SU-2 
The appropriate arylamine (3.7 mmol) and 3-bromo-4- (dimethylamino) benzaldehyde 
(3.7 mmol) were dissolved in benzene (5 mL) supplemented with molecular sieves 
(0.7 g) and stirred at RT for 18 h. The mixture was filtered and the solid material 
washed with dichloromethane. The combined filtrate was dried with magnesium 
sulfate, filtered and the solvent removed by rotary evaporation. The crude imine was 
dissolved in 1-butanol (6 mL), combined with dimedone (2 mmol) and heated to 
reflux for 2 h. The reaction mixture was cooled and solvent removed by rotary 
evaporation. The crude product was purified by silica gel chromatography using 1:1 
hexanes:ethyl acetate as the eluent. 
3.2.2.4 Synthesis of additional compounds 
Additional compounds having a compound 968-like scaffold were synthesized as 
shown below. 
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General synthetic scheme for inhibitor analogs of the 968 scaffold 
 
The appropriate aryl amine, 1,3 cyclohexanedione and aryl aldehyde were mixed in 
equal molar ratios and heated to reflux in ethanol. The resulting product generally 
precipitates from solution and is recovered by filtration. Representative NMRs are 
shown in Figures 8A–B. 
SU-11 and compounds having a compound SU-11-like scaffold were 
synthesized as shown below. 
General synthetic scheme for inhibitor analogs of the SU-11 scaffold 
 
The appropriate aryl amine and aryl aldehyde were mixed in equal molar amounts in 
dichloromethane, and 1.3 molar equivalents of sodium triacetoxyborohydride was 
added and the mixture stirred at room temperature overnight. The product was purified 
by silica gel chromatography.  
3.2.3 Covalent cross-linking of photo-reactive compounds in vitro 
WT GAC, org GAC containing the mutations K316E/D391K/R459E, was purified as 
detailed 2.4.1. The GAC proteins were incubated with increasing concentrations of the 
compound SU-22, and excited with a hand-held UV lamp for 120 seconds. 
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Immediately following UV exposure, samples were loaded onto a 4-20% Tris-Glycine 
polyacrylamide gel after the addition of SDS-PAGE sample buffer (50 mM Tris-HCl 
(pH = 6.8), 2% SDS, 10% glycerol, 1% β-mercaptoethanol, 12.5 mM EDTA, 0.02% 
bromophenol blue), and visualized on a UV light box.  
Conditions of in vitro cross-linking of WT GAC, and the 
K316E/D391K/R459E GAC mutant, were adapted for efficient cross-linking and 
purification of the cross-linked protein product. WT GAC and the 
K316E/D391K/R459E GAC mutant, both containing the N-terminal His-tag, were 
diluted to a concentration of 100 nM in 20 mM Tris-HCl (pH = 8.6), 100 mM NaCl, 
upon which 10 μM SU-22 and 2 mg/mL BSA were added.  Following a preincubation 
time of 5 minutes, samples were exposed to UV light under a hand-held 500W UV 
lamp to initiate the photo-cross-linking. To isolate the cross-linked product, 2.5 mg 
cobalt agarose beads (Clontech) were added and the solution was gravity filtered.  The 
beads were first washed with 10 column volumes of 50 mM Tris-HCl (pH = 8.6), 10 
mM NaCl, and with 5 column volumes 50 mM Tris-HCl (pH = 8.6), 10 mM NaCl 
containing 5 mM imidazole, followed by 3 column volumes 50 mM Tris-HCl (pH = 
8.6), 10 mM NaCl containing 20 mM imidazole, and finally the cross-linked product 
was eluted using 4 column volumes of 50 mM Tris-HCl (pH = 8.6), 10 mM NaCl 
containing 320 mM imidazole. The purified cross-linked protein was then 
concentrated using spin columns with a 30 kD molecular weight cutoff and quantified 
using UV-vis spectroscopy, where the protein was quantified by A280 (ε280 = 38,850 
M-1 cm-1) and the cross-linked SU-22 by A350 (ε350 = 18,900 M-1 cm-1).  Ratios of 
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cross-linked SU-22 to WT and K316E/D391K/R459E GAC were 0.52 and 0.78, 
respectively.  
To further illustrate specific cross-linking, the cross-linked 
K316E/D391K/R459E was analyzed using analytical size exclusion chromatography, 
where 100 μg of cross-linked K316E/D391K/R459E was injected onto a Superdex 200 
10/300 GL (GE Healthcare) column equilibrated in 50 mM Tris-HCl (pH = 8.6), 20 
mM NaCl, with a flow rate of 0.3 mL/min, by monitoring both the absorbance 
wavelengths at 280 nm and 350 nm.  
The cross-linked WT GAC was subjected to an overnight typsinization by first 
reacting all purified cross-linked WT GAC (2.5 mg) with 10 mM iodoacetamide, 
followed by addition of 25 μg sequencing grade trypsin (Roche), and then rotated 
overnight at 37°C. Following overnight trypsin digestion, the solution was filtered 
using a 10 kD MW cutoff spin filter and injected onto a SunFire C18 100 Å 5 μm, 4.6 
mm x 150 mm (Waters). Peptides were eluted using a binary gradient elution protocol, 
where mobile phase A (5:95:0.1 acetonitrile:water:trifluoroacetic acid) and mobile 
phase B (95:5:0.1 acetonitrile:water:trifluoroacetic acid) were varied to produce an 
increase in acetonitrile up to 80% over 20 minutes at a flow rate of 1 mL/min. The 
wavelengths 254 nm and 35 nm were monitored.  
3.2.4 Covalent cross-linking of photo-reactive compounds in cells. 
Cross-linking of SU-22 was also performed in cells transformed by the 
oncogene, Dbl. For these experiments, Dbl-induced MEFs, as detailed in Example 1 
above, were cultured in 150 mm
2
 dishes to approximately 80% confluency in DMEM 
supplemented with 10% FBS. Cells were then washed and DMEM supplemented with 
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1% FBS and 5 μM SU-22 was added, and cells were cultured overnight. Cells were 
then exposed to 60 seconds of UV light by a hand-held 50W UV lamp to initiate the 
in-cell cross-linking, followed by washing with DMEM supplemented with 1% FBS 
without SU-22. Cells were incubated with DMEM supplemented with 1% FBS 
following UV exposure for 20 minutes. The cells were then trypsinized, and 
mitochondria were isolated as outlined in Frezza et al. (2007) [25]. Briefly, suspension 
of trypsinized cells were spun 600 x g 10 minutes at 4°C and suspended in 
mitochondrial isolation buffer (10 mM Tris-MOPS (pH = 7.4), 1 mM EGTA/Tris, and 
200 mM sucrose). Cells were homogenized in a glass potter with a Teflon pestle using 
a Dounce homogenizer operated at approximately 1600 rpm for 35 strokes. The 
homogenate was centrifuged 600 x g 10 minutes at 4°C and the supernatant was 
isolated. The pellet was lysed in RIPA lysis buffer and used as the P1 fraction 
containing the nucleus and unbroken cells. The supernatant was centrifuged at 7000 x 
g 10 minutes at 4°C, where the resultant pellet contained the isolated mitochondria and 
the supernatant represented the soluble cytosolic and microsomal fractions. The 
supernatant was isolated and centrifuged at 200,000 x g 1 hour at 4°C, and the 
resulting pellet was taken to be the S200 fraction containing cytosolic and microsomal 
components. The mitochondrial pellet was resuspended in mitochondrial isolation 
buffer and spun again at 7000 x g 10 minutes at 4°C, where the resulting pellet was 
taken to be the purified isolated mitochondria. 
 For experiments where cells were visualized using confocal fluorescence 
microscopy, cells were cultured in the same conditions as stated above in MakTek 50 
mm
2
 dishes. Cells were treated with 5 M SU-22 overnight in DMEM supplemented 
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with 1% FBS.  Following 30 seconds of UV exposure, media was replaced with fresh 
DMEM (1% FBS) and incubated at 37°C for 2 hours. The media was then switched  to 
DMEM (1 FBS) containing 250 nM of the mitochondrial fluorescent probe 
MitoTracker CMXRos and incubated at 37°C for 30 minutes, at which point the media 
was changed to DMEM (1% FBS) without the MitoTracker for an additional 30 
minutes. Cells were then fixed in 4% para-formaldehyde and 0.1% glutaraldehyde and 
imaged on an inverted Axio Observer.Z1 microscope using the 405 laser line for 
excitation of the SU-22 small molecule and 514 laser line to excite the MitoTracker.  
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3.3 RESULTS 
3.3.1 A real-time binding and inhibition assay to distinguish 968 derivatives from 
BPTES class inhibitors. 
 The real-time readout of the binding of 968-like inhibitors to the fluorescently 
labeled 488-GAC provided a useful strategy to simultaneously assay both inhibitor 
binding and the accompanying effects on enzyme activity. Figure 3.1 illustrates this 
approach, where the highly fluorescent 488-GAC is used to measure both the binding 
of 968, coupled with the immediate assaying enzyme activity. First, 968 is added to 
488-GAC and the fluorescence quenching of the 488-probe is monitored, reflecting 
the binding of 968. Immediately after the binding measurement, the substrate 
glutamine, and the allosteric activator inorganic phosphate, are added to stimulate 
GAC activity, converting glutamine to the products glutamate and ammonia. Enzyme 
activity is measured using fluorescence, where a coupled enzymatic reaction catalyzed 
by glutamate dehydrogenase (GDH) is used to convert the glutamate, the product of 
the GAC-catalyzed reaction, to -ketoglutarate, with the concomitant reduction of 
NAD
+
 to NADH. The highly fluorescent NADH is easily monitored. Thus by using 
highly sensitive fluorescence assays, the binding of small molecule inhibitors of the 
968-like scaffold to GAC, and their inhibition of GAC activity, can be monitored 
simultaneously. 
The real-time binding and inhibition assays were developed using a 
fluorescence cuvette, where the temperature and sample mixing could be readily 
controlled. Figure 3.2A illustrates the results of this coupled assay using both the 
inhibitors 968 and BPTES.  
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FIGURE 3.1 – Coupled real time binding and inhibition assay. The highly 
fluorescent 488-GAC is first preincubated with a small molecule drug (e.g. 968), 
where the change in 488-fluorescence is monitored (490 nm excitation, 520 nm 
emission) as a direct read-out for drug binding. Immediately following drug 
binding, the substrate glutamine, and the allosteric activator inorganic phosphate, 
are added to stimulate GAC activity. The product of this reaction, glutamate, is 
then converted by glutamate dehydrogenase (GDH) to -ketoglutarate with the 
concomitant reduction of NAD
+
 to NADH, with the latter compound being highly 
fluorescent (360 nm excitation, 450 nm emission), such that it serves as a read-out 
for this coupled enzyme reaction. 
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It has been shown previously that BPTES does not bind to the same allosteric site as 
968. Therefore, BPTES does not cause a quenching of the 488-GAC fluorescence, 
whereas the addition of 968 to 488-GAC potently quenches the reporter group 
emission (Figure 3.2A, compare (—) to (∙∙∙) and (---) (left axis)). Both 968 and BPTES 
potently inhibit glutaminase activity, as read out by NADH fluorescence, compared to 
the control experiment where the drug vehicle DMSO was used (Figure 3.2A, 
compare (—) and (∙∙∙) to (---) (right axis)). These results demonstrate that the real-time 
quenching is specific for 968-like inhibitors. 
To further validate the assay, we compared the dose-dependent quenching and 
inhibition of 488-GAC versus unlabeled WT GAC, i.e. to account for any effects 
arising from the covalent attachment of a fluorescent probe to GAC. Unlabeled WT 
GAC was assayed using the same protocol, however, without the monitoring of 488-
fluorescence. The dose-dependent inhibition of WT GAC by 968 was in good 
agreement with the quenching and inhibition of 488-GAC (Figure 3.2B). This newly 
developed assay now provides a convenient method to examine small molecule drug 
candidates that inhibit GAC activity through the same allosteric mechanism as 968, as 
opposed to the other allosteric mechanism of BPTES inhibition. 
  
-105- 
 
 
  
FIGURE 3.2 – Simultaneous binding and inhibition assays of GAC specific for 
968. (A) Real time binding (green curves, left axis) and activity (blue curves, right 
axis) of GAC were monitored in the same cuvette. Addition of 10 M of 968 (—), 
BPTES (---), or DMSO (∙∙∙), to 488-GAC yielded a 968-dependent quenching of 
488-fluorescence. The activity of GAC was monitored directly upon drug binding, 
where both 968 (—) and BPTES (---) were found to inhibit GAC activity when 
compared to the DMSO (∙∙∙) control. (B) Overlay of the dose-dependent drug 
binding, represented by the quenching of 488 fluorescence (, left axis), and GAC 
inhibition, for 488-labeled GAC () and WT GAC (), using this coupled assay.  
-106- 
 
  
A 
B 
-107- 
 
3.3.2 A high-throughput binding and inhibition assay for screening 968 
analogues. 
 Although compound 968 has been an effective inhibitor both in vivo and in 
vitro, we were interested in modifying the central scaffold in search for new and 
improved inhibitor molecules. One primary goal was to increase the aqueous solubility 
of 968, a noticeable drawback for its use as a therapeutic agent. To accomplish this, 
we took advantage of the facile synthetic route for 968 synthesis (Figure 3.3A). Here, 
the central 968 scaffold could be easily modified by using alternate reactants 
(highlighted in blue, green, and orange). Substitutions were made that could be readily 
synthesized, and were later tested for their efficacy against recombinant GAC. In 
Figure 3.3B, the compounds are grouped by the modification of the central scaffold, 
and in decreasing order of their inhibition against recombinant GAC activity. 
Having the developed real-time binding and inhibition assays in hand, we were 
interested in adapting this approach to a more high-throughput assay using 96-well 
microtiter plates and a fluorescence reader. To accomplish this, we scaled the 
reactions appropriately to fit within 200 L, and monitored the fluorescence signal of 
488-GAC and NADH in succession, upon the addition of drug, followed by the 
addition of substrate (Gln) and activator (Pi). This assay proved to be a robust readout 
for monitoring drug binding and enzyme inhibition, similar to the single-cuvette assay 
depicted in Figure 3.2A. Here, multiple drug concentrations could be analyzed 
simultaneously and in triplicates to give statistical validation of inhibitory and binding 
constants (IC50 and KD values, respectively). 
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FIGURE 3.3 – 968 derivatives used for binding and inhibition assays. (A) 
General synthetic route for the synthesis of 968 derivatives, where fragments from 
each starting material are differentiated by the colors blue, green, and orange. (B) 
Synthesized 968 derivatives, with significant changes color coded by the fragment 
that was altered from the 968 structure. The prototype compound, 968, is 
highlighted with a red box. Names for the compounds, along with IC50 values (± 
s.d.) from inhibition assays using 488-GAC, are included to the right of each 
compound.  
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FIGURE 3.4 – Inhibition and binding constants for 968 derivatives. (A) The IC50 
values obtained from the real-time binding and inhibition assays against 488-GAC 
are plotted from most to least potent from left to right. (B) IC50 values represented 
in (A), plotted against the KD values obtained from the binding portion of the 
coupled assay, show good agreement when fit by linear regression (slope = 1.09, 
Pearson’s R = 0.799, n=30). The prototype, compound 968, is highlighted in blue 
for reference. 
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The screening of the compounds presented in Figure 3.3B against 488-GAC, 
using the real-time binding and inhibition assays, described above, resulted in a 
distribution of IC50 values (Figure 3.4A), which were then plotted with respect to the 
measured KD values (Figure 3.4B). Importantly, the measured IC50 values and KD 
values were in good agreement with respect to one another, as a plot of IC50 versus KD 
gave a linear relationship with a high correlation coefficient. This further demonstrates 
that the inhibitory potency of the compound is directly related to its ability to bind to 
GAC, and not due to an allosteric mechanism that depends on the placement of 
specific functional groups within the binding pocket.  
Unfortunately, the original 968 scaffold was not significantly improved with 
the substitutions that were synthesized. The general trend for increasing the potency of 
inhibition tracked with the addition of hydrophobic groups, such as aromatic rings 
(compare SU-14, SU-13, and SU-10, from left to right, in Figures 3.3B). However, 
unexpectedly, we identified a smaller scaffold that did not require the addition of the 
dimedone reactant (green, Figure 3.3A), but maintained potency when compared with 
968 (compare SU-11 in second column to 968 in first column, Figure 3.3B). 
Furthermore, this smaller scaffold based from SU-11 was optimized to have a similar 
potency to 968, where the substituents around the phenyl ring were changed from a 
dimethyl amine to a pyrrolidine, while the bromine was substituted for a nitro group. 
These optimizations resulted in a new scaffold with a similar potency as that for 968. 
This new scaffold now represents an even more tractable synthetic route for 
synthesizing new derivatives, where only the naphthylamine and benzaldehyde are 
needed. Derivatives can be made simply through the nucleophilic addition of a moiety 
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containing a primary amine to a benzaldehyde to form the imine intermediate, 
followed by a reductive workup to give the final product. This simple scaffold 
optimization, together with the assays developed for the direct read-out of drug 
binding and inhibition, represents an attractive route for a concerted drug discovery 
effort to fully optimize the SU-11 molecule for an effective therapeutic reagent.  
3.3.3 Functionalized 968 derivatives as useful tool compounds 
 Although the newly developed binding and inhibition assays helped guide new 
synthetic routes for making more potent or structurally divergent molecules around the 
968 scaffold, some outstanding questions remained regarding 968’s specific action 
against the GAC enzyme both in vitro and in vivo. These include the specific binding 
site for 968 on GAC, how 968 binding to the GAC monomer affects oligomerization 
of the enzyme, and whether GAC was indeed the direct target of 968 in vivo. To 
address these questions, we made simple derivatives of 968 that contain useful 
moieties, such as a fluorescent moiety and UV-activated covalent cross-linking 
groups.  
First, a fluorescent 968-derivative was made by substituting an additional 
aromatic ring on the naphthyl group, to give the highly fluorescent anthracene moiety 
(Figure 3.5A). The fluorescence spectrum of this compound, shown in Figure 3.5B, 
was found to exhibit a large Stökes shift, with an excitation maximum at 345 nm and 
an emission maximum at 485 nm. This new fluorescent compound, named SU-14, was 
found to be a slightly better inhibitor for recombinant GAC than 968, suggesting this 
modification yielded a valuable 968-analogue for investigating the actions of this class 
of inhibitors in cells (Figures 3.4A,B).  
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FIGURE 3.5 – Development of highly fluorescent 968 derivatives as tool 
compounds. (A) Compounds SU-14 (left) and SU-22 (right) both contain the 
highly fluorescent anthracene ring (highlighted in green). Additionally, SU-22 
contains a phenyl-azide, a common photo-activated cross-linking group (B) 
Fluorescence excitation and emission spectrum of compound SU-14, showing a 
strong fluorescence signal with a Stokes shift of >100 nm, making it useful for 
fluorescence assays.  
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Additionally, a derivative of SU-14 containing an UV-activated cross-linking moiety, 
designated SU-22, also exhibited potent inhibitory and binding properties (Figures 
3.4A,B and 3.5A). The added UV-activated cross-linking group was incorporated into 
SU-14 by replacing the dimethyl amine, previously shown to be critical for 968’s 
action, to give the phenyl azide. Phenyl azides are known to convert to the highly 
reactive nitrene intermediate upon UV excitation (< 350 nm), which rapidly reacts 
with any available nucleophile (i.e. primary amines or aliphatic groups) within close 
proximity. This group is useful for creating proximity-dependent covalent 
modifications, due to its rapid reaction rates, once the nitrene is formed, and high 
reactivity towards any available nucleophile within an immediate proximity. 
3.3.4 The interactions of the fluorescent photo cross-linking compound SU-22 
with GAC in vitro. 
The new molecule, SU-22, represents an excellent tool compound to 
investigate 968’s mechanism of action. It has potent inhibition and binding properties, 
and is capable of intrinsic fluorescence and of being covalently cross-linked to GAC, 
as depicted in Figure 3.6A. The SU-22-conjugated GAC can be visualized by the 
fluorescence of SU-22, such as under UV illumination following the separation of 
unreacted SU-22 by SDS-PAGE (Figure 3.6B). 
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FIGURE 3.6 – Covalent conjugation of a fluorescent 968-analogue prefers the 
monomeric form of GAC. (A) Depiction of the photo-cross-linking of SU-22 to 
GAC. Upon UV illumination (<350 nm), the phenyl azide reacts with a 
nucleophile within immediate proximity, resulting in the covalent conjugation of 
SU-22 to GAC. (B) SDS-PAGE of the WT, dimeric (D391K), and monomeric 
(K316E-D391K-R459E) mutants of GAC, following incubation with increasing 
concentrations of SU-22 and UV illumination. The labeled enzyme was visualized 
upon UV illumination. 
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To demonstrate the utility of SU-22, we first tested its ability to preferentially 
bind to the monomeric form of GAC, similar to what was previously observed for the 
prototype compound 968 (Chapter 2, Section 2.3.3). However, in the previous studies, 
the real-time binding assay was performed on a fluorescently-labeled GAC (488-
GAC) to determine 968’s binding affinity for the WT, dimeric, and monomeric forms 
of GAC, using novel GAC mutants. Here, we used the fluorescence of SU-22, and 
SDS-PAGE, to perform a similar experiment, monitoring the labeling of WT along 
with the dimeric and monomeric mutants of GAC with SU-22 (Figure 3.6B). We 
found that the labeling of WT GAC with SU-22 was indeed dose-dependent and 
within the concentration range expected by the binding and inhibition assays (1-20 
M). This labeling was slightly improved when the dimeric form of GAC was used. 
However, the labeling was significantly improved for the monomeric form of GAC. 
The observation that the monomeric form of GAC exhibited the most robust labeling 
by SU-22 is consistent with previous results presented in Chapter 2 (section 2.3.3), 
where 968 was shown to prefer binding the GAC monomer. 
The conjugation of GAC with this fluorescent 968-like small molecule, SU-22, 
offered a new strategy to investigate the effects of 968 binding to GAC; in particular, 
the purification of a uniformly conjugated GAC species with a 968-like derivative. 
The motivation for this was to allow further biophysical studies to be performed on a 
GAC protein with a 968-like molecule covalently bound, such as crystallization trials 
to obtain an X-ray crystal structure, or mass spectrometry studies to identify the 
covalently modified residue. We began with the purification of the SU-22 conjugated 
monomeric GAC mutant (K316E-D391K-R459E), due to its higher affinity for 968 
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and SU-22. A method was developed whereby the bulk conjugation of SU-22 to an N-
terminally His(6x)-tagged monomeric GAC and subsequent purification was 
accomplished using a Co
2+
 affinity column (Figure 3.7A). Here, SU-22 was added to a 
mixture of purified His(6x)-tagged GAC and bovine serum albumin (BSA), which was 
included to enhance SU-22 solubility and to prevent non-specific binding. Following a 
preincubation period, the solution was illuminated with UV light and then subjected to 
a Co
2+
 affinity column to re-purify the His(6x)-tagged monomeric GAC from any 
excess unreacted SU-22 and BSA. As shown in Figure 3.7A, this method resulted in 
the elution of a highly fluorescent SU-22 GAC adduct (fraction 8, compare top gel 
visualized under UV excitation to lower gel visualized using total protein stain). The 
resulting SU-22:monomeric GAC adduct was quantified for labeling stoichiometry 
using UV absorbance, and found to be 0.7:1 (SU-22:GAC) (Appendix Figure 7.2A). 
Similarly, this method was then used to purify SU-22 conjugated to WT GAC, and a 
lower labeling stoichiometry was observed (0.25:1, SU-22:GAC) (Appendix Figure 
7.2B). The SU-22:monomeric and SU-22:WT were then assayed for 968 binding and 
enzyme activity, using methods described in Chapter 2 (Figures 3.7B,C). Both the 
enzymatic and 968-binding activities were inhibited to the same degree for the SU-22-
conjugated GAC when compared to the unconjugated enzyme (Figure 3.7D,E). These 
results suggest that SU-22 only labels ~50% of the GAC protein. Furthermore, the 
population of SU-22-labeled GAC is inactive and does not bind 968, as would be 
expected, presumably due to SU-22 occupying the 968 binding site. 
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FIGURE 3.7 – Purified SU-22-conjugated GAC both prevents 968 binding and 
GAC activity. (A) SDS-PAGE of selected fractions from the purification protocol 
of SU-22-conjugated GAC, where SU-22:GAC was identified using UV 
illumination of the gel (top) and total protein by Coomassie Blue Stain (bottom). 
The purification of SU-22:GAC was accomplished by first conjugating SU-22 to 
GAC under UV illumination, followed by His-tag affinity chromatography, where 
the eluted protein results in robust fluorescence due to the cross-linked SU-22 
molecule (fraction 8). (B) Purified SU-22:monomeric GAC was labeled with the 
AlexaFluor-488 probe (as described in Section 2.4.1) and subjected to the real-
time 968 binding assay (Section 2.4.3), where a significant inhibition of 968 
binding was observed. (C) Additionally, SU-22:GAC (WT) was purified by this 
same method described in (A) and assayed for GAC activity, where an inhibition 
of WT glutaminase activity was observed for SU-22-conjugated GAC when 
compared to unlabeled GAC. (D),(E) Inhition of 968 binding to SU-22:monomeric 
GAC (D), and 968 inhibition of glutaminase activity (E), was in good agreement 
with the measured labeling stoichiometry of SU-22 to GAC.  
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Having the SU-22-conjugated GAC protein in hand, we then sought to study 
the effects of the conjugation on the oligomerization of GAC. To accomplish this, we 
used analytical size exclusion chromatography (SEC) to determine the relative size of 
the SU-22:monomeric GAC adduct and compared it to the unlabeled monomeric and 
dimeric GAC (Figure 3.8A). The monomeric form of GAC was previously 
characterized in Chapter 2 above (section 2.3.1), where a uniform monomeric 
molecular weight species was identified using SEC-MALS; however, the SU-
22:monomeric GAC adduct did not follow the same profile. A second peak was eluted 
before the monomeric peak (i.e. a predicted higher MW species) in the conjugated 
sample, suggesting that the conjugation of SU-22 to the monomeric form of GAC 
allowed for another oligomer to form (Figure 3.8A, compare (—) to (∙∙∙)). When 
comparing the elution of this second peak to the dimer form of GAC, we found that it 
had an overlapping elution volume, suggesting this second larger MW species 
represented a dimeric form of the enzyme (Figure 3.8A, compare (—) to (∙∙∙)). Both 
the monomeric and dimeric forms of the conjugated GAC species contained SU-22, as 
read out by the unique absorbance of the small molecule at 350 nm (Figure 3.8A, 
compare (—) to (—)). Taking these observations together leads to the model where 
968 binds to the monomeric form, perhaps at the interface of two monomers to form a 
dimer, and then helps to promote dimer formation.  
Now, with a purification protocol and efficient labeling strategy, we were 
poised to try to identify the site of modification. However, as shown in Figure 3.8A, a 
homogenous solution of monomeric units of GAC becomes a heterogeneous 
population of monomers and dimers, presenting a significant challenge for 
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crystallization trials. Of the conditions tested, protein aggregation was a significant 
problem. We then turned to a proteomics approach, where tryptic peptides were 
separated on a RP-C18 microbore HPLC column and analyzed using MS/MS at the 
Mass Spectrometry and Proteomics Resource Core at Harvard University. However, 
these efforts failed to identify the modification site, most likely due to imperfect 
parameters for the identification of this novel modification. As an alternative, we 
analyzed the tryptic fragments of an SU-22:WT GAC adduct on a RP-C18 HPLC 
column, using UV absorbance as a detector, and identified a single unique peak at 350 
nm that was eluted only with high concentrations of acetonitrile in the mobile phase, 
characteristic of a highly hydrophobic peptide fragment (Figure 3.8B, (—) to (—)). 
This single peak with 350 nm abosrbance is presumably the SU-22-conjugated peptide 
fragment, as only SU-22 has an absorbance at that wavelength. Moreover, only one 
peak was observed with an absorbance of 350 nm, suggesting this modification is site-
specific, and not reacting at multiple sites. Furthermore, analysis of partial tryptic 
peptides of SU-22-conjugated GAC revealed a similar fragmentation pattern as that 
for 488-labeled GAC (Appendix Figure 3), where the 488-probe was identified within 
the catalytic domain of GAC (Appendix Figures 1A-E). 
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FIGURE 3.8 – SU-22 conjugated to a GAC monomer is site-specific and induces 
the transition to a GAC dimer. (A) Analytical size exclusion chromatography 
profile of a purified sample of SU-22:monomeric GAC contains two distinct peaks 
for both the absorbance wavelengths of 280 nm (—) and 350 nm (—), where 
absorbance at 350 nm is unique to the SU-22 molecule. The peak with the later 
elution volume overlays with the unlabeled GAC monomer (∙∙∙), whereas the 
earlier elution volume overlays with the unlabeled GAC dimer (∙∙∙). (B) Peptides 
obtained from the complete trypsin digestion of purified SU-22:WT GAC were 
separated by RP-HPLC, using an increasing acetonitrile:H2O gradient. Both 
absorbance wavelengths of 254 nm (—) and 350 nm (—) were monitored 
simultaneously, where the absorbance at 254 nm is characteristic of the eluted 
peptides, while absorbance at 350 nm is due to the SU-22 molecule (red arrow).  
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3.3.5 Fluorescent photo cross-linking compound SU-22 in transformed cells. 
The SU-22 tool compound was found to behave as would be predicted for a 
968 analogue; it bound preferentially to the monomeric state of GAC, as well as 
competitively blocking the binding of 968 and, upon its covalent attachment to GAC, 
inhibited enzyme activity. We then examined whether SU-22 behaves like 968 in 
cells. We set out to address this question by first turning to a model cell system, 
previously used to examine the actions of 968 against oncogenic transformation. The 
cell system used here was an inducible model, where the oncogenic form of Dbl (for 
diffuse B-cell lymphoma) is robustly expressed in mouse embryonic fibroblasts 
(MEFs) upon the removal of the antibiotic doxycycline (Dox), thereby causing normal 
MEFs to exhibit the transformed characteristics of cancer cells. First, we investigated 
the effect of SU-22 in a cell saturation density experiment. In this experiment, non-
transformed cells grow to confluency and saturate to a uniform monolayer due to cell-
cell contact inhibition (Figure 3.9A, left), but cells transformed by onco-Dbl continue 
to grow through a monolayer due to their oncogene-driven loss of cell-cell contact 
inhibition. We show that SU-22 behaves like 968 by inhibiting the saturation density 
of the transformed cells (Figure 3.9A, compare middle to right). 
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FIGURE 3.9 – Compound SU-22 inhibits Dbl-induced saturation density and 
labels GAC in cells. (A) SU-22 inhibition of cell growth saturation density using 
mouse embryonic fibroblasts (MEFs) transformed by the induced expression of 
the oncoprotein Dbl (onco-Dbl). Control cells only grow to a confluent monolayer 
(left), whereas cells transformed by the induced expression of onco-Dbl overcome 
cell-cell contact inhibition and grow to a confluent multilayer (middle), which SU-
22 potently inhibits (right). (B) Cartoon depiction of cell labeling with SU-22. 
First SU-22 is incubated with cells, and then exposed to UV light, washed, and 
their mitochondria isolated. (C) SDS-PAGE of onco-Dbl-expressing cells labeled 
with SU-22, following the workflow from (B), where 25 g of protein from the 
whole-cell lystate (WCL), S200 fraction (cytoplasm and microsomes), and the 
mitochondrial fraction (mito) was visualized under UV-illumination for 
fluorescent SU-22:protein adducts (left), followed by immunoblotting for both 
KGA and GAC (right). GAC/KGA are clearly enriched in mitochondria (right 
lane), and exhibit an overlapping signal with the fluorescence image (green 
boxes). 
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Having established SU-22 as an inhibitor of the transformed growth phenotype 
exhibited by Dbl-transformed cells, we sought to develop methods to label these 
transformed cells to identify SU-22 binding partners in vivo. Figure 3.9B depicts this 
approach, where SU-22 is first incubated with Dbl-induced MEFs to saturate its target 
in cells, followed by UV illumination to stimulate photo-cross linking, and subcellular 
purification of mitochondria (i.e. where GAC is localized). Proteins from the whole-
cell lysate, cytoplasmic and microsomal, and mitochondrial fractions were separated 
by SDS-PAGE and analyzed under UV illumination to visualize the fluorescent SU-
22:protein adducts, followed by immunoblotting for both KGA and GAC. 
Interestingly, a relatively small number of proteins were labeled with the photo cross-
linking 968 analogue in the whole cell lysate, with a significant labeling in the 
mitochondrial fraction (Figure 3.9C, compare WCL to Mito). Moreover, the 
fluorescent bands found within the mitochondrial fraction were also identified using 
an antibody recognizing GAC/KGA (Figure 3.9C, green box). These data show that 
the labeling of Dbl-induced cells, which are highly sensitive to treatment with this 
compound, results in SU-22-labeled protein adducts that are consistent with the 
mobility of GAC on SDS-PAGE. Furthermore, these results show that the SU-
22:protein adducts are indeed localized within the mitochondria, i.e. matching the 
localization of GAC.  
To extend these studies, we analyzed Dbl-transformed cells treated with SU-
22, using confocal fluorescence microscopy. As shown in Figure 3.10, Dbl-
transformed cells treated with SU-22 and the mitochondrial labeling dye, MitoTracker, 
demonstrate the subcellular localization of SU-22, with a considerable overlap with 
-131- 
 
the mitochondrial marker (Figure 3.10, compare top left, middle, and right panels). 
Additionally, the labeling of SU-22 in cells was shown to be dependent on UV 
illumination, where cells that were not illuminated to initiate covalent cross-linking 
showed little detectable fluorescence of the SU-22 compound, when compared to cells 
that were illuminated (Figure 3.10, compare bottom left two panels to top left two 
panels). These fluorescence images directly show the SU-22 compound localizing to 
an intracellular organelle that has an overlapping structure with a mitochondrial 
marker. These results highlight that this novel 968 analogue indeed localizes to 
mitochondria, and are consistent with the contention that this small molecule targets 
the mitochondrial KGA/GAC enzymes.  
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FIGURE 3.10 – Confocal fluorescence images of cross-linked SU-22 in Dbl-
induced cells. Dbl-induced cells were labeled with the fluorescent molecules SU-
22 and MitoTracker, by first incubating cells with SU-22, and then cross-linked by 
UV illumination followed by labeling with MitoTracker to identify mitochondria 
(top). Cells that were not exposed to UV light to stimulate photo-cross-linking 
followed the same treatment, however, without exposure to UV light (bottom). 
Cells were then fixed in 4% para-formaldehyde and 0.1% glutaraldehyde and 
imaged on an inverted Axio Observer.Z1 microscope using the 405 laser line for 
excitation of the SU-22 small molecule and 514 laser line to excite the 
MitoTracker. 
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3.4 DISCUSSION 
 The initial discovery of 968 as a lead compound for the inhibition of the 
growth and oncogenic properties of cells transformed by hyperactive Rho-GTPases, 
namely Rho, Rac1, and Cdc42, posed significant questions as to its mechanism of 
action [10]. The discovery was the result of a high-throughput screen of a Rho-
dependent growth phenotype in yeast. The hit compounds found to inhibit the yeast 
phenotype were then assayed on mammalian cells transformed by hyperactive Rho-
GTPases accompanying the expression of the Dbl oncogene. Compounds that were 
not specific to inhibiting Rho-dependent transformation in mammalian cells were 
removed from the collection of hit compounds. This top down approach identified the 
968 scaffold as a highly potent and specific inhibitor of oncogenic transformation 
induced by the hyper-activation of the small G-proteins within the Rho family. 
However, the target of this lead compound, when identified using a mass spectrometry 
assay of proteins that bound to an immobilized version of the active moiety of 968, 
surprisingly was not a G-protein, nor any type of conventional signaling protein. The 
identified target was in fact a metabolic enzyme, GAC, which had no known 
association with the small G-protein signaling pathways. 
 The identification of this metabolic enzyme, GAC, as the target of 968 was 
validated by assaying the glutaminase activity within mitochondria of 968 treated and 
untreated cells, along with single point enzyme assays of the purified recombinant 
enzyme. Activity assays of the purified enzyme did not suggest a competitive mode of 
inhibition, but rather a non-competitive inhibitory mechanism, thus suggesting that 
968 was an allosteric inhibitor. Protein docking studies of this small molecule to the 
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available X-ray crystal structures of GAC revealed a distinct binding pocket within the 
interface of the GAC dimer (Figure 3.11, orange spheres)  [11]. These studies, when 
combined with a select group of 968 derivatives, demonstrated a viable model for 968 
inhibition of GAC activity. However, the lack of a co-crystal X-ray structure of 968 
bound to GAC presented significant challenges to further optimize the 968 scaffold, 
and furthermore, raised the fundamental question as to how binding at such a distal 
allosteric interface affected GAC activity. 
 In this study, we were able to first make use of a newly described method of 
detecting 968-like molecules to directly bind to GAC. These methods, when coupled 
with read-outs of enzyme activity, allowed a higher through-put effort in optimizing 
the molecule scaffold. This assay was used to profile new smaller 968-analogues, 
where SU-29 now represents the lead compound. Furthermore, we successfully 
designed 968-derivatives to act as tool compounds to investigate the actions of 968 on 
GAC both in vitro and in cells. The prototypic tool compound, SU-22, was found to 
have properties directly in line with what would be predicted for a 968-derivative. 
First, we showed that SU-22 interacted preferentially with the monomeric form of 
GAC, and to a significantly lesser extent to the GAC dimer. Next, we demonstrated 
the ability of the SU-22, when covalently linked to the GAC monomer, to 
competitively block the binding of 968. Furthermore, we observed that SU-22 could 
induce the formation of a GAC dimer. This observation leads to the model presented 
in Figure 3.11, where 968 binds to the surface of a GAC monomer that interacts with a 
second monomer to form the dimer.  
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FIGURE 3.11 – Model of 968 binding to the GAC monomer-monomer interface. 
Using the previously reported docked structure of 968 to GAC, a model can be 
proposed whereby a 968 molecule (orange spheres) binds to a hydrophobic pocket 
of monomeric GAC that enables the binding of another monomer unit to form a 
dimeric 968-GAC complex. 
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When 968 is bound, a second unbound GAC can then favorably interact with the 968-
bound GAC monomer to create a 1:2 968:GAC dimer. Finally, we concluded that the 
purified SU-22 bound to WT GAC was inactive, resulting from SU-22 covalently 
attached to the 968 binding site. This modification on WT GAC was found to be site 
specific, through the identification of a unique peptide signal in the HPLC trace of a 
full trypsin digestion of the SU-22:WT GAC adduct. 
 Having validated this novel tool compound to behave as would be predicted 
against the GAC enzyme, we then described its reactivity in cells. Here, we made use 
of the original cell line that highlighted the inhibitory activity of 968 against 
transformation. We showed that this new 968 derivative, SU-22, was a potent inhibitor 
of onco-Dbl induced growth density at saturation, similar to the actions of 968. 
Importantly, when SU-22 was used to label proteins within live cells, the most 
significant band identified was within the mitochondrial fraction, a result that 
establishes this class of molecules as acting specifically within mitochondria. These 
results were further supported by confocal fluorescence microscopy studies of this SU-
22 molecule covalently cross-linked within cells. The fluorescence signal of the SU-22 
molecule was localized within subcellular structures that colocalized with 
mitochondria, consistent with the principle target of the 968-class of compounds being 
GAC. 
 These results provide a strong foundation for the building of a more concerted 
effort to develop 968-like therapeutics. The high-throughput binding and inhibition 
assay presents a reliable method for the characterization of 968-derivatives. Similarly, 
the chemical tools presented here have now helped to provide fundamental insights 
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into how 968 interacts with its target protein, GAC, both in vitro and in cells. The use 
of these 968-derived molecular tools to investigate the binding pocket for 968, and the 
localization of GAC within a variety of cells, reinforces the view that this small 
molecule binds to mitochondrial glutaminase in vivo. 
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CHAPTER FOUR 
Conformational changes in the activation loop of mitochondrial glutaminase C: A 
direct fluorescence read-out that distinguishes the binding of allosteric inhibitors from 
activators 
4.1 INTRODUCTION 
As outlined in Chapter 1, the increased reliance of glutamine catabolism by 
proliferating cancer cells has recently attracted significant attention as a route to 
developing new therapeutics that target this unique metabolic requirement of 
transformed cells [1]–[4]. As discussed above, studies of the enzymes that support this 
aberrant glutamine metabolism have found that the increased expression of a C-
terminal splice variant of kidney-type glutaminase (KGA), known as GAC, is the gate-
keeper enzyme for this glutamine addiction, making both KGA and GAC attractive 
therapeutic targets [5], [6]. Recently, clinical investigations have begun that are 
exploring the impact of therapeutics inhibiting glutamine metabolism, with trials being 
performed in cancers such as triple-negative breast cancer, multiple myeloma, and 
acute-lymphoblastic leukemia [7]–[9]. However, the mechanisms by which these best-
in-class inhibitors block GAC enzyme activity is still being fully eluciated.  
There are three known classes of inhibitors for KGA and GAC. 
Benzophenanthridines, described in Chapters 2 and 3, act as a non-competitive 
allosteric inhibitor of GAC, appear to interfere with GAC monomer-monomer 
interactions [10]–[13]. A second class, analogs of the substrate glutamine, such as 
diazo-O-norleucine (DON), act as competitive inhibitors that bind to the active site of 
glutaminase to modify the catalytic serine (S291) [14]. The third class, depicted in 
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Figure 4.1A, consists of a number of bis-thiadiazole derivatives, the prototype being 
BPTES,  recently described to inhibit glutaminase by binding to a flexible loop within 
the dimer-dimer interface of the GAC tetramer [7], [8], [12], [15], [16]. These 
compounds are a class of bis-thiadizaole derivatives, with the prototype being BPTES 
(bis-2-(5 phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide) (Figure 4.1A). Gross 
and colleagues (2015) have reported an improved BPTES derivative, CB-839, which 
is a more potent inhibitor than BPTES, and described its effectiveness against triple 
negative breast cancer cells [7]. CB-839 efficacy has been examined in vivo, and 
subsequently employed in clinical trials [7]–[9], [17]. Furthermore, medicinal 
chemistry approaches have identified molecular derivatives that have proven effective 
in vitro and in cancer cells, making this class of GAC inhibitors of great interest [18], 
[19]. 
The discovery of BPTES as an inhibitor of glutaminase activity was first 
reported by Robinson et al. (2007) [13]. BPTES was shown not to be a glutamine 
competitive inhibitor, but rather competed with the allosteric activator, inorganic 
phosphate, through an ill-defined mechanism. The binding site for BPTES was 
elucidated through X-ray crystallographic studies of this small molecule bound to the 
GAC enzyme, and demonstrated its interaction with the flexible loop critical for GAC 
activation [7], [8], [12], [15], [16]. Indeed, mutations along this loop 
(
316
KEPSGLRFNKLF
327
) can markedly impact enzyme activity. The outcome of these 
mutations vary from inducing constitutive activation in the absence of phosphate 
(K325A) [20], to shifting the dose response for phosphate-stimulated activity 
(F322Y/F327S, K316A) [15], to inhibiting the formation of higher order oligomers 
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(K316Q) [21]. Therefore, the conformation of this loop, and how small molecules 
affect its orientation, will provide a more detailed understanding of the fundamental 
mechanisms underlying the activation of KGA/GAC enzymes. 
4.2 METHODS 
4.2.1 Protein production 
Recombinant GAC was purified as described previously [11]. Briefly, a plasmid 
encoding the mouse kidney-type glutaminase isoform 2 (GAC, NP_001106854.1) 
(residues 72-603) was cloned into a pET23a vector containing an N-terminal histidine 
(His)-tag and thrombin cleavage site. The expressed protein was purified using Co
2+
 
affinity beads (Clontech), followed by anion exchange (GE healthcare) and gel 
filtration chromatography. Purified GAC was stored in a high salt-containing buffer 
(20 mM Tris-HCl pH 8.5, 500 mM NaCl, 1 mM NaN3) at -80°C, following snap 
freezing in liquid N2 for long term use. 
4.2.2 Protein labeling with FRET pairs 
Labeling recombinant GAC with small molecule probes was performed by previously 
described methods [11]. Briefly, 1.5 mg of GAC was first exchanged into 50 mM 
HEPES, pH 7.2, and 100 mM NaCl (labeling buffer), using a PD10 desalting column 
(GE healthcare). The enzyme was then incubated with 50 M (5-fold excess of 
enzyme) of either AlexaFluor 488 succinimidyl ester or QSY9 succinimidyl ester 
(Molecular Probes) for 1 h at 4°C. After 1 h, the labeling reaction was quenched with 
150 mM Tris-HCl, pH 8.5, and unreacted probe was separated from labeled-enzyme 
using a PD10 desalting column, eluting labeled-GAC back into the high salt-
containing buffer.  
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4.2.3 Inducible Dbl cell system 
Inducible MEFs were generated as described previously [11]. Briefly, the gene 
encoding oncogenic-Dbl was sub-cloned into the pTRE-HA vector (Clontech). The 
pTRE-HA-onco-Dbl was then co-transfected with pMET-Puro in a 20:1 ratio into 
parental MEFs (Clontech), which contained the transcriptional transactivator (tTa), 
with Lipofectamine (Invitrogen). Cells were placed under puromycin selection at 48 
hours post transfection, and colonies were selected after 2-4 weeks for doxycycline-
dependent expression of HA-onco-Dbl using HA.11 antibody (Covance). Cells were 
maintained in DMEM supplemented with 10% (v/v) FBS (clontech) and 100 g/mL 
G418 (Gibco). To suppress Dbl expression, 1 g/mL doxycycline was added to the 
medium every 2 days. Cells were induced by re-plating in doxycycline-free medium 
where residual doxycycline was removed by replacing the medium 3 hours after 
plating. 
4.2.4 Inducible MEF saturation density analysis 
DMEM medium supplemented with 10% FBS with or without 1 μg ml−1 doxycycline 
was added to 6-well plates (2 ml per well), and then seeded with 1 × 105 MEFs per 
dish. Following cell attachment (4 h), growth medium was replaced with DMEM 
supplemented with 5% FBS. Following an overnight incubation (~16 hrs) medium 
was replaced again with DMEM supplemented with 5% FBS containing the 
appropriate drug concentrations where appropriate. Growth medium was subsequently 
replaced at 48 h intervals. At day 8, growth medium was removed and 1.5 ml 3.7% 
formaldehyde solution in H2O was added for 30 min. The formaldehyde solution was 
removed, and 1.5 ml crystal violet solution was added for 20 min at room temperature. 
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This was then removed, the dishes washed with H2O, and allowed to dry before 
imaging. 
4.2.5 SEC-MALS analysis 
Purified GAC and GAC mutants were subjected to multi-angle light scattering 
(MALS) as previously described by Moller et al. (2013) [22]. Briefly, 50 L samples 
of 5 mg/mL GAC, with or without 30 min preincubation with 100 M BPTES, were 
injected onto a BioSep-SEC-S4000 size-exclusion column (Wyatt technology), 
coupled to a static 18-angle light scattering detector (DAWN HELEOS-II) and a 
refractive index detector (OptiLab T-rEX, Wyatt Technology), at 23°C.  The size-
exclusion column was equilibrated with 20 mM Tris-HCl, pH 8.5, and 200 mM NaCl, 
and when approprite 50 mM K2HPO4 or K2SO4. The flow rate was kept at 1 mL/min. 
RMS radius and mass distribution (polydispersity) were analyzed using the ASTRA 
software, with monomeric BSA (Sigma) serving to normalize the light scattering 
signal. 
4.2.6 End-point glutaminase assays 
Activity assays used to evaluate the activity of GAC mutants and inhibition by BPTES 
and CB-839 followed a two-step protocol adapted from Robinson et al. (2007) (17).  
Briefly, for phosphate activity profiles, 20 L of 20 mM glutamine, 50 mM Tris-
acetate, pH 8.5, and 0.1 mM EDTA, containing the appropriate concentration of 
K2HPO4 or K2SO4, was added to a UV-transparent Costar 96-well plate (Corning). For 
inhibition assays, drugs dissolved in DMSO were added to give the appropriate 
concentration to 20 L of 20 mM glutamine, 50 mM Tris-acetate, pH 8.5, 0.1 mM 
EDTA, and 50 mM K2HPO4. To initiate the reaction, 5 L of a solution of the 
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appropriate concentration of GAC to give 50 or 100 nM, in 20 mM Tris-HCl, pH 8.5, 
100 mM NaCl, and 1 mM NaN3, was added to the glutamine solution and incubated at 
23°C for 2 min before the reaction was quenched using 2.5 L of 3 M HCl. The 
second step was initiated by the addition of 200 L of 12 units/L GDH, 2 mM 
NAD+, 100 mM hydrazine (Sigma), and 100 mM Tris-HCl, pH 9.2, on top of the first 
quenched reaction and incubated for 45 min at 23°C before reading NADH 
absorbance.  Glutamate produced by the first reaction was determined from the 
amount of NADH generated in the second reaction by using the extinction coefficient 
for NADH (6,220 M-1 cm-1). 
4.2.7 Fluorescence experiments 
Fluorescence experiments were performed using a Varian Cary Eclipse Fluorometer in 
the counting mode.  Experiments were all performed using 1-mL samples with 
continuous stirring at 20°C in 50 mM Tris-Acetate, pH 8.5, 0.1 mM ethylenediamine 
tetraacetic acid (EDTA). For FRET assays, 75 nM QSY9-labeled GAC was added to 
25 nM 488-labeled GAC while monitoring fluorescence emission at 520 nm, exciting 
at 490 nm. After equilibration for 10 min, either 100 mM K2HPO4 or K2SO4, 500 nM 
BPTES or CB-839 was added and equilibrated for 5 min. Finally, 1 M unlabeled WT 
GAC was added. For tryptophan emission scans, excitation and emission wavelengths 
were 285 and 310-390 nm, respectively. For kinetics experiments, excitation and 
emission wavelengths were 285 and 340, respectively. For drug titrations, BPTES and 
CB-839 at appropriate concentrations were added to 100 nM F327W-GAC to give less 
than 0.5% DMSO. Points for the dose-dependent quenching were taken from the 
equilibrated kinetics curve and fit to a bimolecular ligand binding equation after 
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correcting for fractional saturation, using the relation of free and unbound 
enzyme/drug complex (i.e. fbound + ffree = 1, where fbound = F/Fmax). Similarly, 1 M 
BPTES was added to 100 nM D391K-F327W. For allosteric activator titrations, 75 
mM K2HPO4 was injected into increasing concentrations of F327W-GAC. Likewise, 
100 mM of K2HPO4 or K2SO4 was added to 500 nM F327W-GAC. For titrations, the 
appropriate concentration of K2HPO4 or K2SO4 was added to 500 nM F327W-GAC. 
Points for the titration curves were taken from the equilibrated portion of the kinetic 
curves.  
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4.3 RESULTS 
4.3.1 Comparison of the effects of allosteric activators and BPTES-class 
inhibitors on GAC. 
Previous work by our laboratory and others have demonstrated the requirement 
for both KGA and GAC to form homo-tetramers in order to become activated [11], 
[13], [14], [23], [22]. As described in Chapter 2 (section 2.3.2) above, using the 
developed FRET assay that detects GAC’s ability to form tetramers, the effect 
allosteric activators and inhibitors have on tetramer formation can be monitored in 
real-time. Using this assay, we observed an increase in the degree of FRET by the 
addition of the allosteric activators, inorganic phosphate and sulfate (Figure 4.1B). 
The phosphate/sulfate-bound tetramers were found to be readily reversible upon the 
addition of excess unlabeled GAC subunits, which competes with the GAC FRET 
pairs, effectively decreasing the observed FRET signal. Similarly, the addition of the 
allosteric inhibitors, BPTES and CB-839, to GAC FRET pairs increased the FRET 
read-out, reflecting the rapid formation of tetramers upon inhibitor binding (Figure 
4.1C). However, in the presence of either BPTES or CB-839, tetramers were resistant 
to dissociation following the addition of excess unlabeled GAC subunits, 
demonstrating the formation of stable inhibitor-bound GAC tetramers. Under the same 
conditions, in the absence of BPTES or CB-839, addition of excess unlabeled GAC 
results in the exchange of dimers and the effective dilution of donor-acceptor FRET 
pairs (Figure 4.1C; compare DMSO (—) vs. CB-839 (—) and BPTES (—) curves).  
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FIGURE 4.1 – Both allosteric activators and BPTES-class inhibitors induce GAC 
tetramer formation.  (A) The anionic allosteric activators, inorganic phosphate and 
sulfate, and inhibitors, BPTES and CB-839. (B),(C)  FRET assay where the FRET 
signal of 25 nM 488-labeled GAC fluorescence (i.e. FRET donor) is stimulated by 
the addition of 75 nM QSY9-GAC (i.e. FRET acceptor), representing the 
formation of tetramers. Addition of 100 mM of the anionic activators, inorganic 
phosphate (—) or sulfate (—)  (B), or 500 nM of either BPTES (—) or CB-839 
(—) (C), rapidly increases the FRET signal, characteristic of the formation of 
GAC tetramers. The increase in FRET is not readily reversible by the addition of a 
10-fold excess of unlabeled GAC subunits when compared to DMSO control (—), 
therefore representing the formation of a stable drug-induced tetramer, but is 
readily reversible in the presence of activators. (D) Scheme illustrating the 
oligomer transitions from a GAC dimer to tetramer, where the tetramer species is 
depicted giving rise to the FRET signal and being the active species. Allosteric 
activators inorganic phosphate and sulfate are depicted at the dimer to tetramer 
transition to emphasize their ability to activate GAC, whereas inhibitors BPTES 
and CB-839 bind to the FRET pairs at the dimer-dimer interface forming a stable 
BPTES-bound inactive tetramer (BPTES shown in green spheres). 
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The tetramer formation that underlies the FRET changes and the stabilization provided 
by anions that potentiate glutaminase activity (i.e. SO4
2-
 and HPO4
2-
) or inhibitors 
which enhance the formation and stability of tetramers (i.e. BPTES and CB-839) are 
summarized schematically in Figure 4.1D. 
We also compared the ability of BPTES and CB-839 to inhibit recombinant 
GAC activity, by monitoring the NADH fluorescence that accumulates as a result of a 
coupled real-time enzyme assay [11]. Figure 4.2A shows a direct comparison of 
inhibition by BPTES and CB-839 following initiation of the reaction by glutamine, 
but prior to the addition of the activator HPO4
2-
 (i.e. basal activity). Consistent with the 
ability of CB-839 to increase the stability of GAC FRET pairs, when compared to 
BPTES (Figure 4.1B; compare (—) to (—)), GAC treated with CB-839 was more 
resistant to phosphate activation (Figure 4.2A; compare BPTES (—) and CB-839 (—) 
traces). The relative phosphate stimulated activity is shown in Figure 4.2B, where an 
initial rate analysis reveals a persistent inhibition of CB-839 in the presence of excess 
phosphate.  
Previous studies have established the efficacy of the dibenzophenanthridine-
class of glutaminase inhibitors to reverse cell transformation induced by oncogenic 
Dbl, a guanine nucleotide exchange factor for Rho-GTPases [10], [11]. Activation of 
the Rho-GTPases, through the tetracycline dependent expression of the oncogenic 
form of Dbl, has been shown to stimulate glutaminolysis that is required for 
transformation [10], [11], [24]. Despite the differences between BPTES and CB-839 
inhibition in vitro, both compounds were found to inhibit the proliferation of MEFs 
driven by the induced expression of onco-Dbl at similar potencies (Figure 4.3). 
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FIGURE 4.2 – CB-839, but not BPTES, potently inhibits phosphate stimulated 
GAC activity. (A) Real-time NADH activity assay of GAC activity, where the 
evolution of NADH that results from the coupled reaction in which GAC catalyzes 
glutamate production and GDH catalyzes the conversion of glutamate to -
ketoglutarate (and NAD
+
 to NADH). Basal activity of 10 nM GAC was first 
measured upon the addition of 20 mM glutamine, followed by treatment with 1 
M BPTES (—), CB-839 (—), or the vehicle DMSO (—), and finally the addition 
of 100 mM HPO4
2-
 (Pi) (B) Relative rate analysis was performed on the inhibition 
of phosphate-stimulated GAC activity from (A) and normalized to the DMSO 
control. Error bars represent the S.D. of three independent experiments. 
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Taking these observations of the inhibitory properties of the BPTES-class of 
molecules towards glutaminases, as well as an established link between the degree of 
cellular glutaminase activity and glutamine dependence in cancer cells, the 
mechanistic detail of how either compound affects the activity of GAC/KGA is still 
not well defined. Of particular interest is how these small molecules interact with the 
activation loop within the dimer-dimer interface where BPTES binds. Here, we set out 
to engineer a fluorescence reporter group within the flexible activation loop in order to 
monitor its movements in response to allosteric inhibitors and activators. 
4.3.2 Examination of the BPTES binding site on GAC. 
 With respect to their ability to drive tetramer formation, both inhibitors and 
activators result in similar FRET increases yet result in opposite outcomes for enzyme 
activity.  In order to examine this at a structural level, we compared the available X-
ray crystal structures for KGA and GAC in order to better understand the allosteric 
control of their enzymatic activity. Currently, there are 16 high resolution X-ray 
crystal structures for either GAC or KGA. It is important to note that KGA and GAC 
have identical sequences and differ only in their C-termini, which are unresolved in all 
X-ray crystal structures. Upon analysis of each structure, only six of these provide 
sufficient electron density of the activation loop (comprising residues 
320
GLRFNKL
326
) to resolve atomic positions unambiguously [12], [15], [16]. Of the 
six structures with a resolved activation loop, four are co-crystal structures with 
BPTES (3VOZ, 3VP1, 3UO9, 4JKT), one is a co-crystal structure with the active site 
inhibitor DON (4O7D), and the other is without either BPTES or DON but includes 
two inorganic anions of sulfate per KGA monomer (3VOY).
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FIGURE 4.3 – Both CB-839 and BPTES inhibit Dbl-induced growth at saturation 
density. Inhibition of cell-cell contact-independent growth assays of Dbl-
transformed cells. MEFs were induced to express onco-Dbl upon removal of the 
antibiotic doxycycline (dox), and then treated with increasing concentrations of 
BPTES and CB-839. Cells were plated at 1x10
5 
density and grown for 6 days in 
DMEM supplemented with 5% FBS, with or without dox, fixed and stained with 
crystal violet.  
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Interestingly, in the activator/KGA complex, one sulfate is bound proximal to the 
activation loop resolved in 3VOY through interactions formed directly with tyrosine 
399 and lysine 403, and represents the probable binding site for allosteric activators. 
We also noted significant differences when comparing the two apo-structures 
that have sufficient resolution of the activation loop, but without BPTES (4O7D, 
3VOY), to all other BPTES-bound glutaminase structures. To illustrate this, Figure 
4.4A presents a space filling model of a DON-bound GAC tetramer (4O7D), which 
has been aligned with the BPTES/SO4
2-
-bound GAC structure (3VOZ), to show the 
BPTES and SO4
2-
 binding sites. The marked changes in the orientation of the 
activation loop are illustrated in Figure 4.4B, with the loop in the DON-bound GAC 
(cyan) being significantly displaced relative to its position in the BPTES-bound GAC 
structure (magenta). The displacement of the activation loop represents the extremes 
of the observed conformational states in X-ray crystal structures to date, where the 
loop assumes a variety of conformations. We reasoned that we might be able to 
observe this conformational transition in real time by replacing a wild-type residue 
with the environmentally sensitive amino acid tryptophan. With this in mind, three 
residues were selected for tryptophan substitution, F323, F327, and Y399. F323 and 
F327 are significantly displaced in the BPTES-bound structures (Figure 4.4B, the 
movement of F327 is shown with a red arrow), and Y399 is directly adjacent to the 
thiadiazole ring of BPTES. These residues have previously been shown to be critical 
for the activation of the enzyme, as well as for the inhibition of catalytic activity by 
BPTES [20], [21].  
  
-160- 
 
  
FIGURE 4.4 – Comparison of BPTES-bound and unbound GAC structures. (A) 
Surface representation of the crystal structure of the GAC tetramer bound with 
ligands DON (4O7D), BPTES, and sulfate (aligned from 3VOZ), where BPTES 
and sulfate bind proximal to the activation loop and DON binds within the active 
site. (B) Zoomed in region of the aligned DON-bound (cyan) and BPTES/SO4
2-
 
bound (magenta) GAC structures depicting the marked reorientation of the 
activation loop. The ~180° rotation of the F327 residue with and without BPTES 
are highlighted (red arrow).  
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4.3.3 The F327W mutation is sensitive to inhibitor binding and provides a direct 
read-out for BPTES and CB-839 
Upon substitution of these three residues to tryptophan, we analyzed their 
fluorescence (excitation = 285 nm, emission = 310-390 nm) before and after the 
addition of BPTES. Of the positions selected for mutagenesis, we found that 
substituting tryptophan for phenylalanine at position 327 resulted in a marked 
quenching of the tryptophan fluorescence upon BPTES addition (Figure 4.5B, 
compare (—) to (—)). However, no changes in fluorescence emission were observed 
in wild-type GAC (Figure 4.5B) or the F323W or Y399W mutants in the presence of 
BPTES (not shown). We then determined the molecular weight profiles of WT GAC, 
and the individual tryptophan mutants, in both the absence and presence of BPTES, 
using multi-angle light scattering downstream of size exclusion chromatography 
(SEC-MALS). A significant shift in the molecular weight distribution for the F327W 
mutant and WT GAC was observed, but not for F323W or Y399W, following pre-
incubation with BPTES (Figures 4.5C-D; solid lines represent elution of GAC, broken 
lines represent the calculated molecular weight). This trend of an increase in the 
molecular weight distribution from a GAC dimer to a tetramer, following pre-
incubation with BPTES, observed for the F327W mutant, further verifies the ability of 
the F327W mutant to bind and respond to BPTES. Additionally, the F327W mutant 
retained a WT activity profile, with a Vmax and K1/2 for phosphate activation closely 
matching that of WT GAC (Figure 4.5E).  
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FIGURE 4.5 – F327W detects BPTES binding while retaining WT properties. (A) 
Tryptophan fluorescence spectrum of both WT GAC and (B) the F327W mutant, 
before (—) and after (—) addition of 1 M BPTES, shows no change for WT 
GAC but a significant quenching for the F327W mutant. (C) SEC-MALS elution 
profile (solid lines) and molecular weight distribution (broken lines) of a 5 mg/mL 
sample of WT GAC and F327W (D) before ((—), (---)) and after ((—), (∙∙∙)) pre-
incubation with 50 M BPTES. A significant shift from a heterogeneous 
population of dimers and tetramers, to a more homogenous population of 
tetramers, is observed following pre-incubation with BPTES. (E) The F327W 
mutant () retains its catalytic properties when compared to WT GAC (), with 
an observed K1/2 of 15.0 ± 1.7 mMol/L and a Vmax value of 435 ± 19 Mol/min, 
versus a K1/2 of 16.4 ± 0.4 mMol/L and a Vmax value of 453 ± 8 Mol/min for WT 
GAC. 
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The ability of the F327W mutation to read-out BPTES binding is most likely 
due to its interactions with BPTES through its peptide bond, and not the outcome of a 
direct contact with the indole side-chain (Figure 4.6A). The orientation of the native 
phenylalanine in the BPTES-bound GAC structures shows no interaction of the amino 
acid side-chain with other residues. However, DeLaBarre and colleagues (2011) 
described the electrostatic interaction of BPTES with the peptide backbone of residues 
L326 and F327 [15]. These interactions, which they refer to as a “-basket”, are 
formed between the peptide backbone and the nitrogen atoms within the thiadiazole 
ring of BPTES (Figure 4.6A, dotted lines). Interestingly, both Cassago et al. (2012) 
and Thangavelu et al. (2012) also reported the electrostatic interaction between 
BPTES and the peptide backbone of these two residues, but involving the sulfur atom 
of the thiadiazole ring rather than the nitrogens (Figure 4.6B) [12], [16]. The 
requirement of BPTES analogues to possess these thiadiazole rings is apparently 
absolute in order to maintain potency, where bis-thiadiazoles were the original 
scaffold that characterized the first generation of glutaminase inhibitors [13], [18], 
[25]. Although tryptophan fluorescence is sensitive to the environment of the indole 
sidechain, it is also sensitive to the electrostatics of its main chain amino and carboxyl 
groups, and hence the likely cause of the marked quenching observed here. 
Derivatives of BPTES have been proven to be effective inhibitors in vivo, with 
compound CB-839 being the most potent to date with a reported IC50 value of ~30 
nM.  
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FIGURE 4.6 – F327 peptide backbone interacts with the thiadiazole ring of 
BPTES-class inhibitors. (A) Close-up of the interaction of BPTES in two different 
orientations from two separate published structures ((A) 3UO9, and (B) 4JKT) and 
the native residues L326 and F327 of GAC [15],[16]. Interactions of the peptide 
backbone of these residues to the bis-thiadiazole ring of BPTES are highlighted 
with dashed lines. 
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However, the inhibitory properties of CB-839 were shown to be distinct from that of 
BPTES, where CB-839 increased its potency following pre-incubation with GAC, and 
retained its inhibitory activity for a longer time period upon removal of excess 
inhibitor (i.e., suggesting that it has a slower off rate from the enzyme compared to 
BPTES) [7]. Here, we sought to utilize the quenching of the tryptophan fluorescence 
of the F327W mutant to compare the kinetics and binding efficiency of both BPTES 
and CB-839.  
Our results show that addition of BPTES or CB-839 to the F327W mutant 
resulted in a rapid, dose dependent quenching of tryptophan fluorescence (Figures 
4.7A,B). We found each inhibitor reached equilibrium within 10 minutes, with CB-
839 displaying slightly slower binding kinetics than BPTES. Somewhat unexpectedly, 
the binding isotherms for each inhibitor gave very similar profiles and KD values 
(Figure 4.7C). CB-839 exhibited a slightly shifted binding curve, with a KD of 34 ± 5 
nM, compared to BPTES, with a KD of 70 ± 5 nM. This shift in binding affinity 
represents the difference in the apparent ability of these two compounds to bind to the 
activation loop, and suggests that they have a similar potency. The two-fold difference 
for the binding affinities as read out by F327W fluorescence quenching was in good 
agreement with the dose dependent inhibition of WT GAC (Figure 4.7D, CB-839 IC50 
= 23 ± 1 nM versus BPTES IC50 = 108 ± 17 nM). 
One aspect of BPTES binding to GAC that has not been investigated is 
whether BPTES binds to a preformed GAC tetramer, or to the peptide loop of a GAC 
dimer to promote tetramer formation.  
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FIGURE 4.7 – F327W fluorescence as a binding assay for BPTES-like 
molecules. Addition of increasing concentrations of BPTES (A) and CB-839 (B) 
quenches the tryptophan fluorescence of 100 nM F327W. (C) Fluorescence 
quenching of F327W mutant by BPTES (—) and CB-839 (—) quantified and fit to 
a bimolecular interaction equation, giving a KD value of 70 ± 5 nM and 31 ± 5 nM 
for BPTES and CB-839, respectively. (D) Inhibition of 50 nM WT GAC activity 
by BPTES () and CB-839 (), giving IC50 values of 108 ± 17 nM for and 23 ± 1 
nM respectively.  
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To demonstrate the requirement of BPTES to bind to the tetrameric form of 
KGA/GAC, we took advantage of a mutation along the dimer-dimer interface, namely 
D391K, previously shown in Chapter 2 (section 2.3.1) to block the ability of GAC to 
form tetramers [11]. Aspartate 391 is critical for tetramer formation, where it forms a 
salt bridge with K401, both of which reside at the interface between two dimers. Due 
to the 2-fold axis of symmetry of the GAC tetramer, the single change of aspartate 391 
to lysine, and hence the introduction of a charge-charge repulsion, results in four 
disrupted salt bridges per GAC tetramer that is sufficient to prohibit tetramer 
formation [11]. To investigate whether BPTES binds to the activation loop of a 
constitutive GAC dimer, we introduced the D391K mutation into the GAC (F327W) 
background and found that this single substitution completely ablated the ability of 
BPTES to induce a change in the tryptophan fluorescence (Figure 4.8A, compare (—) 
to (—)). We further examined the GAC(F327W, D391K) double mutant using SEC-
MALS to confirm that it existed in the constitutive dimeric state, both with and 
without pre-incubation of BPTES. We found that the double mutant indeed exhibited a 
molecular weight distribution consistent with a dimeric species, in the presence and 
absence of BPTES, thus further illustrating the requirement of a GAC tetramer to form 
in order for BPTES to bind and induce an inhibitory state of the enzyme (Figure 4.8B, 
solid lines represent elution of GAC and broken lines represent the measured MW). 
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FIGURE 4.8 – GAC tetramer formation is required for BPTES binding. (A) 
Tryptophan fluorescence of 500 nM of the F327W GAC mutant (—) is rapidly 
quenched following the addition of 1 M BPTES, but does not quench the 
fluorescence of 500 nM of the dimeric mutant GAC (F327W, D391K) (—). (B) 
SEC-MALS analysis of 5 mg/mL GAC (F327W, D391K) mutant shows a 
constitutive dimer molecular weight distribution, both before (---) and after (∙∙∙) 
pre-incubation with 50 M BPTES. 
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4.3.4 Allosteric activators enhance F327W fluorescence 
Previous studies of the activation of the KGA/GAC enzymes revealed that their 
enzymatic activity was markedly increased upon the addition of various inorganic 
anionic ions [13], [22], [26], [27]. The most potent of these activators, inorganic 
phosphate, has been highly studied, having been shown to affect the oligomeric state 
of both Gls isoforms. Additionally, recent high resolution X-ray crystal structures have 
revealed potential binding sites for these anions (see Figure 4.4A,B), and suggest that 
they exert their effects on enzymatic activity by changing the conformation of the 
activation loop [12].  
Here, we examined the effects of these anionic activators on the tryptophan 
fluorescence of the F327W mutant, in order to further elucidate the mechanism by 
which they stimulate GAC activity. We first tested those anions that have been 
reported to lead to the activation of glutaminase enzymes, namely phosphate and 
sulfate. Unlike the changes observed for BPTES and CB-839, the addition of these 
anions to GAC (F327W) resulted in the marked enhancement of the tryptophan 
fluorescence (Figure 4.9A), thus providing evidence that these anions directly affect 
the conformation of the activation loop. Interestingly, we found that the dose 
dependent increases of fluorescence enhancement correlated well with the ability of a 
given anion to activate GAC. More specifically, sulfate was ~50% as effective as 
phosphate, which correlated well with their abilities to enhance the tryptophan 
fluorescence of GAC (F327W) (i.e. 15% versus 25%, respectively). Titrations with 
these anions yielded binding curves that were in good agreement with their ability to 
activate WT GAC (Figure 4.9B, compare (●) and (●) to (♦) and (▲)), suggesting 
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they indeed act through a similar mechanism by affecting the conformation of the 
activation loop.  
We next investigated the effects of these ions on the molecular weight 
distribution of GAC, as read-out by SEC-MALS, and found that sulfate stimulated the 
formation of a mixture of 16-mer and 8-mer’s, but not the larger oligomers that are 
induced by phosphate (Figure 4.9C, compare (---) and (∙∙∙) representing molecular 
weight for eluted species). This observation is consistent with the overall differences 
in the ability of sulfate versus inorganic phosphate to stimulate GAC enzymatic 
activity and to enhance F327W fluorescence.  
The mechanism by which inorganic phosphate activates GAC activity is still 
unclear. In fact, it has been suggested that phosphate binds within the active site 
following catalysis, where it creates an electrostatic repulsion with the product 
glutamate to increase its off-rate, thereby effectively increasing the catalytic turnover 
[16]. The second proposed mechanism, as mentioned above, suggests phosphate 
interacts with the activation loop at the GAC dimer-dimer interface, much like 
allosteric inhibitors such as BPTES, and allows the loop to access an active 
conformation to stimulate catalysis [12]. The sensitization of the tryptophan 
fluorescence of the F327W mutant observed here is consistent with the latter 
mechanism. Furthermore, we found that the fluorescence enhancement induced by 
phosphate addition was dependent on the GAC concentration, and therefore the 
proportion of tetramers. 
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FIGURE 4.9 – F327W fluorescence is enhanced by allosteric activators and 
proportional to their ability to activate GAC activity. (A) Addition of inorganic 
phosphate (HPO4
2-
) or sulfate (SO4
2-
) to give a 50 mM solution to 400 nM of the 
F327W mutant resulted in the enhancement of tryptophan fluorescence, where 
inorganic phosphate stimulated the greatest enhancement (—), followed by sulfate 
(—).  (B) Glutaminase activity of 50 nM WT GAC was measured in the presence 
of increasing concentrations of the anions phosphate (●) and sulfate (●), giving a 
K1/2 of 20.6 ± 0.4 mMol/L  and 36.4 ± 3.0 mMol/L respectively. Tryptophan 
fluorescence enhancement by addition of these anions to 400 nM F327W is 
overlaid ((♦) and (▲)). (C) SEC-MALS of 5 mg/mL WT GAC, where the anions 
inorganic phosphate (—) and sulfate (—) were included in the running buffer at a 
concentration of 50 mM, shows the shift from a molecular weight distribution of a 
heterogeneous population of dimers and tetramers in the absence of either anion (-
--), to an equilibrium of 8 to 16-mers for sulfate (∙∙∙) up to greater than 32-mers for 
phosphate (∙ ∙ ∙). (D) The increased enhancement of the F327W fluorescence ((●), 
left axis) upon addition of 50 mM HPO4
2-
 to increasing concentrations of GAC 
(F327W) was plotted with previously reported FRET values of 488 and QSY9-
labeled WT GAC, and the specific activity of WT GAC measured in the absence 
of phosphate [11], to give a KD of 75 ± 28 nM for Tryp fluorescence.  
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When this enhancement was plotted with respect to the concentration of GAC, it was 
in good agreement with previous FRET measurements that reflect the binding 
isotherm of GAC dimers to tetramers, and the concentration-dependent activation of 
the WT enzyme (Figure 4.9D, compare (●) and (●) on left axis to (▲) on right axis). 
Taken together, these results suggest that phosphate binding affects its catalytic 
properties by interacting with the GAC tetramer, thereby inducing a conformational 
change with residues within the activation loop. 
4.4 DISCUSSION 
Extensive studies of the structure and function relationships of GAC and KGA 
enzymes have revealed that these metabolic enzymes, which are essential for 
glutamine metabolism within mammalian cells, are governed by their self-association 
to form tetramers [23], [27]–[30]. However, the mechanism by which this tetramer 
formation stimulates enzymatic activity is not fully understood, and represents a 
challenge for describing the activation of this important enzyme family of drug targets. 
The fact that a class of small molecule inhibitors, namely the bis-thiadiazole 
derivatives, binds to the active tetrameric form of the enzyme in order to inhibit 
activity was a surprising discovery and further highlights the interest in the mechanism 
governing activation. Here, we set out to develop a spectroscopic read-out for the 
flexible loop where BPTES binds, to aid in obtaining mechanistic insights into how 
allosteric activators and inhibitors impact the loop and thereby exert their regulatory 
functions.  
Recently, there has been a concerted effort to find small molecule candidates to 
inhibit glutaminase enzymes using medicinal chemistry approaches [18], [19], [31]. 
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Here, we first compared the differences between the allosteric activators, inorganic 
phosphate and sulfate, and the two most commonly used allosteric inhibitors, CB-839 
and BPTES, in fluorescence assays that reflect the dynamics of GAC to form 
tetramers. We showed that both allosteric activators and inhibitors induced the 
formation of GAC tetramers, however inhibitors were readily distinguished from 
activators by their ability to form stable irreversible tetramers. We found that 
compound CB-839 indeed acts similar to BPTES, with the addition of either drug 
quickly inducing tetramer formation, which is not readily reversible upon the addition 
of excess unlabeled GAC subunits. These results agree with previous observations that 
CB-839 acts through a similar mechanism as BPTES, by binding at the dimer-dimer 
interface and promoting the formation of an inactive tetramer. We also sought to 
investigate the difference between these two compounds to inhibit a fundamental 
characteristic of transformed cells, the loss of cell-cell contact inhibition, driven by the 
potent oncoprotein Dbl, and found that each compound inhibited this property of 
cellular transformation.  
To address how allosteric activators and inhibitors both induce tetramer 
formation, but exert opposing effects on enzyme activity, we investigated available X-
ray crystal structures of GAC/KGA enzymes and noticed differences between the 
conformations of the activation loop. We reasoned that by comparing the activation 
loop in the BPTES-bound GAC structure, versus that for free GAC, we might be able 
to identify potential residues, that when substituted with the fluorescent amino acid 
tryptophan, would be sensitive to the dynamics of the loop. We show here that the 
selective substitution of a single amino acid within the activation loop, phenylalanine 
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327, to a tryptophan, retains the normal catalytic activity of the enzyme, and provides 
a useful readout for the binding of allosteric inhibitors and activators. This native 
phenylalanine residue has been shown previously to be an important residue for the 
activation of the KGA/GAC isoforms. Additionally, F327 is one of the only two 
residues that differ between Gls2/Gls isozymes along the activation loop, where 
phenylalanine at position 323 on Gls is a tyrosine in Gls2, and phenylalanine 327 is a 
serine [12], [15]. Both of these isozymes have been described to have markedly 
different catalytic properties, and it was of interest here that only the F327W mutant 
preserved WT GAC activity.  
The efficacy of CB-839, when compared to BPTES, has been suggested to be 
far superior, with reported IC50 values of 30 nM for CB-839 and between 80 nM and 3 
M for BPTES [12]–[15], [18], [32]. Here, we used the GAC (F327W) mutant to 
directly test the binding of these two compounds in real time, and found that they have 
similar dissociation constants (30 nM and 70 nM for CB-839 and BPTES, 
respectively). Additionally, when the activity of the WT enzyme was monitored in real 
time under identical conditions (i.e. at 100 nM GAC concentration), their IC50 values 
were in good agreement with the binding data. Consistent with these molecules 
binding to the active GAC tetramer, we expected that introducing a mutation which 
prevents GAC from forming tetramers, i.e. the D391K mutant, would similarly 
compromise the binding of BPTES. Indeed, we observed that the binding of BPTES 
was completely ablated using both the fluorescence assay of the F327W mutant and 
SEC-MALS, further emphasizing the prerequisite of GAC’s ability to form tetramers 
to bind BPTES (Figure 4.10). 
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Allosteric activators, such as inorganic phosphate, have been shown to 
promote and or stabilize oligomer transitions of GAC/KGA enzymes. However, 
although GAC/KGA oligomer formation has been consistently observed, the binding 
site for these anionic activators, as well as the mechanistic outcome of oligomer 
formation, is still not well understood. Recent studies have shown that mutations along 
the activation loop of GAC/KGA result in the hyper-activation of these enzymes, such 
that anionic activators elicit no additional activation [15], [20], [21]. These 
observations suggest that the allosteric activators act through the activation loop 
through an undescribed mechanism. Our findings show that these allosteric activators 
elicit an enhancement of the tryptophan fluorescence of the F327W mutant, directly 
correlating with their ability to stimulate GAC activity. These results suggest that the 
allosteric activators bind at the dimer-dimer interface, changing the conformation and 
environment of the loop to varying degrees to promote activated GAC tetramers 
(Figure 4.10).  
In conclusion, our results further elucidate the complex role that the critical 
residues along the activation loop of GAC play in regulating GAC/KGA activity. The 
results presented here show that BPTES and CB-839 interact with the activation loop 
in a very similar manner and reveal the utility of this novel F327W mutant for 
screening the ability of bis-thiadaizoles to bind to the activation loop of KGA/GAC 
enzymes. Additionally, we show that potent allosteric activators directly impact the 
conformational dynamics of the activation loop, and the potential usefulness of the 
F327W mutant in screening for other small molecule activators. 
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FIGURE 4.10 – Model of oligomeric species of GAC induced by allosteric 
activators and BPTES-class inhibitors. Inactive dimers associate to form active 
tetramers in the absence of allosteric activators or inhibitors, stimulating GAC’s 
basal activity. Anionic activators, such as inorganic phosphate (Pi), bind to the 
GAC tetramer at the activation loop to stimulate an active conformation, inducing 
“phosphate-stimulated” activity. BPTES-class inhibitors bind to the activation 
loop in either phosphate-bound or unbound GAC tetramers, locking the activation 
loop in an inactive state, forming highly stable drug-bound tetramers. 
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CHAPTER FIVE 
Glutamine metabolism is directly related to a dimer-to-tetramer shift of GAC in 
transformed cells and mouse tissues 
5.1 INTRODUCTION 
Emerging evidence indicates that oncogenes and tumor suppressors, 
responsible for driving normal cells to the oncogenic state, directly impact cellular 
metabolism to support the metabolic requirements of uncontrolled growth [1]–[5]. As 
mentioned earlier, the principal metabolic shift observed in a variety of cultured 
cancer cell lines is the shift from glucose to glutamine fueled anaplerosis, and causing 
the cells to exhibit glutamine-dependent growth such that they are deemed to be 
‘glutamine addicted’. This glutamine addiction has been explored in both mouse 
models and human tumors and is currently understood as a means for cells to adapt to 
the nutrient and oxygen stressed environment of the tumor stroma [6], [7]. However, 
the molecular mechanisms by which these oncogenes and tumor suppressors alter the 
cells metabolic pathways remain unclear. More specifically, it remains poorly 
understood how oncogenes exert their influence on metabolic enzymes to affect their 
enzyme catalysis.  
Recent metabolic flux studies take advantage of stable isotope tracing of 
13
C, 
2
H, or 
15
N isotopes in transformed cells, and using these methods have identified the 
unique metabolic phenotypes associated with individual transformation events [8], [9]. 
For example, Son et al. (2013) have shown K-ras mediated increases in glutamine 
metabolism in a pancreatic ductal adenocarcinoma (PDAC) model [10]. Similarly, Le 
and colleagues (2012) characterized the reliance of human Burkitt lymphoma cells on 
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glutamine dependent anaplerosis resulting from their transformation by the expression 
of the MYC oncogene [11]. Comparable results have been found in a variety of cancer 
cells, transformed by a particular lesion within an oncogene or tumor suppressor, such 
as the loss of the Von Hippel Lindau (VHL) tumor suppressor in renal cell carcinoma 
[12]–[14] or loss of the phosphatase and tensin homolog (PTEN) in T cell acute 
lymphoblastic leukemia (T-ALL) [15]. These metabolic flux studies, which utilize 
stable isotope tracing methods, have served to bring clarity to how the metabolic 
rewiring is directed by oncogenic transformation. 
In most cases, the observed increase in glutaminolysis in cancer cells that are 
deemed glutamine addicted is attributed to the increased expression of the 
mitochondrial glutaminase enzyme, GAC. One such case recently discovered by our 
laboratory was the increased expression of GAC directly downstream of JNK 
signaling pathways in a panel of breast cancer cell lines, thereby providing a 
molecular description of GAC up-regulation in breast cancer through increased GAC 
transcription and translation [16]. Additionally, post-transcriptional regulation 
mechanisms, such as those through the micro-RNA regulation of RNA transcripts, 
have also been described. The oncogene MYC and proliferative signaling molecule 
NF-B, specifically p65, have been shown to regulate GLS translation through this 
micro-RNA mechanism by repressing the micro-RNA miR-23a/b, which acts to 
negatively regulate GLS transcripts [17], [18]. Indeed, increased glutaminolysis, 
leading to a glutamine dependent phenotype, is consistently reported for MYC 
transformed cells [11], [19]–[24]. However, it remains uncertain how GAC activity is 
impacted within mitochondria. As described previously in Chapter 2, KGA/GAC 
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enzymes depend on the formation of tetramers to become activated, but this has yet to 
be demonstrated as a direct result of oncogene expression in cells.  
In order to study the role of GAC up-regulation and activation in oncogenic 
transformation, we make use of a model cell system using tetracycline controlled gene 
expression in mouse embryonic fibroblasts (MEFs) to examine the effects of induced 
expression of the oncogenic Rho GTPase GEF (guanine nucleotide exchange factor) 
Dbl (for Diffuse B-Cell Lymphoma) and subsequent hyper-activation of Rho GTPases 
(Figure 5.1A). Using this model cell system, we show the increased glutaminolysis 
that results from the induced expression of Dbl, and its inhibition by the small 
molecule inhibitor described previously in Chapter 3, compound 968. We then extend 
these studies by directly assaying the oligomeric state of GAC in Dbl induced cells, 
and show that Dbl induction indeed drives the formation of GAC tetramers. We go on 
to show the utility of this method in assaying the oligomeric state of GAC in other 
cancer cells and solid tissues, where it is proven useful for determining the proportion 
of GAC dimers and tetramers directly that are present in the mitochondria of cells. 
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FIGURE 5.1 – Oncogenic Dbl gives rise to Rho-GTPase driven transformation. 
(A) Cartoon depiction of GTPase cycle, where a Rho G-protein in the inactive 
(GDP-bound) state is activated by a guanine nucleotide exchange factor (GEF) to 
exchange GDP for GTP. The GTP-bound Rho is a signaling-active species (Rho*) 
that can bind effectors to give rise to actin cytoskeleton remodeling, cell cycle 
progression, and gene expression of a myriad of targets. To complete the cycle, a 
GTPase-activating protein (GAP) stimulates the intrinsic GTPase activity of the 
G-protein, causing the hydrolysis of GTP to GDP, thereby returning the G-protein 
to the signaling-inactive state. (B) Protein domains of the proto-Dbl and onco-Dbl 
GEFs, where the oncogenic form is an N-terminal truncation of proto-Dbl that 
lacks the spectrin domain and is no longer susceptible to an auto-inhibitory 
mechanism, thereby causing Dbl to function as a de-regulated, activated GEF 
towards the Rho-GTPases Rac, Rho, and Cdc42. (C) Onco-Dbl activates the Rho-
GTPases Rac, Rho, and Cdc42, which give rise to distinct cellular phenotypes. 
Aberrant Rac, Rho, and Cdc42 activation is known to stimulate formation of 
lamellipodia, stress fibers, and filopodia, respectively.  
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5.2 METHODS 
5.2.1 Isogenic, Dbl-inducible cell system culture conditions and 
immunofluorescence staining 
Inducible oncogenic Dbl cell lines were created using the TET-OFF system in mouse 
embryonic fibroblasts (MEFs) following the manufacturer’s instructions (Clontech).  
Briefly, PCR products for onco-Dbl-containing NotI and XbaI restriction 
endonuclease sites were cloned in the pcr2.1 vector using the TOPO-TA cloning kit 
(Invitrogen) and subsequently subcloned into the p-TRE-HA vector (Clontech).  The 
pTRE-HA-onco-Dbl was then co-transfected with pMET-Puro in a 20:1 ratio into 
parental MEFs (Clontech), which contained the transcriptional transactivator (tTa), 
with Lipofectamine (Invitrogen).  Cells were placed under puromycin selection at 48 
hours post transfection, and colonies were selected after 2-4 weeks for doxycycline-
dependent expression of HA-onco-Dbl using HA.11 antibody (Covance).  Cells were 
maintained in DMEM supplemented with 10% (v/v) Tet system-approved FBS 
(clontech) and 100 g/mL G418 (Gibco).  To suppress Dbl expression, 1 g/mL 
doxycycline was added to the medium every 2 days.  Cells were induced by re-plating 
in doxycycline-free medium where residual doxycycline was removed by replacing 
the medium 3 hours after plating.  Immunofluorescence was conducted on cells grown 
48-72 hours on glass cover slips and fixed with 3.7% formaldehyde.  Fixed cells were 
permeabilized with 0.2% Triton-X 100 and co-stained with -HA (rabbit polyclonal, 
Covance) and -actin (mouse monoclonal, Covance) for 1 hour at 37° C, followed by 
incubation with Oregon green-conjugated -rabbit IgG (Molecular Probes) and 
-193- 
 
Rhodamine-conjugated -mouse IgG (molecular probes).  Digital images were 
collected using a Zeiss fluorescence microscope and AxioVision 3.1 software. 
5.2.2 Metabolic tracing and saturation density assays 
DMEM medium supplemented with 10% FBS with or without 1 μg ml−1 doxycycline 
was added to 6-well plates (2 ml per well), and then seeded with 1 × 105 MEFs per 
dish. Following cell attachment (4 h), growth medium was replaced with DMEM 
supplemented with 5% FBS. Following an overnight incubation (~16 h), medium was 
replaced again with DMEM supplemented with 5% FBS containing the appropriate 
drug concentrations where appropriate. Growth medium was subsequently replaced at 
48 h intervals. At day 8 for Dbl-MEFs, growth medium was removed and 1.5 ml 3.7% 
formaldehyde solution in H2O was added for 30 min. The formaldehyde solution was 
removed, and 1.5 ml crystal violet solution was added for 20 min at room temperature. 
This was then removed; the dishes washed with H2O, and allowed to dry before 
imaging.  
Methods for mass isotopologue distribution analyses using [U-
13
C]glutamine 
or [U-
13
C]glucose (Cambridge Isotope Laboratories) were adapted from Cheng et al. 
(2011) (1). Briefly, induced (16 h in complete media without Dox) or non-induced 
cells (complete media with 1 g/mL Dox) were plated into 100 mm2 dishes at a 
density such that the cells were approximately 60% confluent when adhered, at which 
point the cells were washed with PBS and grown to 80% confluence in DMEM 
supplemented with 1% Tet-approved FBS and 8 M 968/WPK968 for drug treated 
samples, or 0.8% DMSO for control samples, with or without 1 g/mL Dox (i.e. 
overnight). When 80% confluent, cells were then washed with PBS and 
13
C-labeling 
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media containing the appropriate drug, DMSO, and Dox concentrations. Media was 
prepared from glucose- and glutamine-free DMEM powder (Sigma) and supplemented 
with 1% Tet-approved FBS, 2 mM L[U-
13
C]glutamine and 15 mM  unlabeled glucose 
or 15 mM D[U-
13
C]glucose and 2 mM unlabeled glutamine (Figure S1F-G), together 
with 1 g/mL dox for non-induced samples. For samples containing [U-13C]glutamine, 
cells were incubated for 1 hour before extracting metabolites, whereas samples 
containing [U-
13
C]glucose were incubated for 8 hours. Metabolites were extracted by 
first washing cells twice with ice cold normal saline (0.9% w/v NaCl), followed by 
addition of 0.5 mL of a 1:1 methanol:water mixture (-20°C).  An internal standard (50 
nmol of 2-oxobutyrate) was added and samples were subjected to 3 freeze-thaw 
cycles, after which macromolecules were separated by centrifugation.  The 
supernatant was evaporated completely and remaining metabolites silylated in 100 L 
of a trimethylsilyl donor (Tri-Sil, Thermo) for 30 min at 42°C. Metabolites were 
subjected to GC-MS analysis using an Agilent 6970 gas chromatograph networked to 
an Agilent 5973 mass selective detector. Metabolites were identified and isotope 
enrichment calculated as described by Cheng et al. (2011) (1). 
Metabolites were quantified from fresh culture medium after 6 h of both non-
induced and induced cells in the presence of compound 968 or compound 27 using the 
GDH assay as described by the manufacturer (Megazyme, Bray Ireland). 
5.2.3 Mitochondrial isolation and solubilization by detergents 
Mitochondria were isolated from induced and un-induced Dbl-MEFs, TSE cells, HeLa 
cells, and ruptured mouse kidney and liver tissues as described by Frezza et al. (2007) 
[36]. Briefly, Dbl-MEF’s, TSE, and HeLa cells were harvested from four 15 cm2 
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dishes following an overnight serum starvation in DMEM or RMPI supplemented 
with 1% FBS. First, cells were washed with PBS (3x) before being scrapped, added to 
a 50 mL-conical tube, and centrifuged 600g at 4°C for 10 min. Cells were suspended 
in 3 mL in isolation buffer (IC, 10 mM Tris-MOPS, 1 mM EGTA/Tris, 200 mM 
sucrose, pH 7.4), and then homogenized in a glass potter with a Teflon pestle using a 
Dounce homogenizer operated at approximately 1600 rpm for 35 strokes. The 
homogenate was centrifuged 600 x g 10 minutes at 4°C and the supernatant was 
isolated. The supernatant was centrifuged at 7000 x g 10 minutes at 4°C, where the 
resultant pellet contained the isolated mitochondria and the supernatant represented 
the soluble cytosolic and microsomal fractions. The mitochondrial pellet was 
resuspended in mitochondrial isolation buffer and centrifuged again at 7000 x g 10 
minutes at 4°C, where the resulting pellet was taken to be the purified isolated 
mitochondria. Mitochondria were suspended in solubilization buffer (SB, 50 mM 
NaCl, 50 mM imidazole/HCl, 2 mM 6-aminohexanoic acid, 1 mM EDTA, pH 7.0) 
then solubilized in 2% dodecylmaltoside and incubated on ice for 20 min. Solubilized 
proteins were taken from the supernatant following centrifugation at 16,700g 10 
minutes at 4°C. 
 Purification of mouse kidney and liver tissue was performed similarly with 
minor alterations. First, adult mice were euthanized under CO2 for 5 minutes followed 
by cervical dislocation. Organs were harvested and washed thoroughly with ice cold 
isolation buffer to remove visible amounts of blood. Then, organs were minced using 
sterile blades and homogenized in a glass potter with a Teflon pestle using a Dounce 
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homogenizer operated at approximately 1600 rpm for 5 strokes on ice. Mitochondria 
were purified and solubilized in 2% DDM following the same protocol as above.   
5.2.4 1 and 2-Dimensional blue-native/SDS-PAGE assays 
Blue native PAGE gels were prepared by methods adapted by Wittig et al. (2006) 
[26]. Briefly, 4-13% acrylamide gels with a 3.5% stacking gel were prepared from a 
mixture of acrylamide and bis-acrylamide (AB-3, 48g acrylamide and 1.5g 
bisacrylamide per 100 mL) and 3x gel buffer (75 mL imidazole, 1.5 M 6-
aminohexanoic acid, pH 7.0). For 2-D BN/SDS-PAGE assays, 5 L 50% glycerol and 
2.5 L Coomassie blue G-250 was added to 400 g DDM solubilized mitochondrial 
proteins and then added to each lane, whereas for sucrose fractions, 30 L of each 
fraction was directly loaded. Proteins were separated using the cathode buffer B (50 
mM Tricine, 7.5 mM imidazole, 0.02% Coomassie blue G-250) and anode buffer (25 
mM imidazole) at 4°C at 100 V for ~ 1 h. Once proteins entered the resolving gel, the 
cathode buffer B was removed and cathode buffer B/10 was added (Cathode buffer B 
with 0.002% coomassie blue G-250) and electrophoresis was continued at 15 mA for 
2-4 hours. The gel was then either stained directly using the manufacturer’s protocol 
for Coomassie blue staining (Pierce) or transferred to PVDF for immunoblotting with 
only one modification from standard procedures. Following transfer to PVDF, the 
membrane was briefly rinsed in 25% methanol 10 % acetic acid to remove excess blue 
dye. 
 For 2-dimensional BN/SDS-PAGE assays, lanes were cut from the BN-PAGE 
described above and incubated in a 1% SDS solution for 10 mins. Individual lanes 
were then added on top of a prepared 10% Tricine SDS-PAGE gel described by 
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Herman Schagger (2006) [37]. Briefly, a 10% Tricine gel was prepared using AB-3 
mix described previously and 3x gel buffer (3 M Tris base, 1 M HCl, 0.3% SDS, pH 
8.45) with a 4% stacking gel. Samples were electrophoresed using cathode buffer (100 
mM Tris, 100 mM Tricine, 0.1% SDS, pH 8.25) and anode buffer (100 mM Tris, 22.5 
mM HCl, pH 8.9) at 4°C using 30 V until samples entered the resolving gel, then at 
190 V. Gels were then transferred to PVDF as described above.  
5.2.5 Continuous sucrose density gradients and activity assays 
Continuous sucrose density gradients were prepared in 5 mL thinwall polypropylene 
ultracentrifugation tubes compatible with the SW 55 Ti rotor. Gradients were prepared 
using equal volumes of 50 mM Tris/MOPS, 2 mM EDTA, 0.02% DDM, pH 7.4 buffer 
containing 5%, 10%, 15%, 20%, 25%, 30%, or 50% sucrose (w/v) and equilibrated at 
either room temperature for 4 hours or 4°C overnight. 2.5 mg of solubilized 
mitochondria (2.5 mg total protein) were added to the top of the prepared sucrose 
gradient and centrifuged 32,500 x g for 16 h at 4°C. Equal volume fractions were 
manually isolated from top to bottom. Fractions were assayed for glutaminase activity 
as described in Section 2.4.4 above with minor alterations. Reactions were performed 
in 50 L, comprised of 40 L of each isolated sucrose gradient fraction, with the 
reaction being started with 10 L of a 100 mM mixture of glutamine and 500 mM 
K2HPO4. Reactions were incubated 30 minutes at 37°C. The glutaminase reaction was 
quenched by adding 5 L 3 mM HCl. Then, 200 L 2 mM NAD+, 10 U/mL GDH, 
130 mM Tris-acetate, 100 mM hydrazine, pH 9.4, was added to the quenched 
glutaminase reaction to initiate the coupled reaction, reducing NAD
+
 to NADH.  
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5.3 RESULTS 
5.3.1 Transformation by onco-Dbl relies on glutamine-fueled anaplerosis  
Originally, the classification of a gene product as an “oncogene” could be 
ascribed if the transfection of the gene into mouse fibroblast cells (i.e. NIH3T3 cells) 
was sufficient to cause cellular transformation. Cellular transformation is reflected by 
the ability of cells to overcome a normal growth phenotype, enabling the normal 
NIH3T3 fibroblasts to no longer exhibit cell-cell contact inhibition and thus form foci, 
or to exhibit anchorage-independent growth. Both of these cellular characteristics, 
cell-cell contact inhibition and anchorage-dependent growth, are fundamental 
properties of normal cells that transformed cancer cells are able to overcome. With 
this in mind, we sought to investigate the effects of the Dbl oncogene on the metabolic 
state of mouse embryonic fibroblasts (MEFs). To accomplish this, we developed an 
inducible TET-OFF model cell system, where the Dbl oncogene is under the tight 
regulation of a transcriptional regulator that is inhibited by the antibiotic doxycycline 
(Dox). Removal of Dox allows for the robust expression of the Dbl oncogene, causing 
the normal MEFs to be a uniformly transformed population of cells. 
 Given that the Dbl oncogene is a founding member of a major family of 
Rho GEFs, it is capable of causing dramatic changes in cell morphology through 
activation of Rho G-proteins and their abilities to trigger actin cytoskeletal 
rearrangements. These cytoskeletal rearrangements are readily observed in our 
inducible cell system, where following a 24 hour induction period, the cell 
morphology shows marked changes as observed by normal phase contrast (Figure 
5.2A) and immunofluorescence images probing for filamentous actin (Figure 5.2B, top 
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panes). Additionally, immunofluorescence images probing for HA-tagged Dbl in cells, 
before and after induction, show a robust expression of the oncogene, correlating with 
the observed morphological changes (Figure 5.2B, bottom panes). 
We then sought to investigate the sensitivity of these Dbl-inducible MEFs to 
treatment with 968. In Chapters 2 and 3 above (sections 2.2.3 and 3.1-3.2), we 
described the binding and inhibition of the glutaminase enzyme, GAC, by 968 and 
various 968-analogues. These small molecules have been validated to inhibit GAC in 
vitro, however, they have not been examined for their ability to inhibit glutamine 
metabolism in cells. To describe the action of this small molecule in transformed cells, 
we used the prototype compound 968 and a less potent derivative, compound 27, both 
shown to bind to and target GAC in Chapter 3 (section 3.2.1), above, with in vitro IC50 
values of 3.5 M and 20.0 M, respectively (Figure 5.3A). Indeed, these compounds 
followed the same trend for their ability to inhibit Dbl-induced cell growth at 
saturation density, a principal characteristic of these transformed cells (Figure 5.3B, 
compare results under (+) Onco-Dbl). 
 To show the inhibition of GAC in Dbl-transformed cells, we measured the 
accumulation of the products of the glutaminase reaction, namely glutamate and 
ammonia, in extracellular media. These metabolites have been shown previously to be 
a reliable measure of the level of glutamine metabolism within cells [20], [25]. The 
induction of the Dbl oncogene resulted in an increase in both glutamate and ammonia 
levels in the extracellular media (Figure 5.4A, compare black to gray). Additionally, 
Dbl induction promoted the expression of GAC within the mitochondrial fraction 
(Figure 5.4B).  
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FIGURE 5.2 – Induction of onco-Dbl gives rise to transformed morphological 
phenotypes. (A) Dbl induction results in a significant alteration in cellular 
morphology, characteristic of the onco-Dbl-induced activation of Rho-GTPases, as 
shown by phase contrast images. (B) The activated Rho-GTPases induce the 
formation of actin stress fibers, which are visualized by imaging the actin 
cytoskeleton using anti-actin antibodies (middle panels). The robust expression of 
the HA-tagged Dbl oncogene, upon induction, is visualized using 
immunofluorescence with an anti-HA antibody (bottom panels).  
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FIGURE 5.3 – Treatment of Dbl-induced cells with 968 inhibits cell growth at 
saturation density. (A) The reaction catalyzed by mitochondrial glutaminase 
converts intracellular glutamine to glutamate with the release of ammonia, and is 
inhibited by the small molecule 968, but not by the inactive 968-analogue, 
compound 27. (B) Dbl-expressing MEFs (1x10
5
 cells) and control (uninduced) 
MEFs are grown to saturation density in DMEM supplemented with 5% FBS for 
10 days, with the Dbl-expressing cells also being treated with either 968 (7.5 M), 
compound 27 (7.5 M), or left untreated. After 10 days of growth, the cells were 
fixed with formaldehyde and stained with crystal violet to visualize cell density. 
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FIGURE 5.4 – Dbl induction stimulates increased mitochondrial Gls expression 
as well as glutamate and ammonia secretion. (A) The metabolites glutamate and 
ammonia were quantified in the extracellular media using an enzyme-coupled 
spectroscopic assay from uninduced cells, and cells that were induced to express 
the Dbl-oncogene with and without the treatment of 8 M 968 or 8 M compound 
27 for 12 h. Bars represent the mean (± SD) of triplicate determinations.  P-values 
were determined by the Students t-test (* p < 0.05, ** p < .005). (C) Mitochondria 
were isolated from uninduced and induced cells and probed for Gls expression 
using an antibody that recognizes the KGA and GAC isoforms. The WCL was 
analyzed for HA-Dbl expression, showing a robust expression of the oncogene in 
induced cells only. VDAC, a mitochondrial marker, was used to normalize protein 
for the mitochondrial fraction.  
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The increased secretion of both glutamate and ammonia was potently inhibited by 
compound 968, but not by the inactive 968-analogue, compound 27 (Figure 5.4A, 
compare dark grey to light blue). These results are consistent with Dbl-induced 
increases in glutamine metabolism, which are sensitive to treatment with 968, but not 
the inactive analogue 27.  
 Recently, there has been a greater appreciation for the role imported glutamine 
plays in the refilling of TCA cycle intermediates, i.e. glutamine-fueled anaplerosis. 
This anaplerotic process is driven by alterations frequently observed in highly 
proliferative cells, where the Warburg effect diverts glucose carbon from the TCA 
cycle to be secreted as lactate. To supplement this shift in glucose metabolism, 
glutaminolysis is often up-regulated to provide glutamine-derived carbons to refill 
depleted TCA metabolite pools. To show the increase in glutamine-fueled anaplerosis 
in Dbl-transformed cells, we used a 
13
C stable isotope tracing method (Figure 5.5A). 
Here, Dbl-inducible cells were cultured in glutamine-free DMEM supplemented with 
uniformly labeled 
13
C-glutamine ([U-
13
C]-glutamine). Upon import of [U-
13
C]-
glutamine, downstream metabolite pools resulting from glutamine metabolism are 
enriched in this 
13
C isotope, which can be readily extracted from cells and quantified 
using mass-spectrometry.  
 Treatment of both Dbl-induced and uninduced cells with [U-
13
C]-glutamine 
resulted in a significant increase in glutamine-fueled anaplerosis, detected by the 
selective enrichment in 
13
C-containing TCA cycle intermediates (Figure 5.5B, 
compare black to dark grey). These results are consistent with observations that Dbl-
induction causes an increase in GAC expression and in the secreted metabolites, 
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glutamate and ammonia (Figure 5.4). Importantly, these stable isotope tracing results 
provide evidence that increased glutaminolysis facilitates the up-regulation of 
glutamine-fueled anaplerosis. Treatment of Dbl-induced cells with the GAC inhibitor, 
compound 968, potently inhibited the 
13
C enrichment below that of un-induced MEFs, 
showing that 968 inhibits the increase of glutamine-fueled anaplerosis in Dbl 
transformed cells (Figure 5.5B). Furthermore, treatment with the less effective GAC 
inhibitor, compound 27, resulted in only a minor inhibition of the 
13
C enrichment from 
[U-
13
C]-glutamine (Figure 5.5B). A modest inhibition of glutaminolysis by 968 was 
also observed in MEFs not expressing Dbl (see Appendix 4A for the M+5 histograms 
for Dbl-OFF, +/- 968, and the M+4 histograms in Appendix 4B,C). However, these 
effects were not accompanied by reductions in cell growth, suggesting that glutamine 
metabolism is critical for supporting the transformed phenotypes accompanying 
oncogenic Dbl expression, but not for the proliferative capability of normal MEFs. 
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FIGURE 5.5 – Glutamine anaplerosis is up-regulated by Dbl induction and 
potently inhibited by 968. (A) Diagram showing 
13
C enrichment from [U-
13
C]-
glutamine into TCA cycle intermediates, where GAC activation downstream from 
Dbl is highlighted. 
13
C-carbons are shown as dark-filled circles and 
12
C-carbons as 
light-filled circles. (B) Glutamine-derived metabolites (glutamate M+5, fumarate 
M+4, malate M+4, citrate M+4) were normalized to 
13
C enrichment observed for 
MEFs not expressing Dbl. Comparisons were made between treatment with 968, 
its less potent analog WPK968, and untreated cells. Bars represent the mean (± 
SD) of triplicate determinations. P-values were determined by the Students t-test 
(* p < 0.05, ** p < .005). 
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5.3.2 Tetrameric GAC is readily observed in Dbl-induced cells and other 
glutamine dependent cell lines and tissues. 
As demonstrated in Chapter 2 above, in vitro FRET studies of GAC 
oligomerization has established the necessity for GAC to form a tetramer in order to 
become activated. Additional fluorescence studies have shown that the two distinct 
classes of inhibitors, namely derivatives of benzophenanthridines, where 968 is the 
prototype, and derivatives of bis-thiadiazoles, where BPTES is the protoype, target 
discrete oligomeric states of the enzyme by interacting at the monomer-monomer or 
dimer-dimer interfaces. Therefore, given the importance of this oligomer transition for 
activity, we were interested in developing a method to screen for the oligomeric 
species of KGA/GAC enzymes in Dbl-transformed cells. To accomplish this, we 
developed a workflow where mitochondrial enzymes were first isolated by 
solubilization in a non-denaturing detergent (dodecylmaltoside, DDM), followed by 
their separation using 2-dimensional gel electrophoresis (Figure 5.6). In the first 
dimension, detergent solubilized proteins were separated by their native size using 
non-denaturing blue-native polyacrylamide gel electrophoresis (BN-PAGE) [26]–[28]. 
This method was adapted by Wittig et al. (2006), where the hydrophobic anionic dye, 
Coomasie Blue G-250, is added to detergent solubilized proteins to allow for their 
electrophoretic separation in a gradient polyacrylamide gel (Figure 5.6, (1)) [26]. 
Then, this single BN-PAGE lane is incubated with the denaturant sodium dodecyl 
sulfate (SDS) and loaded on top of a denaturing SDS-PAGE gel to separate the native 
protein complexes into their individual components (Figure 5.6, (2)).  
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FIGURE 5.6 – 2-Dimensional Blue-Native/SDS PAGE assay for mitochondrial 
complexes. Mitochondria are isolatedd from cultured cells by differential 
centrifugation techniques and solubilized with the complex stabilizing detergent, 
dodecylmaltoside (DDM). DDM solubilized proteins are then incubated with the 
anionic dye Coomassie Blue G-250 to allow protein complexes bound with the 
anionic dye to be separated through a gradient polyacrylamide gel by 
electrophoresis (1
st
 dimension). Once separated, the gel is incubated with the 
denaturant sodium dodecyl sulfate (SDS) and stacked on a SDS-PAGE gel to 
separate multi-protein complexes into their individual constituent proteins (2
nd
 
dimension). Green spheres represent hypothetical GAC monomers, where dimers 
and tetramers can readily be separated using this 2D BN/SDS-PAGE assay. 
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Finally, this second gel, where the proteins are first separated by native molecular 
weight (left to right), and then by their denatured molecular weight (top to bottom), is 
immunoblotted with an anti-Gls antibody. 
 The 2-D BN/SDS-PAGE assay was used to determine the oligomeric state of 
GAC in Dbl-transformed cells. MEFs were either induced to express Dbl or 
maintained under Dox-controlled repression, and their mitochondria harvested using 
differential centrifugation methods adapted from Frezza et al. (2007)  [29]. Analysis 
of the isolated mitochondrial proteins using 2-D BN/SDS-PAGE and western blotting 
for KGA/GAC revealed a homogenous population in the un-induced MEFs consistent 
with a GAC dimer (Figure 5.7A, white circle). However, for MEFs induced to express 
Dbl, two distinct populations of GAC were observed in the native dimension, but only 
one population in the denatured dimension, consistent with a GAC dimer and tetramer 
comprised of GAC monomers (Figure 5.7A, white circles). Additionally, there was an 
apparent increase in total GAC protein as read out by the intensity of each blot, 
consistent with previous observations that Dbl induction results in an increased 
expression of GAC.  
 To extend these studies, we sought to investigate the oligomeric state of GAC 
in other transformed cancer cells previously shown to exhibit a significant glutamine 
dependency [16], [30]. Interestingly, using this 2-D BN/SDS-PAGE assay in both 
HeLa and TSE cancer cell lines, we observed GAC exclusively as a tetramer (Figure 
5.8). Both of these cell lines are known to be highly proliferative and dependent on 
glutamine metabolism to support their growth phenotype, along with having a robust 
expression of the GAC enzyme.  
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FIGURE 5.7 – GAC tetramer formation is induced by onco-Dbl in cells. Western 
blot of 2D-BN/SDS-PAGE assay of mitochondrial proteins from uninduced (A) 
and Dbl transformed MEFs (B) probed with anti-Gls antibody. Uninduced cells 
have only one population of GAC oligomers consistent with a GAC dimer in the 
first dimension (112 kD) and monomeric GAC (white circle, 56 kD) in the second 
dimension. Induced cells have two distinct populations of Gls oligomers in the 
first dimension (224 kD and 112 kD) that correspond to monomeric GAC (white 
circles, 56 kD) in the second dimension.  
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These results demonstrate the utility of this 2-dimensional assay for profiling the 
oligomeric state of the GAC enzyme directly in cancer cells. 
They also then raised the question whether this assay could be useful for 
determining the oligomeric state in mitochondrial extracts of tissues. In addition, we 
wondered whether the metabolic condition of the host organism could impact the 
distribution of the GAC oligomers. To determine this, we prepared organ tissue from 
white lab mice that were either fed ad libitum or fasted overnight to induce an acute 
state of famine. Specifically, the kidneys were isolated to perform the 2-D BN/SDS-
PAGE analysis due to their high expression of KGA/GAC isoforms and their 
physiological role in controlling the concentration of glutamine within plasma in 
response to changes in blood pH (Figure 5.9A) [31], [32]. Interestingly, we found that 
the KGA/GAC enzymes comprised a heterogeneous population of dimers and 
tetramers, representing a dynamic equilibrium between oligomeric states (Figure 
5.9B,C). The result of fasting significantly increased the total amount of KGA/GAC, 
and shifted the population towards the tetrameric state, hence representing enzyme 
activation.  
Although the purpose of developing this 2D-BN/SDS-PAGE assay was to 
investigate the degree of GAC dimers versus tetramers in cells, this assay provided the 
potential for resolving even higher molecular weight species. To our surprise, we 
observed a high molecular weight form of GAC in the mitochondrial extracts of 
mouse kidneys (Figure 5.9B,C, white asterisk). This high molecular weight GAC 
species (~1.2 MD) was isolated in both the fed and fasted states, with a significant 
increase observed in the fasted state. 
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FIGURE 5.8 – GAC is a constitutive tetramer in cancer cells. Western blot of 2D-
BN/SDS-PAGE of mitochondrial proteins purified from highly proliferative TSE 
breast cancer cells (A) and HeLa cells (B) using anti-Gls antibody. The western 
blots suggested one population of Gls oligomers in the first dimension consistent 
with a Gls tetramer (224 kD), and monomeric GAC (56 kD) in the second 
dimension. 
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The detection of a large molecular weight population of GAC suggests that the 
enzyme is participating in either a multi-protein complex, or it exists as a high 
molecular weight homo-oligomer. Cassago et al. (2013) have characterized an 
oligomeric form of the GAC enzyme in vitro, where GAC tetramers stack end-on-end 
to form a long linear polymer [33]. They described this GAC polymer formation to be 
promoted by the allosteric activator, inorganic phosphate, offering the hypothesis that 
GAC polymer formation is required for activation. However, the results of our native 
gel assays are not consistent with a polymer form of GAC, but rather suggest that 
GAC assumes a discrete high molecular weight form. To further demonstrate this, we 
used purified recombinant GAC to assay its oligomerization, in response to inorganic 
phosphate, using the native gel assay together with the light scattering technique, 
SEC-MALS (Figure 5.10A,B). Indeed, we observed a shift in the oligomerization of 
GAC in response to phosphate using the 1-dimensional BN-PAGE assay; however, the 
changes in oligomerization represented discrete populations of GAC monomers, 
dimers, tetramers, and octamers (Figure 5.10A, right most lane). This observation is 
consistent with the size distribution curve from the analysis of GAC using SEC-
MALS in the presence of inorganic phosphate. Here, although a high molecular 
weight oligomer greater than 1MD is the primary form of GAC, it consists of a 
polydisperse population of GAC oligomers (Figure 5.10B, compare --- to - -). 
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FIGURE 5.9 – GAC oligomer distribution in kidney mitochondrial extracts is 
dependent on metabolic state. (A) Diagram of proposed biological function of Gls 
enzymes in kidney tissues, where glutaminase activity produces ammonia in 
response to acidotic conditions. Western blot of 2D-BN/SDS-PAGE from purified 
mitochondrial proteins of kidney tissues from mice either fed ad libitum (B) or 
fasted 16 h (C) and blotted using an anti-Gls antibody shows a distribution of Gls 
dimers and tetramers. For mice fasted for 16 h, Gls expression was increased and 
harbored a significantly greater proportion of Gls tetramers when compared to 
kidney mitochondria from mice fed ad libitum. Both mouse kidney mitochondrial 
extracts contained a significant population of a large molecular weight species (> 1 
MD, marked with a *) that was also increased for mice fasted versus fed. 
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FIGURE 5.10 – In vitro assays of phosphate induced GAC oligomerization by 
BN-PAGE and SEC-MALS shows a polydisperse population of oligomers. (A) 4-
12% BN-PAGE of 5 g recombinant GAC incubated with increasing 
concentrations of phosphate and visualized by Coomassie blue protein staining. 
(B) Multi-angle light scattering profiles of 250 g injection (each) of WT GAC 
with (—) and without (—) 100 mM phosphate added to the running buffer, where 
the solid line represents the elution of each species by monitoring refractive index 
(R.I.), and the broken line designates the calculated molecular weight for the 
species eluted at that time. Reference lines for the molecular weights of the 
monomer, dimer, and tetramer forms of the enzyme are included at 58 kD, 116 
kD, and 232 kD respectively. 
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5.3.3 Isolation of oligomeric states in mouse tissues correlates with active 
KGA/GAC tetramers and identifies an active high molecular weight species. 
 Results from the 2D BN/SDS-PAGE assay of mouse tissues demonstrated a 
distinct distribution of KGA/GAC within mitochondria. However, while this assay 
identifies the oligomeric status of KGA/GAC in vivo, we were interested in assaying 
the activity of the isolated enzyme populations. We were particular interested in 
examining the activity of the high molecular weight enzyme complex. To accomplish 
this, we developed continuous sucrose density gradient ultracentrifugation techniques 
to fractionate the detergent solubilized proteins from mouse kidney and liver 
mitochondria. Here, liver mitochondria were included due to their abundance of 
KGA/GAC isozymes and physiological role in regulating glutamine levels within 
plasma. Liver hepatocytes are thought to process the glutamine secreted by muscle 
tissues to recycle nitrogen, through the coupling of glutamine deamidation to urea 
production [32]. Therefore, we were interested in comparing the oligomer status of 
KGA/GAC in both kidney and liver tissues, where they both play vital but distinct 
roles in glutamine homeostasis.  
 First, mitochondria were prepared from white lab mice by differential 
centrifugation as mentioned previously and solubilized in 1% DDM. Solubilized 
proteins were then added to the top of a continuous sucrose gradient (5%-50%) and 
centrifuged (>100,000 x g) to separate proteins throughout the density gradient by 
their molecular size, with larger proteins and protein complexes having the greatest 
mobility. Equal volume fractions were then analyzed by SDS-PAGE and 
immunoblotting.  
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Figures 5.11A,B depicts the results of the sucrose density centrifugation of 
mouse kidney and liver mitochondria extracts. The distributions of KGA and GAC 
were dispersed among fractions 2-8 for both tissues, consistent with a dimer to 
tetramer distribution, when compared to molecular weight markers of control 
experiments. Additionally, multiple bands of KGA/GAC proteins were identified in 
the SDS-PAGE gel. The bands were determined to be the previously described high 
and low molecular weight forms of KGA [34], and the GAC isoform. Each individual 
band, corresponding to the KGA and GAC proteins, co-purified with its own unique 
pattern. The high molecular weight band of KGA (Figure 5.11A, top band, inset of 
lane 3) followed a separate sedimentation pattern (fractions 3-5) when compared to the 
low molecular weight KGA band, which was distributed through fractions 3-8 (Figure 
5.11A, second band, inset of lane 3). Similarly, the GAC protein exhibited a unique 
sedimentation profile when compared to KGA proteins. These results suggest each 
form of Gls associates with itself, instead of yielding heterogeneous populations 
containing both KGA and GAC. This is consistent with previous studies of KGA, 
where Srinivasan and colleagues (1995) originally described high and low molecular 
weight KGA forms of this Gls species [34]. Interestingly, in vitro FRET assays, as 
described in Chapter 2.1 above, demonstrate that GAC and KGA are capable of 
forming heterotetramers when using donor labeled GAC and acceptor labeled KGA 
(Appendix Figure 7.5A,B).  
 Similar to the results described in section 5.2.2 above, a discrete population of 
KGA/GAC was identified in the fraction containing the highest sucrose density, 
characteristic of a high molecular weight complex (Figures 5.11A,B, white asterisks).  
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FIGURE 5.11 – Mitochondrial proteins from mouse kidney and liver tissues 
reveal dimer-to-tetramer distribution and a higher molecular weight species of Gls. 
2.5 mg of detergent solubilized proteins from mouse kidney (A) and liver (B) 
mitochondria separated by continuous sucrose density gradient. 50 L of each 
fraction was separated on a 10% Tricine-SDS PAGE gel and analyzed by 
immunoblotting against KGA and GAC. Fraction 1 represents the top of the 
sucrose gradient (i.e. low density) and fraction 13 the bottom (i.e. highest density). 
Isolated fractions are included to depict the identified proteins, KGA and GAC, 
using fractions 3 and 5 from mouse kidney and liver.  
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When comparing the kidney and liver proteins, we found that this high molecular 
weight species was enriched in the mitochondria isolated from liver tissue. 
Additionally, two molecular weight forms were observed in the same fraction, a high 
molecular weight band (~55 kD) and a low molecular weight band (~25 kD). The 25 
kD band is consistently observed in a variety of cancer cell lines when western 
blotting for KGA/GAC, as well as being present in the inducible Dbl cells. In fact, this 
25 kD KGA/GAC fragment was identified in Section 3.2.5 above (Figure 3.9C), 
where the cross-linking 968 derivative, SU-22, was cross-linked in cells. Moreover, 
this 25 kD band is exclusively found in the bottom fractions of the continuous sucrose 
gradient, characteristic of a high molecular weight protein complex.  
To determine the KGA/GAC enzyme activities and oligomerization states 
within these sucrose fractions, each fraction was assayed for glutaminase activity and 
separated by BN-PAGE (Figure 5.12A-C). Glutaminase activities of each fraction 
were compared to purified recombinant GAC that was separated using sucrose density 
gradient sedimentation. As depicted in Figure 5.12A, glutaminase activity was 
detected within fractions 2-8, agreeing with the distribution from the western blot 
presented in Figure 5.11A,B. The activities observed in fractions 9-12 for the kidney 
mitochondria were found to be from the endogenous GDH enzyme, the same enzyme 
used to read out glutaminase activity through the two-step coupled assay of GAC and 
GDH. Additionally, this activity profile was in good agreement with fractions for 
recombinant GAC that were resolved by the same methods. To determine the 
oligomeric species within each fraction, samples were separated by BN-PAGE and 
immunoblotted for KGA/GAC. A significantly higher proportion of the KGA/GAC 
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enzymes were found to be tetramers in the kidney fractions when compared to those of 
the liver (Figure 5.12B,C). This higher proportion of KGA/GAC tetramers for kidney 
tissues was in good agreement with the enzymatic activity measured for each fraction, 
where the kidney fractions had almost twice the glutaminase activity than the fractions 
from liver (Figure 5.12A, compare (▲) to (■)). However, a significant amount of 
KGA/GAC was found in a high molecular weight complex in fractions 13 and 14 from 
liver, and to a much lesser extent in the kidney (Figure 5.12B,C, top insets). Indeed, 
these fractions contained a measurable glutaminase activity, suggesting this high 
molecular weight complex (i.e. >1 MD) contains KGA/GAC enzymes that are 
catalytically active (Figure 5.11A, asterisks). Taken together, these results demonstrate 
that the KGA/GAC tetramer is the active species in liver and kidney tissues. 
Additionally, a high molecular weight species of KGA/GAC was identified, that was 
found to primarily consist of a short 25 kD form, and contained measureable enzyme 
activity. 
  
-230- 
 
  
FIGURE 5.12 – Glutaminase activity of isolated kidney and liver mitochondrial 
proteins separated by continuous sucrose gradient centrifugation correlates with 
tetrameric and high molecular weight oligomeric species of the KGA/GAC 
proteins. (A) Fractions separated by continuous sucrose density centrifugation of 
250 mg kidney (▲)and liver (■) detergent solubilized mitochondrial proteins and 
5 g recombinant GAC (●) were assayed for glutaminase activity. (B) 50 g of 
fractions from (A) were separated by 4-12% BN-PAGE and immunoblotted for 
KGA/GAC proteins. The top of the gel, representing proteins of a greater MW 
than can be resolved on the gel (i.e. lanes 13 and 14 for kidney and lanes 14 and 
15 for liver proteins) are included as insets.  
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5.4 DISCUSSION 
 Previous work from our laboratory aimed at identifying inhibitors that 
specifically block Rho GTPase-dependent transformation, led to the discovery of the 
benzophenanthridine 968 [35]. Unexpectedly, the protein target for 968 appeared to be 
a specific splice variant (GAC) of a family of enzymes collectively called glutaminase, 
that catalyzes the hydrolysis of glutamine to glutamate with the production of 
ammonia. This highlighted a previously unappreciated connection between the roles of 
Rho GTPases in driving oncogenic transformation and the regulation of glutamine 
metabolism. Given the striking specificity that 968 exhibited in its ability to inhibit 
transformed cells and cancer cells, with little or no effect on their normal cellular 
counterparts, it was of interest to better understand how 968 functions. 
 We took advantage of an inducible expression system for oncogenic Dbl that 
allowed us to temporally control the expression of this upstream activator of Rho 
GTPases in a well-defined manner. Using this system, we were able to establish a 
direct correlation between the ability of 968 to prevent a key outcome of Dbl-induced 
transformation, namely the loss of cell-cell contact inhibition, and to specifically 
inhibit glutaminolysis. Thus, the inhibitory actions of 968 upon oncogenic 
transformation appear to be a direct outcome of its ability to interfere with glutamine 
metabolism. We go on to show that this increased reliance on glutamine metabolism in 
Dbl-transformed cells results from the direct activation of the GAC enzyme, through 
the formation of active GAC tetramers within mitochondria. Taken together, we found 
that the induction of the Dbl oncogene results in an increased expression of GAC 
within mitochondria, where GAC forms active tetramers, and converts imported 
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glutamine to glutamate in order to support TCA cycle function. Lastly, this increased 
glutamine metabolism was directly assayed in cells, where it is indeed potently 
inhibited by compound 968.  
 In efforts to extend these investigations of the oligomerization status of 
KGA/GAC directly in cells, we found the exclusive expression of GAC tetramers in 
the highly proliferative TSE and HeLa cancer cell lines. These cells have been 
previously shown to exhibit a high degree of mitochondrial glutaminase expression 
and glutamine dependency [16], [30], which is consistent with the tetrameric GAC 
species being the predominant oligomeric form. The exclusive isolation of GAC 
tetramers in these highly proliferative cells is a surprising finding, and suggests the 
oligomerization status of GAC is highly regulated within the mitochondria. 
 The physiological role that mitochondrial glutaminase plays within kidney tissues 
has been shown to prompt a response to acidotic conditions, through the release of 
NH3 as an outcome of the glutaminase reaction [32]. Here, we established a minor 
acidotic condition through the fasting of mice, thereby inducing a metabolic switch to 
ketogenesis. Taking advantage of this method, we were able to examine the proportion 
of KGA/GAC oligomers from isolated mouse tissues and their response to fed and 
fasted states. Upon fasting, we observed not only an increase in KGA/GAC 
expression, but a significant shift toward the tetrameric state. Furthermore, we 
identified a large molecular weight complex (>1 MD) that was up-regulated in the 
fasted state. Our results show that this high molecular weight complex does not appear 
to be the same as the supra-oligomeric species of GAC that forms in vitro, as 
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demonstrated previously by Cassago and colleagues (2013) by electron microscopy of 
phosphate stimulated GAC [33].  
 As presented in Chapter 2 above, we originally described the dimer-to-tetramer 
transition to be required for the activation of GAC in vitro, and were therefore 
interested in determining whether this transition is physiologically important in vivo. 
Having identified the oligomeric GAC species from mouse kidneys, we sought to 
resolve each oligomeric form of the enzyme, so as to assay their activities, and in 
particular, determine the activity of the high molecular weight complex. The 
separation of mitochondrial proteins by continuous sucrose gradient centrifugation 
techniques proved useful for the isolation of native protein oligomers, where the 
activity of each fraction could be assayed for activity and examined by native BN-
PAGE and immunoblotting. The activity profile of isolated fractions from mouse 
kidney and liver tissues matched the distribution of KGA/GAC within the density 
gradient, and was directly related to the tetrameric enzyme population within each 
fraction. These results show directly that the oligomerization status of KGA/GAC is 
indeed dependent on KGA/GAC tetramer formation within cells, and in good 
agreement with the biophysical data from in vitro experiments presented in Chapters 
2, 3 and 4 above.  
 To our surprise, the high molecular weight form of GAC harbored significant 
enzymatic activity. Given the data presented here, it is our speculation that KGA/GAC 
enzymes are in fact participating in a large molecular weight complex, whose principal 
components have not yet been identified. Interestingly, the known native molecular 
weight complexes within these fractions are pyruvate dehydrogenase and -
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ketoglutarate dehydrogenase, presenting an attractive hypothesis where glutaminase, 
the first enzyme responsible for glutamine-fueled anaplerosis, engages in cross-talk 
with the principal dehydrogenases within the mitochondria that act as gate-keepers for 
carbon entry to the TCA cycle. 
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CHAPTER SIX 
Conclusions and future directions 
Back to the Future: A new paradigm in cancer cell biology 
 The connection between signal transduction pathways that give rise to cancer 
and altered cellular metabolism has presented cancer researchers a new context for 
developing therapeutic approaches. Recent studies focusing on the metabolic 
requirements of cancer cells have led to new paradigms in cancer biology, revealing 
some cancers to be bona fide metabolic diseases. Many solid tumors and cancer cell 
lines exhibit a highly elevated requirement for an exogenous supply of nutrients to 
support their unregulated proliferation and metabolic demands. Therefore, the direct 
targeting of metabolic enzymes presents a new strategy that holds great promise for 
future therapeutics. Of the metabolic enzymes that have been identified as potential 
drug targets, the mitochondrial enzyme glutaminase represents one of significant 
interest. This is due to the enzyme’s critical role in the first step of glutaminolysis, a 
process that is upregulated in proliferative cells having aberrant glycolytic flux (i.e. 
the Warburg effect) to supply the TCA cycle, depleted of glucose-derived carbon, with 
a glutamine-derived source.  
 Our interest in mitochondrial glutaminase was driven by the identification of a 
small molecule that potently inhibited cells transformed by hyperactive Rho-GTPases, 
but not their non-transformed counterparts. The target of this small molecule, a 
dibenzophenanthridine designated as compound 968, was determined to be the 
alternatively spliced isoform of the kidney-type glutaminase, glutaminase C (GAC). 
Compound 968 was shown to be an allosteric inhibitor, non-competitive with neither 
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glutamine or allosteric activators like inorganic phosphate. However, there was still 
much we did not understand regarding how this inhibitor blocks enzyme activity, nor 
the detailed mechanisms underlying enzyme activation in vitro or within transformed 
cells and cancer cells. Therefore, the motivation for my research was to gain further 
mechanistic insights into the activation and inhibition of GAC in vitro, and to 
complement this information with studies of glutamine metabolism in 
transformed/cancer cells. 
 The glutaminase isoforms KGA and GAC were suggested by early studies to 
require tetramer formation to become activated, although this had never been 
definitively demonstrated. In Chapter Two, I describe a fluorescence resonance energy 
transfer (FRET) assay to study the formation of GAC tetramers and the effects that 
allosteric activators and inhibitors have on GAC oligomerization. I demonstrate the 
requirement of tetramer formation for GAC activity, and report a defined dissociation 
constant that reflects the GAC dimer-to-tetramer transition. Additionally, I 
demonstrate that allosteric activators, namely inorganic phosphate, further enhance 
GAC tetramer formation, and propose a model where phosphate binding drives 
tetramer formation to stimulate enzyme activity. In contrast, two distinct classes of 
GAC allosteric inhibitors, the bis-thiadiazoles (for which  BPTES is the prototype) and 
the benzophenanthridines (with compound 968 being the prototype), exert distinctly 
different effects. The BPTES-class of inhibitors induced the rapid formation of a 
stable BPTES-bound GAC tetrameric complex, whereas 968 neither promoted nor 
inhibited tetramer formation. Instead, 968 was shown to affect the emission of a 
fluorescence reporter group, providing a direct read-out for 968 binding to GAC. This 
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binding assay, together with the development of oligomeric-deficient GAC mutants, 
trapped in either the dimeric or monomeric states, was used to demonstrate the 
preferential binding by 968 to the monomeric form of GAC. Therefore, we propose 
that 968 acts by interfering with oligomer activation through its binding to the GAC 
monomer. 
 The real-time 968 binding assay, described in Chapter Two, was then adapted 
to a high-throughput coupled binding and inhibition assay to screen novel 968-
analogues, described in Chapter Four. This simultaneous binding and inhibition assay 
proved to be a reliable read-out for dibenzophenanthridine derivatives, and lead to the 
identification of a new lead scaffold (SU-29). Additionally, 968-analogues were 
generated that harbored useful physical properties, such as intrinsic fluorescence (SU-
14), and photo cross-linking abilities (SU-22 and SU-24). These tool compounds were 
used to covalently modify GAC in vitro and in transformed cells and then monitor the 
incorporated fluorescence. The cross-linking studies in vitro provided evidence for a 
site-specific covalent cross-linking of the 968-derivative that was localized within the 
monomer-monomer interface of GAC, consistent with 968 binding to the monomeric 
form of the enzyme. Furthermore, this cross-linked GAC established the ability of a 
968-analogue to drive the GAC monomer to form a dimer. This evidence leads to the 
proposed model in which the binding of 968 to the monomeric form of GAC induces 
the formation of a very stable complex of 968-bound GAC dimer. Further studies 
using the SU-22 cross-linker in Dbl-transformed cells not only identified a cross-
linked protein, subsequently identified as mitochondrial GAC, but localized the small 
molecule within mitochondria, consistent with GAC being the cellular target of 968.  
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 In order to examine more closely the mechanism by which the BPTES-class of 
inhibitors exert their effects on GAC activity, I used tryptophan mutagenesis to install 
a fluorescence reporter group within a critical loop, referred to as the activation loop, 
where BPTES binds (Chapter Four). I then took advantage of this novel GAC 
tryptophan mutant (F327W) to monitor the binding of BPTES, and the best-in-class 
BPTES analogue, CB-839, and determine their respective dissociation constants. 
Interestingly, I discovered that allosteric anionic activators (i.e. inorganic phosphate 
and sulfate) induced the opposite effect on the F327W fluorescence from BPTES-like 
inhibitors, i.e. a fluorescence enhancement rather than a fluorescence quenching. 
Taken together, these studies describe direct read-outs for the binding of allosteric 
activators and inhibitors to the activation loop of GAC, demonstrating how their 
influence on the conformation of this loop is specific to their abilities to activate or 
inhibit the enzyme. These results reveal the prerequisite of GAC to form tetramers to 
enable either activators or BPTES-like inhibitors to bind to the enzyme, and present a 
strategy for the screening of new activators and inhibitors.  
 Building upon these studies that highlight the importance of GAC oligomer 
dynamics in vitro, I was interested in how GAC becomes activated in cells. To 
examine this, I described the stimulation of glutaminolysis and glutamine-fueled 
anaplerosis in an inducible model cell system, where mouse embryonic fibroblasts 
(MEFs) were transformed by oncogenic Dbl, which acts to stimulate Rho-GTPase 
signaling. The increase in glutaminolysis was indeed sensitive to treatment with 968, 
which potently inhibits Dbl-induced transformation in these cells. To translate the 
observations of the in vitro studies presented in Chapter Two, where the formation of a 
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GAC tetramer was required for activation, into this inducible-cell system, I developed 
methods to probe the oligomeric status of GAC in cells. Using native gels to identify 
protein complexes, I found that the outcome of Dbl-induction both increases GAC 
expression and induces GAC tetramer formation, whereas only the dimeric form of 
GAC was isolated from un-induced cells. These studies set the stage for investigations 
in well-known human cancer cell lines. Using the highly proliferative and glutamine-
addicted TSE breast cancer and HeLa cervical carcinoma cells, I isolated the active 
tetrameric form of GAC, demonstrating the utility of this method for probing the 
activation status in transformed cells. I extended these studies into whole organ 
tissues, where GAC plays an essential physiological role for regulating glutamine 
homeostasis, and readily identified the monomeric, dimeric, tetrameric, and a high 
molecular weight (>1 MD) complex form. 
 In summary, this thesis describes the oligomerization of GAC in vitro and in 
vivo, and highlights the impact allosteric activators and distinct classes of allosteric 
inhibitors have on the oligomeric transitions. I present strategies for the screening of 
both the 968-class and BPTES-class inhibitors, as well as allosteric activators, such as 
inorganic phosphate. Finally, I demonstrate methods to investigate the oligomeric 
status of GAC directly in cells and tissues, translating the biophysical studies of 
purified GAC presented here into the relevant biological context of glutamine 
dependent cancer cells. 
Future Directions 
 The studies described in this thesis point to multiple areas worthy of further 
investigation. One aspect warranting further development would build upon the 
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mechanistic studies described in Chapters Two, Three, and Five concerning 968’s 
mode of action, in order to optimize a 968 analog that could be used in cell culture and 
tumor models. Efforts made in this direction would further this cancer targeting 
strategy, with the hope of developing a new therapeutic for clinical trials. A significant 
challenge for advancing this drug scaffold has been the lack of optimization of the 
chemical space to develop a stable, bioavailable drug. There is also significant 
potential for the utility of the chemical tool compounds, described in Chapter Three, to 
gain insight as to the specific binding interaction of 968 at the monomer-monomer 
interface of GAC, as well as for a broader picture as to the localization of this small 
molecule in a variety of cell lines.  
 Another aspect of this thesis that could be expanded upon would be the utility 
of the novel tryptophan mutant (F327W GAC), described in Chapter Four, to screen 
BPTES-analogues, as well as search for new allosteric activators. The physiological 
role phosphate plays in the activation of GAC in vivo remains uncertain, where lines 
of evidence suggest other anionic ligands (i.e. intracellular metabolites) could 
potentiate GAC activity in cells. Furthermore, point mutations, included within the 
F327W background, could be introduced to investigate their impact on the binding of 
allosteric activators, in the hope of gaining more detailed information regarding 
phosphate binding and subsequent activation. Lastly, this tryptophan substitution and 
the readout it provides would be useful for comparing the two glutaminase isozymes, 
the liver-type (Gls2) and kidney-types (Gls), for their ability to bind allosteric 
activators and inhibitors. Both Gls2 and Gls are uniquely expressed in different cell 
types and harbor different activation profiles. Their respective contributions in 
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supporting the cancer phenotype promises to be an area of active research in the years 
to come.  
 Lastly, the methods for investigating the oligomeric forms of KGA/GAC in 
cells and tissues, described in Chapter Five, present a particularly exciting opportunity 
for identifying potential binding partners and the constituent subunits in the high 
molecular weight GAC complex. Metabolic enzymes are known to participate outside 
their canonical roles as enzymes acting on metabolites, through regulating critical 
cellular functions through protein-protein interactions. The cellular signaling networks 
connecting intracellular metabolism, glutamine dependent growth, and cell 
homeostasis are complex, and represents an area ripe for new important discoveries 
regarding the nature of cancer cell growth and survival.  
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APPENDIX ONE 
Complementary data   
  
FIGURE A7.1 – Partial trypsin digestion of 488-labeled GAC. WT GAC (800 
g) was incubated with porcine trypsin (37.5 g) 1 h on ice and quenched with 
soybean trypsin inhibitor (37.5 g). (A) The reaction mixture was separated by a 
superdex 75 10/300 GL gel filtration column equilibrated with 20 mM Tris-HCl 
pH 8.4, 100 mM NaCl, 1 mM NaN3. Peaks were monitored by UV/vis absorbance 
at 280 nm (protein) and 490 nm (488-probe). Fractions were collected (1 mL) and 
pooled to give 5 fractions (depicted by dashed red lines). (B) Fractions from (A) 
were concentrated to 100 L, and 25 L aliquots were analyzed by SDS-PAGE 
along with unlabeled and 488-labeled GAC (5 ug) that were not cleaved by 
trypsin. Bands were visualized using UV-illumination and western blotting (C) 
using an antibody prepared within our laboratory that recognizes the C-terminus of 
GAC (approx. residues 500-520). A band that was visualized by both UV-
illumination (i.e. 488-fluorescence) and immunoblotting was submitted to the 
Cornell Proteomics Core and analyzed by LC-MS/MS. (D) Peptides identified 
from the submitted bands are highlighted in red, and the structural region that 
correlates to the observed MW by SDS-PAGE and residues identified is 
represented in (E), red dashed circle. 
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FIGURE A7.2 – UV-vis absorbance of SU-22-conjugated monomer and WT 
GAC. GAC (WT) and GAC (K316E,D391K,R459E) was reacted with SU-22 and 
purified as described in  Chapter 3 (section 3.2.3). Resulting concentrated SU-22-
conjugated monomeric GAC (A), WT GAC (B), and unreacted SU-22 (10 M) 
(C) was analyzed by UV-vis spectroscopy. Molar absorptivity and A280 
correction factor for unreacted SU-22 was calculated by the spectrum displayed in 
(C), and used to calculate the concentrations of both GAC and SU-22, and the 
labeling efficiency, depicted in (D) 
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FIGURE A7.3 – Partial trypsin digestion of SU-22-labeled and 488-labeled GAC. 
Trypsin (50 g) was added to SU-22-labeled and 488-labeled GAC (56 g each). 
Aliquots (20 L) were quenched with soybean trypsin inhibitor (20 g) at 
increasing time intervals. Samples were then analyzed by SDS-PAGE and 
visualized by UV-illumination (i.e. fluorescence of SU-22 or 488 probes). 
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FIGURE A7.4 – Isotopologues of TCA cycle intermediates derived from [U-
13
C]glutamine in non-induced and induced Dbl-MEFs with 968 and compound 27 
treatment. (A-D) Isolated and quantified TCA cycle isotopologues following a 1 h 
incubation of Dbl-MEFs with U-
13
C-glutamine in both the induced (- DOX) and 
non-induced states (+ DOX), with overnight treatment of 8 M 968, WPK968 or 
DMSO control to illustrate effects on glutamine metabolism (+)/(-) DOX as well 
as with drug treatments. [U-
13
C]glutamine enrichment is noted in the M+5 
isotopologue of glutamate (A), M+4 of fumarate (B), M+4 of malate (C), and 
M+4 of citrate (D), where an inhibition of glutamine metabolism by 968 was 
observed in both induced and non-induced cells as read out by 
13
C enrichment. (E) 
968 treatment causes a modest decrease in glutamate pool sizes in non-induced 
and induced cells while causing no impact on the pool sizes of fumarate, malate, 
and citrate. Metabolites were quantified by normalizing the integrated peaks for all 
mass isotopologues with respect to the internal standard (50 nmol of 2-
oxobutyrate) and protein content.  
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FIGURE A7.5 – KGA forms heterotetramers (KGA:GAC) with the same binding 
affinity as GAC homotetramers. Increasing concentrations of QSY9-labeled 72-
GAC were added to 10 nM 488-labeled 72-GAC (○) and 72-KGA (●), and the 
fluorescence quenching that results from FRET (see Chapter 2, figure 2.2) was 
quantified and plotted with respect to the total concentration of KGA/GAC. The 
curve represents the non-linear fit to a quadratic bimolecular binding isotherm, 
where the association constants were within good agreement when 488-KGA was 
used in place of 488-GAC, representing heterotetramers versus homotetramers, 
respectively.  
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